Classical Hodgkin Lymphoma in Chinese and Dutch populations : epidemiology, EBV and HLA associations by Huang, Xin
  
 University of Groningen
Classical Hodgkin Lymphoma in Chinese and Dutch populations : epidemiology, EBV and
HLA associations
Huang, Xin
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2011
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Huang, X. (2011). Classical Hodgkin Lymphoma in Chinese and Dutch populations : epidemiology, EBV
and HLA associations. [S.n.].
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Univer-§if¥ of «;r-oninaen 
Classical Hodgkin Lymphoma 
in Chinese and Dutch populations: 




--. .. ... . :.. ; 
Classical Hodgkin Lymphoma in Chinese and 
Dutch populations: Epidemiology, EBV and 
HLA associations 
Proefschrift 
ter verkrijging van het doctoraat in de 
Medische Wetenschappen 
aan de Rijksuniversiteit Groningen 
op gezag van de 
Rector Magnificus, dr. E. Starken, 
in het openbaar te verdedigen op 
maandag 20 juni 2010 
om 16. 15 uur 
door 
Xin Huang 
geboren op 15 mei 1978 
te Hubei, China 
Ct·ntr:1k U t'.1cdi�t.he M cl1blioth\!ck C 
Gruningcn G 
� . . ..... -
Stellingen behorende bij het proefschrift 
Classical Hodgkin Lymphoma in Chinese and Dutch populations: 
Epidemiology, EBV and HLA associations 
1. Classical Hodgkin Lymphoma (cHL) is a very heterogeneous disease. 
2. The incidence of cHL is age dependent and both the overall incidence and 
the age dependent incidence are influenced by ethnic origin. 
3. Immune control of Epstein Barr virus (EBV) infection depends on 
polymorphisms within the Human leukocyte Antigen (HLA) genes. 
4. EBV-positive cHL is different from EBV-negative cHL in terms of 
epidemiology, association with ethnic origin and genetic predisposition. 
5. The increased risk of individuals carrying the HLA-A *01 allele to develop 
EBV-positive cHL presumably relates to a less effective immune response 
against EBV derived peptides. 
6. HLA-A *02:07 is an ethnic-specific HLA-A*02 allele variant that is related to 
a higher risk to develop EBV-positive cHL in the Chinese population. 
7. I dreamed a thousand new paths ... I woke and walked my old one. 
8. Be not afraid of growing slowly; be afraid only of standing still. 
9. A book holds a house of gold. 
10. Even Homer sometimes nods (ffi�=f-ffi, �,�-�). Ccmrale u Mcdische M 
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Introduction 
1. 1 General introduction on classical Hodgkin 
lymphoma 
Hodgkin lymphoma(HL) is a distinct malignancy of the human lymphoid system 
and was described for the first time in 1832. It has an incidence of~S per 100, 000 
inhabitants in Western Europe and USA, but is less common in Asia with an 
incidence of <1 per 100, 000(1-3). HL can occur at any age, but is more frequent 
in young adults and elderly(4, 5). HL comprises two clinicopathological entities, 
namely nodular lymphocyte predominant HL(NLPHL) and classical HL(cHL)(6, 7). 
The latter is further subdivided based on the morphology of tumor cells and the 
composition of the background into four subtypes, i. e. nodular sclerosis HL 
(NSHL ), mixed cellularity HL ( MCHL ), lymphocyte-rich HL and lymphocyte­
depletion HL(6). This thesis focuses on cHL, which accounts for about 95% of all 
HL cases. CHL is characterized by a unique morphology in which the major part 
of the tumor mass is made up of various inflammatory cells, while the neoplastic 
cells, termed Hodgkin Reed-Stemberg(HRS) cells account for less than 1% of the 
cells. The HRS cells are identified as large, sometimes bi-nucleated cells with 
prominent nucleoli and an unusual/CD45-, CD30+, CD15+ /-immunophenotype(9). The 
lineage of HRS cells has been enigmatic for a -very long time. After successful 
introduction of the single cell isolation technology approximately two decades 
ago, HRS cells were pro-ven to be of germinal center B-cell origin based on 
presence of immunoglobulin gene rearrangements with a high load of somatic 
mutations(8, 9). 
Although the exact pathogenesis of cHL is still unknown, there is mounting 
evidence that a complex interplay of environmental and genetic factors 
contributes to the neoplastic dewlopment(10). Familial clustering of cHL and a 
3~7 fold increased risk for cHL obseMd in siblings(11, 12) indicates that certain 
inherited traits increase the risk of de-veloping cHL. A major environmental factor 
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is the Epstein-Barr virus(EBV) which is present in the HRS cells in a considerable 
proportion of cHL cases(13). 
1. 2 Epstein Barr virus(EBV) 
The Epstein-Barr virus (EBV), also called human herpesvirus 4 (HHV-4), is a B 
lymphotropic y-herpes virus that establishes a lifelong infection in > 90% of the 
total population wor1dwide, usually without causing symptoms (14). EBV is an 
enveloped virus with a 172-kb double-stranded DNA genome. Two EBV strains 
have been described: EBV-1 and EBV-2 (15). These two Vdriants differ in the 
sequence of genes coding for the EBV nuclear antigens(EBNA-2 and.EBNA-3)  as 
well as in their efficiency to transform 8-cells in vitro. The EBV-2 strain is less 
efficient in transforming B cells than the EBV-1 strain ( 15 ). Epidemiological 
studies demonstrated that the preVdlence of theses two strains Vdries by 
geography. EBV-1 preVdils in Europe, America and Asia, while EBV-2 is 
predominant in Africa(16). The contribution of the different EBV strains to specific 
diseases is still not known, but it has been found that the virus Vdriant that 
preVdils in a certain geographic region is also predominant in the EBV-related 
diseases(17). 
The only known resen.oir for infectious EBV is in the oropharynx and EBV is 
transmitted by saliva. Besides being the causal agent of infectious 
mononucleosis (IM), EBV is directly implicated in the pathogenesis of several 
carcinomas and malignant lymphomas, including nasopharyngeal carcinoma 
(NPC), Burkitt lymphoma(BL), cHL and lymphoproliferative disorders(LPD) arising 
in immuno-compromised individuals(18, 19). EBV can establish a productive(lytic) 
infection within its host cells, but its lifelong persistence depends on a 
nonproductiw(latent)cycle, in which six EBV nuclear antigens(EBNA-1, -2, -3A, -
38, 3C and LP) and three membrane proteins (LMP-1, -2A and -28) can be 
detected(19). All EBV-associated malignancies in\Olve the virus's latent cycle, 
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although in most tumors some of the EBV latency associated genes are not 
expressed(18). Three different types of latency have been established. Type I 
latency is generally found in BL with a predominant expression of EBNA 1. Type II 
latency, as seen in NPC and cHL, is characterized by expression of EBNA1 and 
two membrane proteins(LMP-1 and -2A). In Type Ill latency, all latency genes are 
expressed. Besides the latency type specific genes, EBERs(EBER-1 and -2) and 
BARF0 are usually also expressed in all types of latency. 
LMP1 and LMP2a, the two membrane proteins exclusively expressed by the 
HRS cells of EBV + cHL are well known for their ability to rescue pre-apoptotic 
germinal center B-cells, by mimicking CD40 and BCR signaling pathways (20) 
thereby contributing to or causing cHL development. 
1. 2. 1 Immune control of EBV infection 
In healthy carriers, EBV infection is under the control of strong host immune 
surveillance. Only some indi\iiduals develop cancer in spite of the strong 
oncogenic potential of EBV(2 1). Moreover, the observation of a high frequency of 
EBV-associated cHL and other EBV associated 8-cell non-Hodgkin lymphomas 
in immunocompromised or immunodeficient indi\iiduals ( 22) suggests that a 
defective immunity results in an impaired EBV-specific immunosurveillance and 
permits tumor development. It has been well-established that cellular immune 
responses are mandatory for protective immunity against EBV infection, 
consisting mainly of Natural Killer(NK} cell mediated lysis and T cell adaptive 
immune responses (23, 24). Especially CDS+ cytotoxic T-cell responses are 
considered to be of central importance in both limiting the primary infection and 
controlling the numbers of latently infected B cells (24, 2 5). To initiate an EBV­
specific immune response, EBV-derived antigenic peptides need to be presented 
by HLA class I \iia the endogenous processing pathway(2 3). In addition, there is 
accumulating e\iidence that supports an essential role for HLA class II-restricted 
13 
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CD4+ T cell immune responses in the efficient eradication of EBV-infected cells 
(26, 27). 
1. 2. 2 Infectious mononucleosis 
Infectious mononucleosis(IM) was first described in 1920, but only until the late 
1960s EBV was identified as its cause(28). The epidemiological features of IM with 
regard to its incidence and age distribution are in line with that of EBV infection. In 
Western populations, IM predominantly occurs in adolescents and is one of the most 
common infectious diseases in this age group ( 28, 29 ). In contrast, in Oriental 
populations, IM is a rather rare disease and more often occurs in childhood(30, 31 ). The 
obsen.etion that IM and EBV+ cHL ha\e an o\erlap in age peak has led to a linkage 
hypothesis between these tVvO diseases. Indeed, an excess risk for EBV-associated 
cHL was found in people with a history of IM with a typical incubation period from 
IM to cHL of 4~ 5 years(32-34 ). 
1. 2. 3 Hodgkin lymphoma and associatioos with geography, 
age and subtypes 
The prevalence of EBV infection in cHL is known to be highly variable in different 
geographic regions and racial groups, ranging from 20% in western countries to 
nearly 100% in South-America. In Asia the percentage is around 60% (4, 5, 35, 
36). The fact that EBV can only be detected in a proportion of cHL cases 
suggests that another infectious agent or a different pathogenic pathway is 
im,olved in the development of EBV negative cHL cases. Thus, EBV-associated 
and non-associated cHL may represent two distinct etiological entities (37). In 
different racial groups a high incidence peak of non-EBV-associated cHL is 
always present in young adults. However there is marked heterogeneity in the 
prevalence of EBV-associated cHL with respect to patients' age, gender, race, 
and histological subtype(21, 38). In Western countries, a first incidence peak 
14 
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occurs in adolescence and in young adults(15~ 34 years) and a second peak in 
older adults(> <50 years). In contrast, in Oriental countries a first peak presents 
much earlier in childhood. A second incidence peak in the elderly is similar to 
western countries. A male predominance in the prevalence of cHL, especially in 
EBV-associated cases has been reported by numerous studies(4, 5). In addition, 
EBV-associated cHL has a strong association with the MC subtype. 
1. 3 Human Leukokocyte Antigen associations 
The genes encoding the human major histocompatibility antigen, also called 
human leukocyte antigen ( HLA ) encompass 7. 6 Mb of the short arm of 
chromosome 6 and can be subdivided into HLA-class I and class II genes. This 
region is the most gene dense locus in the human genome and some of its 
extremely polymorphic genes code for the antigen-binding groows of multiple 
HLA molecules. These highly polymorphic genes and codominant HLA 
expression result in a great variation in the repertoire of antigenic peptides that 
can be presented to the immune system. HLA class I is constitutiwly expressed 
on the membrane of all nucleated cells and presents proteasome degraded 
endogenous peptides of 8-11 amino acids in length to CDB+CTLs. In contrast, 
HLA class II has a restricted pattern of expression and can be detected on the 
surface of professional antigen-presenting cells(dendritic cells, macrophages, B 
cells), activated T cells and activated endothelium. The HLA class II molecule 
binds and presents antigenic peptides of 11-17 amino acids in length to CD4+ T 
cells via exogenous processing pathways. 
The potential role of immune-dysregulation in the pathogenesis of human 
cancers in concert with the vital importance of the HLA system in the regulation 
of host immune responses haw attracted special attention on HLA-based 
disease associations. Aberrant expression of classical and non-classical HLA 
class I and II molecules by tumor cells obsen.ed in a number of human 
15 
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malignancies indicates that downregulation or complete loss of HLA molecules is 
a mechanism for tumor cells to escape from host immune surveillance (39-42). 
Moreover, certain HLA alleles have been reported to be associated with disease 
susceptibility and resistance in more than 40 different diseases(41, 42). Certain 
HLA alleles were found to be the most significant genetically determined factor in 
predicting a high or low risk for several common autoimmune diseases, such as 
HLA-B27 and ankylosing spondylitis(AS), HLA-DR1 or HLA-DR4 and rheumatoid 
arthritis ( RA), HLA-DQ2 or HLA-DQB and celiac disease ( CD ) ( 43 ). With 
accumulating evidence supporting a role of host immunosurveillance in cancer 
de\elopment and progression, HLA and cancer associations attracted a lot of 
attention and have been investigated in different human malignancies. HLA­
DQB1*0301 and HLA-DRB1*04051 were reported to confer an increased risk for 
gastric adenocarcinoma in Caucasians and Japanese respectively(44, 45). HLA­
DQB1*0301 also was linked with genetic predisposition to melanoma in 
Caucasians ( 46 ). HLA-A*02 and HLA-A*11 were associated with genetic 
susceptibility or resistance to NPC in the Southern Chinese population. 
1. 3. 1 HLA antigen expression in HRS cells 
Expression of HLA class I and class II antigens by HRS cells in cHL have been 
investigated in the western population by several research groups ( 47-49 ). 
Downregulation or absence of membranous expression of HLA class I by HRS 
cells in cHL ranged from 30 to 40% of cases in different studies. Studies showed 
a positive correlation between HLA class I expression and EBV status in cHL. 
Downregulation or lack of HLA class II expression was observed in the HRS cells 
of 40~ 50% cHL. Diepstra et al(50) reported that HLA class II expression was 
closely correlated with positive EBV status. Although this association was not 
statistically significant in the study of Oudejans et al. , a trend to maintain the 
expression of HLA class II was observed in EBV+patients(49). Another interesting 
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finding was the negative association between HLA class II expression and 
response to first line therapy as well as relative sur..Aval in cHL reported by 
Diepstra et al(SO). 
1. 3. 2 HLA-linked genetic susceptibility in cHL patients 
CHL was one of the first diseases for which an association was observed with 
HLA serotypes and the first description dates back to 1967 (51 ). An important 
rationale for a particular interest in exploring HLA associations with cHL is its 
well-documented infectious etiology. As mentioned earlier, the immune control of 
EBV infection mainly depends on HLA-restricted T-cell responses. Moreover, it is 
well-known that different HLA alleles possess different abilities to bind and 
present EBV-derived antigenic peptides to effector cells. This indicates that the 
specificity of HLA alleles is an important determinant for the effectiveness of 
controlling EBV infection. Thus, certain HLA alleles may predispose to the 
development of EBV-related diseases. 
An extensive literature search on the relationship between HLA and cHL 
susceptibility reveals that specific HLA serotypes and alleles can confer a 
decreased or increased risk for both familial and sporadic cHL in Caucasians(52-
54). In a genetic screening approach using polymorphic microsatellite markers, 
two markers located in the HLA class I region were reported to be associated 
with EBV-positive cHL in a Dutch population ( 54 ). Subsequent studies 
demonstrated that two specific HLA-A alleles, HLA-A*01 and A*02 are 
associated with an increased and decreased risk for EBV-associated cHL 
respectively in a Dutch and Scottish population (55). Moreowr, recent studies 
also proposed that individuals carrying the HLA-A * 01 allele have an increased 
risk to dewlap IM(56), further substantiating the etiological linkage(EBV infection) 




Classical HL is a distinct malignancy of the lymphoid system with an unusual 
and complex morphology, epidemiology and etiology. It's evident that the HRS 
cells employ multiple strategies to escape from host immune surveillance and 
the quality of antigen presentation in the context of HLA might be a crucial 
pathogenic factor. Accordingly, multiple HLA associations with cHL have been 
reported. Moreowr, associations specifically with EBV associated cHL 
strengthen the importance of HLA in cHL. The potential effect of HLA alleles on 
the outcome of EBV infection suggests a HLA-linked genetic susceptibility to 
EBV-associated cancers. Furthermore, because of the highly polymorphic nature 
of the HLA system and its ethnic linkage, the HLA associations may explain the 
epidemiological heterogeneity of this disease. In addition, it might also pro�de an 
opportunity for the generation of �rus-specific HLA-restricted T-cells to be used 
in immunotherapeutic approaches. 
1. 4 The scope of this thesis 
This thesis focuses on the comparison between cHL patients with a different 
ethnic background for the association of EBV, HLA antigen expression as well as 
HLA-based immunogenetics. A description on epidemiological features of 371 
cHL patients from Northern China diagnosed during 1997 - 2008 is giwn in 
chapter 2. In chapter 3, for the first time, the expression of HLA antigens by HRS 
cells in association with EBV status is shown in a group of Chinese cHL patients. 
Since the highly prevalent HLA-A * 02 allele was found to be protective against 
EBV+ cHL in a Dutch population, we next studied the significance of this allele 
in Chinese cHL patients in chapter 4. In chapter 5, a comprehensive screening of 
all classical HLA alleles was carried out using DNA samples from 338 Dutch cHL 
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Abstract 
Background: The incidence of classical Hodgkin lymphoma ( cHL ) and its 
association with Epstein-Barr virus ( EBV ) varies significantly with age, sex, 
ethnicity and geographic location. This is the first report on epidemiological 
features of cHL patients from Northern China. These features are compared to 
data from a previously published Dutch cHL population. 
Methodology/ Principal Findings: 371 cHL patients diagnosed between 1997 and 
2008 in the North of China were included. EBV status was determined by 
immunohistochemistry for latent membrane protein 1 and/or in situ hybridization 
of EBV- encoded small RNAs. The Dutch population-based cohort included 515 
cHL patients diagnosed between 1987 and 2000. In the Chinese population, tumor 
cells of 41% of the cHL patients were EBV+and this was significantly associated 
with male sex, mixed cellularity subtype and young age(< 20y). Median age of 
Chinese patients was 10 years younger than that of Dutch patients(27y vs 37y). 
In addition, the age distribution between the two populations was strikingly 
different in both the EBV+subgroups(p= 1. 8x1O8 ) and the EBV- subgroups(p= 1. 
8x10-4 ). Chinese patients had a higher male-to-female ratio than Dutch patients(2. 
1 vs 1. 4 in all patients and 3. 3 vs 1. 9 in the EBV+subgroup). 
Conclusion/Significance: CHL patients from Northern China show a distincti\e 
age distribution pattern with a striking incidence peak among children and young 
adults. In comparison to Dutch cHL patients there are pronounced differences in 
age distribution, sex, subtype and EBV status, presumably caused by complex 
gene-environmental interactions. 
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Introduction 
Classical Hodgkin lymphoma ( cHL) is a heterogeneous malignancy with a 
complex etiology and epidemiology. In general, cHL accounts for about 1 %  of all 
cancers and~ 30% of the lymphoid malignancies worldwide ( 1 ). Epidemiologic 
studies of cHL demonstrate a remarkable di\ersity of the incidence according to 
age, sex, ethnic background, geographic location and socioeconomic status (2, 
3). The highest incidence was reported among Caucasians, followed by African 
Americans and Hispanics, and the lowest incidence was found in Orientals (3). 
Data from the International Agency for Research on Cancer (http://globocan. iarc. 
fr/) shows a nearly 6-fold difference between Western Europe and East Asia with 
an incidence of 2. 3 and 0. 4 per 100, 000 inhabitants per year respecti\ely in 
2008. A genetic explanation for this difference has been shown in a multi-ethnic 
study of cHL in the United States that reported the lowest incidence rate in Asian 
immigrants in comparison to other ethnic origins ( 4 ). Howe\er, a trend of 
increasing incidence of HL was reported among Chinese immigrants in western 
countries(4, 5), suggesting an influence of westernization. The incidence pattern 
by age was also shown to be different between Caucasian and Oriental 
populations(6, 7). Western populations typically haw a bimodal age distribution 
with two peaks near 25 and 60ys. In Orientals, a first incidence peak usually 
presents in childhood with a second peak in the elderly, although in Japanese 
cHL patients the early incidence peak was reported to be absent(4, 8). 
In a proportion of cHL patients, Epstein-Barr \1rus (EBV) is present in the 
tumor cells and EBV is accepted as a causal agent in these patients(?, 9). There 
is a striking variability in the percentage of EBV im,olwd cases between racial 
groups and geographic locations (2, 10). The proportion of EBV in\Olwment is 
almost 100% in Hispanic cHL patients(1 1), much lower in Caucasians(20~ 40%) 
(2, 12) and intermediate in Orientals(13, 14). In general, the EBV association with 
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cHL is related to age, being the strongest in children and the elderly(15 , 16). In 
addition, male sex and the mixed cellularity ( MC )  histological subtype are 
associated with EBV+cHL worldwide(15 , 17). 
The current study was undertaken to in\€stigate the epidemiological 
characteristics of cHL patients from Northern China. In addition, these 
characteristics were compared to data from a previously reported Dutch cHL 
patient population(18). 
Materials and Methods 
Patient selection and data collection 
371 cHL patients, of whom sex, age, histological subtype and EBV status were 
known, were included in this study(19). These patients resided in the Northern 
area of China and were diagnosed with cHL during the period of 1997 to 2008 at 
the Dept. of Pathology, Health Science Center, Peking University. 198 of these 
cHL patients were diagnosed and treated in the affiliated hospitals of Peking 
University. The other 173 patients were submitted for consultation to confirm the 
diagnosis and were mainly from other hospitals in Beijing City and the hospitals 
of its neighboring city or provinces including Tianjin City, Hebei Province, Shanxi 
Province and Jilin Province. For all patients we retrieved the original data 
including patients' sex , age, histological subtype and tumor cell EBV status at 
the time of diagnosis from the pathology database. Ethical approval for this study 
was not required by these institutions as the experiments carried out did not 
�elate to patients privacy or treatment. Research was conducted adhering to the 
Declaration of Helsinki and according to Dutch regulations (http://www. federa. 
org/). The institutional review board ( the Medical Ethics Review Board of the 
University Medical Center Groningen) specifically waived the need for ethics 
approval. 
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Histopathological reclassification 
Haematoxylin and eosin-stained slides from 157 formalin fixed paraffin embedded 
tissue blocks were available for histological reclassification according to the most 
recent WHO classification system ( 1 ) which categorizes cHL into four 
histological subgroups, i. e. nodular sclerosis (NS ), mixed cellularity ( MC ), 
lymphocyte rich(LR) and lymphocyte depletion(LD). Cases without enough tissue 
for proper evaluation of the background architecture were designated as cHL not 
otherwise specified(NOS). 
EBV status 
For 246 cases latent membrane protein 1 (LMP1) staining was performed by 
immunohistochemistry ( IHC) in a routine diagnostic setting to determine the 
presence of EBV using the CS1-4 antibody(DAKO, Glostrup, Denmark). For 236 
cHL cases, presence of EBV in tumor cells was determined by EBER in situ 
hybridization(ISH) with a fluorescein-conjugated PNA probe specific for the EBV­
encoded EBER RNAs ( DAKO, Glostrup, Denmark) using standard laboratory 
protocols. Appropriate positive and negative controls were included in all 
analysis. 
Statistical analysis 
Differences between EBV + and EBV-groups in relation to age, sex and 
histopathological subtype were assessed by Chi square test, Fisher's exact test 
or Mann Whitney U test. The data were analyzed with SPSS for Windows, 




Detection of E BV 
IHC for LMP1 was performed in 246 patients and was positiw in 32% . ISH for 
EBERs was carried out in 236 cHL patients and rewaled presence of EBV in 
44% . For 111 cases EBV status was determined with both methods and the 
concordance rate was 87 .  4% {Table 1 ). In the 14 discrepant cases, 12 were 
negatiw for LMP1 and positiw for EBER and 2 were negative for EBERs and 
positiw for LMP1. Since EBER ISH has been widely accepted as· the golden 
standard for detection of EBV latent infection, we used the results of the EBER 
ISH for these 14 cases. Taking the results of the EBER ISH(n=236) together with 
those of the cases that were analyzed only by LMP1 staining(n= 135) rewaled 
EBV positivity in 41% (n=152) of patients. 













32(28. 8% +) 
79 
1 1 1  
157 cHL cases were re-evaluated for histological classification of the subtype. 
The histological subtype could not be unequi\Ocally determined in 29(18%) cases 
and was designated cHL-NOS. Six and 9 of these cases were previously 
classified as LR and MC subtype respectiwly. Discrepancies in the classification 
were obserwd in 5 out of 13 LR cases and 6 out of 57 MC cases which were 
reclassified as MC and NS subtype respectively. All original NS diagnoses were 
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reclassified as NS subtype. A consistent classification was achie\ed for 117 of 
128(91. 4%} cHL cases. 
In the total Chinese patient population, NS was the most common subtype, 
accounting for 48% of cases(n= 161 }, followed by MC with 39% (n= 130}, LR with 
12% (n=40} and LD with 0. 3% (n= 1) of cases(Table 2). 
Distribution of age, sex and histological subtypes 
The male to female ratio was 2. 1: 1 in the total group, 3. 3: 1 in the EBV + group 
and 1.6mm: 1 in the EBV- group (p = O. 001}. The MC subtype (63%} was more 
common in EBV+cHL patients and the NS subtype(69% ) was more common in 
the EBV- group(p=1. 9x10-20). The median age of cHL patients in the EBV+group 
was similar to that of the EBV- cHL patient group (27 years, range:3-76ys and 27 
years, range:6-75ys respecti\ely)(Table 2). Howe\er, comparison of the 10 years 
age group distribution between EBV + and EBV- patients did show a highly 
statistically significant difference (p  = 2. 6x10-12 ) (Figure 2 ). Patients in the age 
groups from O to 20 and from 70 to 80 years of age were significantly more often 
EBV+, while patients aged 20 to 30 were significantly more often EBV-. 
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Comparison betvveen Chinese and Dutch cHL patients 
The median age of Chinese patients(27ys, range: 3-76ys} was 10 years younger 
than that of the Dutch population(37ys, range: 8--94ys }(p= 1. 3 X 10-1 1  } and the age 
distribution in 10-year intef'Vclls was significantly different(p=1. 3 X  10 -11)(Figure 1, 
Table 3 }. Similar to the Chinese patients, stratification by EBV status showed 
significant differences in median age bet'Neen EBV+(43 years, range: 8--94} and EBV­
(33 years, range: 9-90) Dutch cHL patients (p = 2. 4 X 105 ). Comparison of the 
EBV+Chinese patient group with the EBV + Dutch patient group showed a striking 
difference in the age distribution (p= 1. 8 X 108 ) (Figure '2A, Table 3). Also the age 
distribution of the EBV- Chinese patients was significantly different from the EBV­
Dutch patients(p=1. 8 X 104 XFigure 2B, Table 3). 35%�----------------------, 30% 25% 
,;> 20% 
5 &;! 15% 
10% 5% � -�-...__,__ ....,_ P=l .3xlff1 1  -- -Dutch -Chinese �--�"­
"'­-� 0% +---.----.-----r----r----,--..---....-----'='--r----.--'----1 
0~10 1 1~20 21~30 31~40 41~50 51~60 61~70 71~80 81~90 91~100 Age group(! Oys) 
Figure 1 Age distribution of Dutch and Chinese cHL patients in consecutiw 10-year inten.els. 
Age distribution is shown for 371 patients from Northern China{black) and 515 patients from the 
Northern part of the Netherlands (grey ). A significant difference was obser\ed in the age 
distribution between these two patients groups (p = 1 .  3 X 10"11  ). These two cunes exhibit a 
somewhat similar trend with apparent differences at the first and sixth decades between the 
Chinese and the Dutch population {9% w 1% and 7% w 12% respectiwly). The Chinese 
population has more patients among the first three decades as compared to the Dutch 
population, both ha"1ng the highest peak in the third decade. The Chinese population does not 
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Figure 2 Age distribution of Dutch and Chinese cHL patients stratified by EBV status. A 
represents the comparison of the age distribution in the two EBV+cHL subpopulations. Olinese 
EBV+cHL patients(black) exhibited a prominent single peak in the first and second decade with a 
maximum percentage of 24% . In contrast, Dutch EBV+cHL patients(grey) demonstrated a clear 
bimodal age distribution pattern with t'M> peaks occurring in the third and se\enth decade respecth.ely 
with a similar incidence for both peaks (17% and 18% ). B shows the age distribution curve of the 
EBV- cHL patients. There is a single incidence peak in the third decade for both populations, 
which is more pronounced in the Chinese population(38% w 27% ). 
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Median Range Median Range 
All patients 371 27 3-76 515 37 8-94 1 .  3x 1011 
EBV- 219 27 6-75 334 34 9-90 1 .  ax 1 04 
EBV+ 152 27 3-76 181 43 8-94 1 .  8X 108 
A significant difference in the sex distribution between Dutch and Chinese 
populations was found in the total cHL patient group with a male to female ratio of 
2. 1: 1 in the Chinese and 1. 4: 1 in the Dutch population(p=0. 0036). This difference 
was more pronounced in the EBV + group where males were owrrepresented in 
the Chinese as compared to the Dutch population (3. 3: 1 vs 1. 8: 1 )(p = 0. 016), 
whereas in the EBV- group there was no significant difference. The differences in 
the male to female ratio in the Dutch population were less pronounced(1. 4: 1 in 
the total, 1. 2: 1 in the EBV- and 1. 8: 1 in the EBV + group) as compared to the 
Chinese population(Table 4). 
Table 4 Diffe1'811ces in sax distribution in Chinese and Dutch EBV positiw and negati\e patients 
Chinese Dutch 
P-wlue 
Male Female ratio male Female Ratio 
All patients 250 121 2. 1 : 1 297 218 1 .  4 :  1 0. 0036 
EBV+ 1 17 35 3. 3 :  1 1 18 64 1 .  8 :  1 0. 016 
EBV- 133 88 1. 5 :  1 180 154 1 .  2 :  1 NS 
T o  rule out a possible bias in the Chinese cHL population caused by 
determining the EBV status only by LMP1 staining, we also compared the 
distribution of age and sex in the Dutch population with that of the 236 Chinese 
patients analyzed by EBER-IS H. The results of this comparison were comparable 
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to those of the total Chinese patient group(data not shown). 
Discussion 
Epidemiological studies on cHL haw shown significant variation in age and 
EBV distribution in relation to ethnic background and geographic location. Asians 
are known to haw the lowest incidence of cHL and an intermediate proportion of 
EBV-associated cHL(3). Previously, a few studies reported on cHL epidemiology 
in Taiwan and Hong Kong, populations that are closely related to the Southern 
Chinese population (13, 20-22). Importantly, the Northern Chinese population is 
genetically different from the Southern Chinese population, especially in the 
distribution of Human Leukocyte Antigen(HLA) types. Undifferentiated nasopharyngeal 
carcinoma ( UNPC ), another EBV-associated malignancy with a latent EBV 
expression pattern similar to EBV+cHL, is endemic in Southern China but not in 
Northern China. Previous studies proposed that the geographic-restricted 
distribution of the UNPC susceptibility allele HLA-A*02:07 might well explain the 
high incidence of UNPC in the Southern Chinese population. Thus, differences in 
cHL incidence and epidemiology might also be expected in different Chinese 
regions. The main aim of this study was to analyze the epidemiology of cHL in 
the Northern part of China, a population that has not been studied before. 
Previous studies found that cHL was EBV+at a frequency of 65% (n=23) and 
61% (n=28) by EBER-ISH and 63% (n=70) by combining the results of LMP1 IHC 
and EBER ISH in cHL patients from Hong Kong, China and Taiwan respectiwly 
(13, 14, 21 ). These frequencies are higher than the 41% of EBV positivity 
identified in the present patient group. Howewr, the patient cohort size in the 
current study(n=37 1) was much larger than these previous studies. The difference 
in EBV positivity was only marginally influenced by determination of EBV status 
by LMP1 IHC in a subset of patients. EBER ISH only slightly increased the 
percentage of EBV positivity from 41 % to 44% . Besides the population size, 
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differences in EBV prevalence might also be influenced by intra-ethnic 
en\Aronmental and genetic variations. Consistent with pre\Aous findings in 
Chinese and other ethnic groups of cHL patients, the incidence of EBV+cHL was 
significantly higher in males and the MC subtype(2}. 
A shift in the histological classification upon histopathological re­
examination was obserwd in 8. 6% (n = 11 } of the cases, partly explained by 
changes in the WHO classification guidelines. Agreement was specifically poor 
for the LR and MC subtypes. Due to the lack of enough tissue for evaluating the 
background architecture, 15 cases pre\Aously diagnosed as LR or MC subtype 
were re-assigned as cHL-NOS. O\erall, the histological distribution was similar to 
those reported in pre\Aous Chinese populations from Hong Kong and Taiwan(13, 
23). 
Until now, there are four studies that inwstigated the age distribution of cHL 
in the Chinese population (13, 20-22}. Three studies, including two from Hong 
Kong(n=23 and n=92)(13, 20) and another one from Taiwan(n=70)(21 ), identified a 
bimodal age distribution with two peaks at the second and sixth decades 
respecth,ely, whereas another study from Taiwan(n= 42}(22) found a single age 
peak at the 3rd decade. Only consistent with this last study, we also found a 
unimodal age distribution with a distinctiw peak incidence occurring at the 3rd 
decade. Only two of the four studies (Hong Kong and Taiwan) included EBV 
status into the analyses(13, 21 }. Our results were consistent with these studies 
for EBV- cHL patients with a single incidence peak in young-adults. Howewr, our 
EBV+cHL patients did not show an incidence peak in the elderly, in contrast to 
both other studies. 
Comparison of the Chinese and Dutch cHL populations rewaled an inter­
ethnic significant difference in the age distribution in the total patient groups and 
also in the EBV+and EBV- subgroups separately. A bimodal pattern for the age 
distribution of cHL in general as well as in the EBV + subgroup is considered 
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typical for the Western population and this was also present in our Dutch cohort. 
It has been reported that in the Asian cHL population, an early peak should be 
less ob'Aous and at a younger age compared to the Western population, whereas 
a second peak at older age should be similar (4, 8). Intriguingly, our Chinese 
population had an e\1dent early peak similar to the Dutch population but lacked 
the peak at older age. It is unlikely that this could be the result of an age 
dependent selection bias in the Chinese population. 
According to the literature, EBV+Asian cHL shows a similar age distribution 
as EBV- Asian cHL. Howe'ver, in the present study EBV+cHL had a different and 
pronounced incidence peak at adolescence. In both the Chinese and the Dutch 
populations a clear peak for the EBV- patients was obser'ved at the 3rd decade. 
Remarkably, this peak was higher in the Chinese population than in the Dutch 
population(38% vs 27% ). 
An inter-ethnic difference was also obseMd for the sex distribution of all 
patients and of the EBV+cHL patients. In general, the Chinese population had a 
higher male-to-female ratio than the Dutch population (2. 1 vs 1. 4) and this 
difference was elven more prominent in EBV + cHL patients (3. 3 vs 1. 9) and 
\1rtually absent in EBV- cHL patients(1. 5 vs 1. 2). 
In conclusion, we demonstrate a distincti've age distribution pattern in by far 
the largest reported group of Northern Chinese cHL patients with a striking 
incidence peak among young adults. Moreo'ver, we identified large inter-ethnic 
differences in the distribution of age, sex, EBV status and histological subtype in 
comparison to a Caucasian population. Both genetic and en\1ronmental factors 
are expected to play a role in these differences. 
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Abstract 
Background: In Caucasian populations, the tumor cells of Epstein Barr �rus 
(EBV }-positi-ve classical Hodgkin Lymphomas ( cHL ) patients more frequently 
express HLA class I and HLA class II molecules compared to EBV-negati-ve cHL 
patients. HLA expression(in relation to EBV) in Asian cHL patients has not been 
pre�ously inwstigated. 
Methodology/Principal Findings : We randomly selected 145 cHL patients with 
formalin-fixed, paraffin embedded tissue blocks available from 5 hospitals from 
the Northern part of China. Hematoxylin & Eosin-stained slides were used to 
reclassify the histological subtypes according to the WHO classification. EBV 
status was determined by �sualization of EBERs in tumor cells using in situ 
hybridization. Membranous expression of HLA molecules was detected by 
immunohistochemistry using antibodies HC-10(class I heavy chain) and anti- 2-
microglobulin for HLA class I, and CR3/43 for HLA class II. EBV+ tumor cells were 
obserwd in 40% (58/145) of the cHL patients. As expected, the percentage of 
EBV+ cases was much higher in the mixed cellularity subtype(71% ) than in the 
nodular sclerosis subtype ( 1 6% )  ( p  < 0. 001 ). Expression of HLA class I was 
obserwd in 79% of the EBV + cHL cases and in 30% of the EBV- cases(p <0. 
001). For HLA class 1 1 ,  52% of EBV+ cHL cases were positi-ve, compared to 43% 
in EBV- cases(p=0. 28). 
Conclusions :The results in the Northern China population were similar to those in 
the Caucasian population for HLA class I, but not for HLA class II. 
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Introduction 
Classical Hodgkin lymphoma ( cHL } is a malignant neoplasm of the immune 
system, characterized by a minority of B cell deriwd tumor cells, named Hodgkin 
Reed-Sternberg cells ( HRS cells } and numerous reactiw cells consisting of 
lymphocytes, histiocytes, eosinophils, and plasma cells. The HRS cells are large, 
sometimes bi- or multinucleated cells vvith prominent nucleoli and a characteristic 
CD20 negati\e to weakly positi\e, CD30 + and CD15 + /- immunophenotype ( 1 ). The 
presence of HRS cells in an abundant inflammatory infiltrate indicates that anti­
tumor immune responses apparently are insufficient for the eradication of HRS 
cells. It has been shown that the tumor cells of cHL employ sewral mechanisms 
to escape from immune responses, ewn more so in Epstein Barr virus ( EBV) 
associated cases (2-4 ). EBV has been acknowledged as the major infectious 
agent causing cHL, although the proportion of EBV associated cHL varies from 
20% to nearly 100% in different populations (3, 5). In addition, the proportion of 
EBV+ cases is also age-dependent with a first high incidence peak in children 
and a second peak in adults around age 60 (3, 5). EBV-infected HRS cells 
consistently express a limited set of proteins, consisting of latent membrane 
protein 1 (LMP1 ). latent membrane protein 2(LMP2} and EBV nuclear antigen 1 
(EBNA 1 } ( 5 ). Antigenic peptides deriwd from these three proteins can be 
processed and presented by the human leukocyte antigen(HLA} class I and class 
II pathways, the efficiency of which largely depends on the peptide binding affinity 
of the highly polymorphic HLA alleles (6-9}. Cytotoxic T lymphocytes {CTLs) are 
known to be the primary effector cells to eradicate EBV-infected B cells that 
present LMP1 and LMP2 antigenic peptides in the context of appropriate HLA 
class I molecules(6, 7). In addition, there's in "1tro evidence that EBV infection 
and the related malignant transformation are controlled by CD4 + T cells, 
depending on HLA class II restricted antigen presentation (10}. In other words, 
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both HLA class I-restricted CTL responses and HLA class II-restricted CD4 + T­
cell responses are essential for a successful anti-tumor immune defense. 
Therefore, downregulation of HLA class I and HLA class II antigens might be 
implicated in the pathogenesis of cHL by allowing tumor cells to escape host 
immunosurveillance. 
Sewral research groups haw studied the association between HLA 
expression and cHL in the Western population(11-16), but nothing is known for 
the Asian population. Since HLA types are known to widely differ between 
Caucasians and Asians, we set out to inwstigate the expression of HLA 
molecules in Chinese cHL cases for drawing comparison between the two 
populations. We studied HLA class I as well as HLA class II expression in 
relation to EBV status in a population from the Northern part of China. 
Materials and Methods 
Patient material 
Formalin-fixed paraffin-embedded tissue blocks of lymph node biopsies from 145 
cHL patients were obtained from 5 hospitals in northern China(Dept. of Pathology, 
Health Science Center, Peking Uniwrsity; Dept. of Pathology, First Hospital of 
Jilin Uniwrsity; Dept. of Pathology, Shougang Hospital, Peking Uni\ersity; Dept. 
of Pathology, Beijing Air Army General Hospital; Zhanye Regional Hospital, 
Gansu Pro\tince). The biopsies were stained with hematoxylin & eosin(H&E) and 
histopathological subtyping was performed according to the WHO classification. 
In situ hybridization 
Detection of EBV in tumor cells was performed by in situ hybridization(ISH) on 
paraffin sections with a fluorescein-conjugated PNA probe specific for the EBV­
encoded EBER RNAs(DAKO, Glostrup, Denmark). A known EBV+tissue section 
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was used as a positive control. 
lmmunohistochemical staining 
4- m thick paraffin sections were deparaffinized by xylene and rehydrated through 
a graded ethanol series into water. Microwave antigen retrieVal was performed 
with Tris-EDTA solution (10mM Tris Base, 1mM EDTA Solution, PH 9. 0) and 
endogenous peroxidase activity was blocked in 3% H2O2. The expression of HLA 
class I was detected using monoclonal antibody HC-10 at a dilution of 1: 200 
(kindly provided by Prof. dr. J. Neefjes, the Netherlands Cancer Institute, 
Amsterdam}, which recognizes HLA B and C molecules, as wel l  as a few HLA-A 
molecules ( 17). In addition, the polyclonal rabbit anti human 2-microglobulin 
(DAKO} at a dilution of 1: 200 was used as an additional marker to detect HLA 
class I. For detection of HLA class 11, we used the CR3/43 monoclonal antibody 
(DAKO} that binds to a specific monomorphic epitope in the � chain of HLA-DP, 
HLA-DQ and HLA-DR. All antibodies were detected using a standard Avidin Biotin 
Complex(ABC} immunoperoxidase method. Diaminobenzidine was used as the 
chromogen and hematoxylin was used for counterstaining. 
Evaluation of HLA class I and class II staining 
HLA class I heavy chain (HC-10} staining was scored simultaneously with 2-
microglobulin staining. The same scoring rules were used for HLA class II. The 
surrounding inflammatory cells were used as an internal positive control and also 
as a reference for assessing the intensity of HLA expression by HRS cells. A 
strong membranous staining on at least 50% of the tumor cells was identified as 
positive. In case the staining intensity on the tumor cells was similar to the 
intensity on the surrounding · reactive cells, membranes in between adjacent 




HLA expression was determined in relation to EBV status. Differences between 
EBV + and EBV-neg groups in relation to HLA expression as well as sewral 
clinicopathologic variables were assessed by Chi square test, Fisher's exact test 
or Mann Whitney U test. The correlation between HLA class I and class II 
expression was evaluated with Chi square test. In addition, multivariate analysis 
using logistic regression was performed to adjust for confounders. The data were 




145 patients diagnosed with cHL were subdi�ded into histological subtypes 
according to the WHO classification. Subtype could not be unequi\Ocally 
determined in 18% ( n = 26 ), usually because there was not enough tissue to 
properly evaluate the background architecture. These patients were classified as 
cHL, not otherwise specified ( NOS ). In the remaining patients the nodular 
sclerosis(NS) subtype was the most common one, accounting for 63% (n= 75) of 
patients, followed by mixed cellularity (MC) with 35% (n = 42) of patients. The 
lymphocyte rich(LR) subtype was rare(n=2) and the lymphocyte depleted subtype 
was absent. The median age of the patients at the time of diagnosis was 28 
years, ranging from 4 to 74 years. There was a clear male predominance with a 
male to female ratio of 2: 1. 
EBV status and clinicopathologic variables 
EBER staining showed consistent nuclear labeling in all HRS cells in 40% of the 
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pat ients(n=58)(see figure 1 ). A low number of pos iti\€ small bystander cells were 
obseMd i n  some cases . 
Subtype and sex demonstrated stat ist ically s ignificant d ifferences between 
EBV+ and EBV-neg cases . As expected , the MC subtype showed the h ighest 
percentage of EBV + cases ( 30 of 42 cases [ 71 % ]). In addition, males more 
frequently had EBV + cHL than females ( 48% compared to 24% ). In terms of 
pat ients' age, no s ign ificant difference was found between EBV-associated and 
non-EBV-associated cHL(Table 1 ). 
Table 1 Distribution of age, sex and histology by EBV status 
All patients EBV-Positiw EBV-Negatiw 
n=145 n=58 n=87 
median age (range) 28(4- 74) 31 (4-74) 28(8-74) 0. 55t 
Sex 
Male 66. 2% {n=96) 79. 3% {n=46) 57. 5% {n=50) 0. 006' 
Female 33. 7% (n=49) 20. 7% (n=12) 42. 5% (n=37) 
Histological subtype 
NS 51 .  7% {n=75) 20. 7% (n=12) 72. 4% (n=63) <0. 001 t 
MC 29. 0% (n=42) 51 . 7% (n=30) 13. 8% (n=12) 
LR 1 .  4% (n=2) 3. 4% (n=2) 0% (n=0) 
NOS 17.  9% (n=26) 24. 2% (n=14) 13. 8% {n=12) 
:t Mann Whitney U test, · Chi square test, t Fisher 's exact test, NS indicates nodular sclerosis; 
MC, mixed cellularity; LR, lymphocyte rich; NOS, not otherwise specified 
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Fig 1 .h sftu hybrldlzalfon{,SH) b' EBER& Jn 
811 ESVilHL case. The EBER-ISH 18\ealed a 
homogeneous posili\E! signal in the nucleus of 
all Hodgkin a'ld Reed--Stemberg(HRS) cells as 
well as in some s mall reactM cells (ori�nal 
magnification ;( 40). 
Fig 2 lmmunolutochaml datectlon d 1-una, Leukocyte Anlgen (I-I.A) axpr988ICl'l on 
formalln-lxad parallrHlfflbeddad Ussue sections c:I claaalcal Hodgkin lymsmma(ctl.� (A)HLA 
class l(using the HC-10 antibody) expression in cHL. All cells show immunoreacti\ffy on the 
membrane. Hodgkin and Reed Stemberg(HRS) cells stand out with their stronger signal(arrow) 
(original magnification x40). (B)HLA class II (CR3/43) expression in cHL. Most HRS cells are 
positiw(arrow), surrounded by negatiw inflammatory cells(original magnification X 40). 
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HLA class I and HLA class II expression 
Expression of HLA class I hea� chains was consistent with that of 
2-microglobulin and the rate of positivity was 50% (n= 72). In most patients with 
HLA class I positive tumor cells, the HRS cells showed a higher staining intensity 
than the reactive background cells, especially in EBV+cases(see figure 2A). For 
HLA class II expression by tumor cells, 46% of patients (n = 67) were positive. 
Usually, the HRS cel ls were surrounded by HLA class II negative reactive cells 
(see figure 28 ). 
In 26% of patients(n=38) there was co-expression of HLA class I and class 11, 
whereas in 30% of patients(n=44) the tumor cells were double negative. Although 
there was a trend for HLA class I negative cases to also be HLA class II negative, 
and vice versa, this correlation was not statistically significant(Table 2). 
Correlation between expression of HLA, EBV status and 
clinicopathologic variables 
The results of HLA class I and HLA class II expression in relation to EBV status, 
the different histological subtypes, sex and age are summarized in Table 3. 
Expression of HLA class I was significantly more frequent in EBV+ than in EBV­
neg cases ( P<0. 001 ). Histological subtypes correlated with HLA class I 
expression, with the highest frequency of positive expression in the MC subtype 
(32/42=76% ) and the lowest in the NS subtype(22/75= 29. 3% )(P<0. 001 ). Using 
multiVdriate logistic regression analysis a significant effect of EBV status on HLA 
class I expression was observed after adjusting for histological subtype 
(P<0. 001). Howewr subtype did not remain significant when correcting for EBV 
status implying that EBV status explained the observed association between 
histological subtype and HLA class I expression. In contrast, HLA class II 
expression was not associated with EBV or subtype. Neither HLA class I nor 
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HLA class II expression was found to correlate with patients' age. In addition, our 
data showed that Chinese female cHL patients more frequently maintained 
expression of HLA class ll(P=O. 01 ), but not expression of HLA class I. 
Comparison betvveen Chinese and Dutch cHL patients 
The data from the current Chinese population were compared with data from a 
population based study in the Netherlands, performed by our group(12). EBV 
positivity and MC subtype were more common in Chinese cHL patients than in 
Dutch cHL patients ( 40% vs. 33% and 29% vs. 11% , respectiwly). In the 
Chinese cHL patients, the proportion of children was higher(age<18:22. 8% vs. 9. 
2% ). while that of the elderly was lower (age> 60: 9. 0% vs. 15. 8% ). A similar 
association of HLA class I expression with EBV status was obserwd in both 
populations. Howewr, expression of HLA class II highly correlated with HLA 
class I in the Dutch population, which was not the case in Chinese patients. Loss 
of HLA class II expression by HRS cells was more common in Chinese compared 
to Dutch patients(54% vs. 41% ). This difference was independent of sex, EBV 
status and histological subtype, shown using a multivariate logistic regression 
model (P=O. 012). Table 4 shows that in Dutch patients the expression of HLA 
class II was strongly associated with EBV positivity (P = 0. 005). Also, the NS 
subtype was more frequently deficient in HLA class II expression than the MC 
subtype (P=O. 016). Neither of these associations was obserwd in the Chinese 
cHL patients. Howe\er, only in the Chinese cHL patients an association between 
sex and HLA class II expression was obserwd (P=O. 0 1  ). 
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Table 2 Correlation between HLA class I and class II expression 
HLA class I p+ 
Positiwn=72 Negatiwn=73 
HLA class II 
Positiw(n=67) 52. 3% (n=38) 39. 7% (n=29) 0. 115 
Negatiw(n=78) 47. 1°/o(n=34) 60. 3% (n=44) 
+ Chi square test 
Table 3 HLA class I and class II expression by HRS cells in relation to EBV status, histology, 
sex and median age 
HLA class I HLA class II 
Posith,e Negatiw P* Positiw Negatiw P* 
n=72 n=73 n=67 n=78 
EBV 
Pos. 64% (n=46) 16%(n=12) < 0. 001 45% (n=30) 36% (n=28) o. 277 
Neg. 36% (n=26) 84%(n=61) 55% (n=37) 64%(n=50) 
Histology 
NS 31% (n=22) 72%(n=53) < 0. 001* 51% (n=34) 53% (n=41) 0. 955* 
MC 44% (n=32) 14%(n=10) 27% (n=18) 31% (n=24) 
LR 3%(n=2) 0% (n=O) 1% (n=1) 1%(n=1) 
NOS 22% (n=16) 14%(n=10) 21% (n=14) 15% (n=12) 
Sex 
Male 67% (n=48) 66%(n=48) o. 907 55% (n=37) 75% (n=59) o. 01 
Female 33 % (n=24) 34%(n=25) 45% (n=30) 25% (n=19) 
median age 
(range) 
33(4-74) 26(6-61) 0. 246 28(4-74) 28(4-74) 0. 666t 
+ Chi square test, · Fisher's exact test, NOS histology not included, + Mann Whitney U test, NS indicates 
nodular sclerosis; MC, mixed cellularity; LR, lymphocyte rich; NOS, not otherwise specified. 
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Table 4 Comparison of the association of HLA class II expression with EBV status and 
histological subtypes between Dutch* and Chinese cHL patients 
Dutch patients· Chinese patients 
HLA class I I  P* HLA class I I  P* 
Positive Negative Positive Negative 
(n=171) (n=121) (n=67) (n=78) 
EBV 
39. 8% 24. 0% 44. 8% 35. 9% 
Positive 0. 005 o. 2n 
(n=68) (n=29) (n=30) (n=28) 
61. 2% 76. 0% 55. 2% 64. 1% 
negative 
(n=103) (n=92) (n=37) (n=50) 
Histology5 
84. 1% 87. 3% 64. 1% 62. 1% 
NS 0. 016+ 0. 795+ 
(n=143) (n=103) (n=34) (n=41) 
14. 7% 5. 1% 34. 0% 36. 4% 
MC 
(n=25) (n=6) (n=18) (n=24) 
0. 6% 3. 4% 1. 9% 1. 5% 
LR 
(n=1) (n=4) (n=1) (n=1) 
0. 6% 4. 2% 
LD 0 0 
(n=1) (n=5) 
Sex 
57. 9% 58. 7% 55. 2% 75. 6% 
Male 0. 89 0. 01 
(n=99) (n=71) (n=37) (n=59) 
42. 1% 41. 3% 44. 8% 24. 4% 
Female 
(n=72) (n=50) (n=30) (n=19) 
Median age 
0. 666" 34(8~88) 32(8~88) 0. 85 28(4~74) 28(4~74) 
(range) 
iChi square test, · Data haw been published(Diepstra A et aI(12), t Comparison was made between NS and 
MC subtype only, # Mann Whitney U test, s Classical Hodgkin lymphoma not otherwise specified excluded, 
NS Indicates nodular sclerosis; MC, mixed cellularity; LR, lymphocyte rich; LD, lymphocyte depleted 
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Discussion 
This study imolved the largest group of northern Chinese cHL patients evaluated 
for expression of HLA class I and HLA class II by HRS cells. HLA class I 
expression was strongly associated with EBV-positi\Aty, similar to the Caucasian 
populations. However, an association between HLA class II expression and EBV 
status was not apparent, in contrast to the data from Western Europe. 
The EBV association with cHL has been investigated by several research 
groups within different geographic locales and ethnicities, showing a common 
association between EBV-associated cHL, male sex and MC subtype (3, 5). 
These associations were also present in this northern Chinese patient 
population. 
Although the pathogenesis of cHL is still not clearly established, immune 
escape mechanisms seem to play an important role, especially in cases that are 
EBV-associated. Downregulation of HLA on the surface of tumor cells has been 
obserwd in various types of human malignancies, including cHL{18). Our present 
data demonstrate that deficiency in membranous expression of HLA antigen by 
tumor cells is quite common in EBV-neg cHL, since 49. 7% and 46. 2% cases 
expressed HLA class I or class II respectively and only 26. 2% cases expressed 
both. Lack of HLA expression is generally thought to be advantageous for the 
persistence of tumor cells by escaping T cell mediated immunosurveillance. 
An intriguing finding is that HLA class I expression is usually retained in 
EBV+ cases, although HLA class I-restricted CTL responses in general play a 
major role in eliminating \Arus infection. This correlation is consistent with the 
results of four previous studies performed on Caucasian cHL populations from the 
Netherlands and the United Kingdom(13, 14, 16). Our data also show a correlation 
between HLA class I expression and MC subtype, which can be attributed to the 
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close relationship of EBV im,oh,ement with MC subtype. It is apparent that not 
only the quantity, but also the quality of HLA molecules determines the ability to 
mount an immune response. The composition of HLA alleles determines the 
peptide- binding ability and the subsequent immune response. A recent report on 
a detailed im,estigation within the HLA region lends proof to this concept, as 
patients with EBV-associated cHL more frequently carry HLA-A *01 in 
comparison to EBV-negati\e cHL patients who usually carry HLA-A * 02 instead 
(11, 15). It should be noted that persistence of HLA class I expression can be 
advantageous for the tumor cells to survive Natural Killer cell-mediated lysis(19). 
HLA class II-restricted CD4 T cell immune responses are largely, but not 
exclusiwly restricted to exogenous antigens and it has become evident that 
these responses are essential for an efficient eradication of EBV infection(10). 
Our group previously reported a significant association of HLA class II expression 
with EBV status in 292 Dutch cHL patients. In contrast, we did not find this 
association in the Chinese population in the current study, although we could see 
a slight non-significant tendency to maintain the expression of HLA class II in 
EBV-associated cHL. 
In addition, the previously reported correlation between the expression of 
HLA class I and class 1 1(12) was absent in the present study. A major difference 
between the Dutch and Chinese population is the percentage of MC subtype 
patients with 10. 6% and 28. 9% of patients respectively. Strikingly, the 
expression of HLA class II in MC subtype patients was wry different between the 
two populations and was much more frequently downregulated in the Chinese 
patients. Since we used the same antibody, staining protocols and scoring 
criteria for evaluating HLA class II expression in both populations, the differential 
expression likely reflects a biological difference between the two different 
populations which presumably relates to HLA-based genetic heterogeneity. The 
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HLA system is extremely polymorphic and allelic frequencies vary dramatically 
between racial groups. A certain HLA allele that is relath.ely uncommon in one 
population can be highly prevalent and associated with a specific disease in 
another. In the Chinese population one or more preVcllent HLA class I I  allele(s) 
might present immunodominant EBV antigenic peptides to the immune system, 
thereby exerting selection pressure to downregulate this molecule. Thus, yet-to­
be-defined ethnic-specific HLA alleles are likely to affect the strength of 
association between HLA class II expression and the strongly EBV associated 
MC subtype. It should be noted that Oudejans et al ( 16 } also studied the 
expression of HLA class II in Dutch cHL patients, but did not find the same 
association. Howe'ver, they used another antibody, recognizing HLA-DR only, the 
sample size of their study was much smaller(n=63) and they used a different set 
of scoring criteria(16). 
An additional association found in the Chinese population was a strong 
correlation between downregulation of HLA class II with male sex. Since male 
sex is associated with EBV + tumor cell status in general, this might partially 
explain the lack of association of HLA class I I  with EBV status in the Chinese 
patients. Howe'ver, there is no obvious explanation for the association of HLA 
class II expression with sex. Interestingly, lack of HLA class II expression is 
related to inferior failure free SUNVcll in the Dutch population (12). An important 
consequence of the differences in HLA class II expression between the Chinese 
and Dutch patients might be that this adwrse prognostic impact of HLA class II 
absence is not necessarily present in other populations. 
In conclusion, our data demonstrate that in northern Chinese patients, EBV 
+ cHL tumor cells more frequently retain HLA class I expression, similar to 
Caucasian populations. Howewr, the association of HLA class II expression with 
positi\e EBV status, as obseMd in Caucasians, is not present in the northern 
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Chinese population. Investigation at the molecular level is needed to further 
explore the role of anti-tumor immune responses in the pathogenesis of cHL. 
Differences in ethnic background should be taken into account and might explain 
discrepancies in incidence pattern, EBV association and other aspects in 
different populations. 
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Background: HLA-A2 protects against Epstein-Barr '.Arus ( EBV )-associated 
classical Hodgkin Lymphoma(cHL) in the Caucasian population, whereas HLA-A 1 
is a risk allele. In the Chinese population HLA-A 1 is uncommon and the 
prevalence of HLA-A2 subtypes is quite different from that in Caucasians. In this 
study, we investigated the association between HLA-A* 02 and specific HLA-A* 
02 subtypes with EBV+cHL in the Chinese population. 
Methodology/ Principal Findings : Formalin-fixed, paraffin embedded tissue blocks 
of 161 cHL patients and 119 controls with benign lymphadenopathy from the 
northern part of China were retrieved. EBV status was determined by in situ 
hybridization for EBERs. DNA was extracted from the tissue blocks and HLA-A2 
quantitative(q)PCR was performed to discriminate between negative and positive 
(including both homozygous or heterozygous) samples. HLA-A2 positive samples 
were subtyped to discriminate between "common and well-documented" HLA-A2 
subtypes by sequence-based typing. 67 (43%) of the cHL patients were EBV+. 
There were no significant differences in percentages of HLA-A2 positivity between 
cHL and controls(65% w 66%) and between EBV+ and EBV- cHL patients(70% 
w 61% ). The frequency distribution of HLA-A2 subtypes was similar for patients 
and controls. The HLA-A * 02: 07 allele frequency was significantly higher in the 
EBV+cHL(36%) as compared to the EBV-(7%) and the control group(19% ). The 
frequency of all other HLA-A2 subtypes combined was clearly decreased in EBV 
+patients(30%) compared to EBV- patients(51 % ) and controls(45% ). 
Conclusion: HLA-A*02:07 is a predisposing allele for EBV+ cHL, while all other 
HLA-A*02 subtypes are protective in the Chinese population. Our findings 
demonstrate the influence of HLA allele differences in ethnic groups on 
epidemiological heterogeneity of cHL. 
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Introduction 
Classical Hodgkin lymphoma (cHL) has a complex multi-factorial etiology with 
both genetic and en\1ronmental factors contributing significantly to its 
de\elopment(1, 2). Epstein-Barr \1rus (EBV), a ubiquitous human gamma-herpes 
\Arus that infects o\er 90% of the population worldwide (3), has been consistently 
linked to the pathogenesis of a subset of cHL(1 ). Despite its strong oncogenic 
potential, only a minority of EBV-infected indi\Aduals de\elop EBV + cHL (3 ), 
probably because of effecti\e anti-\Aral immune responses. 
The incidence of EBV + cHL is strikingly increased in immunocompromised 
patients(4) indicating the importance of an effectiw immune system in controlling 
the EBV+cell population. The human leukocyte antigen(HLA) is a crucial element 
of the human immune system and HLA class I restricted, CD8+cytotoxic T-cell 
(CTL) responses are known to play a pi\Otal role in the control of EBV infection(5). 
In EBV+cHL, expression of \Aral genes by the tumor cells is restricted to the two 
latent membrane antigens(LMP1 and LMP2) and EBV nuclear antigen 1(EBNA1), 
which is a so-called latency type II infection(6). Induction of LMP/EBNA 1-specific 
immune responses has been successful in the context of appropriate HLA 
molecules(7-9). 
Genetic association between HLA and cHL has been widely inwstigated in 
the Caucasian population and HLA-A2 has been consistently reported as a 
protecti\€ allele for de'A9Ioping EBV + cHL, while HLA-A 1 is considered a risk 
allele(10, 11). HLA-A2 has a high prevalence worldwide(12) and is one of the most 
diwrse allele families of the HLA-A locus consisting of o\er 300 allelic variants 
(IMGT/HLA database v 3. 3. 0). These alleles show a marked difference in the 
capacity of peptide binding and presentation(13). For example, presentation of 
EBV deri'A9d peptides by the HLA-A*02: 01 allele induces stronger immune 
responses as compared to other HLA-A*02 sub alleles, including HLA-A *02: 07 
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( 14 ). The distribution of these HLA-A*02 allelic variants differs widely by 
geography and ethnicity(12). In the Caucasian population, > 90% of the HLA-A2 
positiw indi\Aduals carry the HLA-A*02 :01 allele ( 12 ), whereas in the Chinese 
population there are multiple common and well-documented ( CWD ) allelic 
variants, including HLA-A*02:01 , A*02:03, A*02:06, A*02 :07 and A*02: 10 ( 15 ). 
Based on these marked differences, it can be postulated that inter-racial 
variations influence the host immune response and this may lead to different 
HLA-A2 disease associations in different populations. 
Consistent with Caucasian populations, in the \0St majority of Chinese EBV+cHL 
patients the tumor cells express HLA class I at the cell surface(16). In this study, we 
determined the HLA-A*02 phenotype frequency in the same group of Chinese cHL 
patients as well as in controls from the same geographic region. The CWD HLA-A*02 
allelic variants were determined by sequencing-based typing(SBT). 
Materials and Methods 
Study Populat ion 
Formalin-fixed paraffin-embedded (FFPE) tissue blocks of lymph node biopsies 
from 185 cHL patients obtained from 5 hospitals in northern China (Dept. of Pathology, 
Health Science Center, Peking Unh.ersity; Dept. of Pathology, First Hospital of Jilin 
Uniwrsity; Dept. of Pathology, Shougang Hospital, Peking Uniwrsity; Dept. of 
Pathology, Beijing Air Army General Hospital; Zhanye Regional Hospital, Gansu 
Pro\Ance) v.,ere used for this study. Results of the hematoxylin & eosin(H&E) staining, 
reclassification according to the WHO classification and EBER in situ hybridization 
haw been published pre\Aously(16). DNA was extracted from the tissue blocks. Of 
the 121 cHL patients for whom the HLA-A*02 DNA quality was sufficient for HLA­
A*02 qPCR, 4 (36%) patients were EBV+as pre\Aously determined by ISH for EBERs. 
To minimize genetic variations we included a control group of 124 reactiw lymph 
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nodes with lymphoid reacti\e hyperplasia(LRH) or Kikuchi Disease obtained during the 
same period from the Dept. of Pathology, Health Science Center, Peking Uniwrsity 
as a control group. 
FFPE tissue blocks of 21 cHL patients with known HLA genotype were 
retriewd from the Uniwrsity Medical Center Groningen(UMCG), the Netherlands. 
These samples were used to optimize and validate the HLA-A *02 specific 
quantitatiw(q)PCR. These 21 cases consisted of 6 A*02-homozygotes, 7 A*02-
heterozygotes and 8 non-A* 02 genotypes. All procedures were carried out 
according to UMCG METc guidelines. 
DNA isolation 
2~ 3 10µ.m tissue sections were incubated owrnight at 55
°C in 242. 5µL of PK1 
lysis buffer(10mM Tris pH 8. 0, 50mM KCI, 2. 5mM MgCl2, 0. 45% NP40, 0. 45% 
Tween 20, 0. 01% gelatin) with 7 .  5µL Proteinase K ( 20mg/ml, lnvitrogen ). 
Proteinase K was heat inactivated for 5 min at 100°C .  The supernatant containing 
the DNA was carefully transferred to a new tube. DNA was quantified by 
nanodrop-1000 spectrophotometer and diluted to a concentration of 5 and 10ng/ 
µL for the subsequent PCR analysis. 
HLA-A* 02 quantitatiw (q) PCR 
qPCR assays were carried out on an ABI PRISM 7900HT(Applied Biosystems) with 
SYBR-green in a 384-well microtiter plate using primers specific for HLA-A2 and as 
a control quality and quantity we used a primer set for the PTP4A 1 gene. All 
reactions were performed in triplicate in a final reaction '\Olume of 20µ1 consisting of 
1 0µI SYBR? Green PCR master mix{Applied Biosystems), 2µ1(3mM) of each primer 
and 5µ1 (5ng/ µI) DNA. Each sample was analyzed in triplicate, starting with a 2-min 
AmpErase UNG actiwtion step at 50°C and a 10-min hot start at 95 °C ,  followed by 
45 cycles of denaturation at 95°C for 15s and combined annealing/extension at 60°C 
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for 1min. A melting cune was generated(95 °C for 15s, 60°C for 15s, and 95 °C for 
15s) to wrify specificity of the PCR products. Cycle threshold (Ct) \0lues were 
determined by using the default baseline setting of 3 to 15 cycles. All data were 
analyzed by using ABI PRISM 7900 HT Sequence Detector Systems software 
wrsion 2. 3 (Applied Biosystems). Samples with poor DNA quality were excluded 
based on lack of a specific peak in the melting cul'\e or a Ct \0lue higher than 36 for 
PTP4A 1 ( 5 controls and 24 patients were excluded). HLA-A* 02 Ct \0lues were 
normalized against the Ct \0Iue for PTP4A 1, resulting in a delta Ct. Relatiw 
abundance of HLA-A* 02 was calculated by using the formula 2 �Ct. Based on the 
21 previously HLA-A typed samples, cut-off lewis for HLA-A* 02 positivity were set 
at a 2-�Ct \01ue of 0. 1. A 2-�Ct value of 0. 05 or less was considered to indicate 
absence of HLA-A*02. 
HLA-A* 02 subtypes 
Subtyping of HLA-A2 positiw cases was performed by amplification and 
sequence analysis of exon 2 and exon 3 regions that contain a number of SNPs 
that discriminate between the common and well-documented ( CWD) allelic 
variants in the Chinese population(Table1, Figure 1 ). DNA samples were amplified 
in a \Olume of 25µ.I containing 5µ.I(10ng/µ.I) DNA, 5µ.I(2mM) of each primer, 1. 25µ.I 
dNTPs(lnvitrogen), 2. 5µ.I 10X reaction buffer(lnvitrogen), 5. 85µ.I H2O and 0. 4µ.I 
Taq Polymerase (lnvitrogen). Amplification was performed in a GeneAmp PCR 
System 9700 thermocycler(Applied Biosystems) with an initial 3-min hold at 95°C 
and 40 cycles of 15s at 95°C,  30s at 65°C ,  and 1 min at 68°C,  followed by a final 
1 0min extension step at 68°C. PCR products were visualized on a 1 % agarose 
gel and purified by Exo-SAP treatment(USB products, Affymetyrics, aewland, Ohio 
USA). PCR products vvere sequenced using the same primers as the ones used for 
amplification. Due to the longer amplicon size of the exon 2 PCR products a number of 
samples failed for the analysis of the SNPs in this region leading to a less effecti\e 
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discrimination between the 0/VD HLA-A*02 subtypes in these samples. This led to 
ambiguities for some alleles. Using the primer set as indicated abo\e vve vvere not able 
to discriminate between HLA-A*02:01 and HLA-A*02:03, leading to a HLA-A*02:0 1/ 
02 :0 3 ambiguity. Sequence data were analyzed using Seqman software (DNA 
Star, Madison, WI). Percentages were based on the frequency within the HLA-A2 








A*0 : L  
m m � � m � m m m m 
CAG IGCTCCCA CTCCATGAGG TAmCITCA CATCCGTGTC CCGGCCCGGC CGCGGGAGC CCCGCTTCAT CGCCGTGGGCTACGTGGACG ACACGCAGTT 
- T- --- --- --- --- --- --- -A- --- ---
- T- --- --- --- --- --- --- -A- --- ---
- -T- --- � --- --- --- -A- --- ---
- T- ---  --- --- -- -A- -- ---
- �- --- � --- --- --- -�- --- ---
710 720 730 740 750 760 770 780 790 800 
GGGGK'GGGG CCAG lcmcrc ACACCATCCAGATAATGTATGGCTGCGACGTGGGGCCGGACGGGCGCTJ'CCTCCGCGGGTACCGGCAGGA CGCCTACGAC 
-C - - 1-- --G- -GG- -- -T- -T-- --- -AC-T-
-C - -1-- --G- -GG- -- -T- -T-- --- -AC-T-
-C - -
1
-- --C- -GG- -- -T- -T-- � -AC-T-
-C - - -- --G- -GG -- -T- -T-- --- -AC-T-
-C - - -- --G- -GG -- -T- -T-- --- -AC-T-
-c - - -- --G- -GG T -- -T- -T-- --- -AC-T-
Figure 1 Alignment of the HLA-A *02 gene fragments that are amplified and sequenced to 
discriminate bet\Yeen common and well defined HLA-A*02 allele. The four SNPs that are able 
to discriminate between the major HLA-A*02 subtypes(IMGT/HLA database, http://www. ebi. 
ac. uk/imgt/hla/) are indicated by boxes. (A) Two SNPs located at position 228 and 231 are 
specific for HLA-A*02:05, A*02:06 and A*02:10. (B)Another SNP located at position n3 is 
specific for HLA-A*02:05 only and one SNP at position 739 can differentiate both HLA-A*02: 
07 and A *02: 10 from others. Numbers abow the sequences indicate nucleotide positions. 
Nucleotide sequences were aligned to the HLA-A *01 :01 allele. Dashes indicate identity with 




Table1 Primer sequences for allelic discrimination 
Allele specificity Primer sequence*(5' - 3') Location Product size 
HLA-A*02 F:GAGCCCCGCTTCATCGCA Exon 2 150bp 
R:CCCGTCCCAA TACTCCGGA Exon 2 
PTP4A1 F:GCACAGCACGACCTCTATGC Exon 2 142bp 
R:CCAGGTCAGAACTCTTGTAAAA TGC Exon 2 
HLA-A *02 exon 2 F:CTCTGTGGGGAGAAGCAAC lntron 1 191bp 
R:GTCGTCCACGTAGCCCACT Exon 2 
HLA-A*02 axon 3 F:GCGGGGCTCGGGGGACC lntron 2 131bp 
R:GCCGTCGTAGGCGTACTGG Exon 3 
• F, forward primer; R, rewrse primer. Nucleotides in bold indicate the positions of the SNPs specific for the 
CWD HLA-A*02 alleles. 
Statistical Analysis 
Significant differences in HLA-A*02 positi'Aty and in phenotype frequency of HLA­
A*02 subtypes between the total cHL group and the control subjects as well as 
those between EBV+ and EBV- cHL patients were assessed by chi-square tests. 
All statistical analyses were performed in Microsoft Excel 2003. 
Results 
Validation of the qPCR 
Analysis of the 21 cHL samples with a pre'Aously typed HLA-A genotype revealed 
a clear separation between indi'Aduals lacking HLA-A2 alleles and indi'Aduals 
heterozygous or homozygous for the HLA-A2 allele ( figure 2 ). The relative 
expression values varied between 0. 002 and 0. 027 for negative patients and 
between 0. 63 and 4. 26 for positive patients. 
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Figure 2 Validation of the HLA-A*02 specific primer set on indi'Aduals with known HLA 
genotypes. A clear difference can be obsened between samples possessing at least one HLA­
A2 allele and those without HLA-A2 alleles. 
HLA-A2 carrier frequency 
24 cHL patients and 5 controls were excluded due to bad DNA quality. HLA-A*02 
carrier frequency of the remaining 161 cHL patients and 1 19 controls rewaled no 
significant difference between the total cHL patient group(104 out of 1 61 ,  65% ) 
and the control group(79 out of 1 19, 66% ). In contrast to the strong significant 
association obserwd in the Western population, no difference was observed 
between the HLA-A2 frequency in EBV+(47 out of 67, 70% ) and EBV-(57 out of 
94, 61% ) chinese cHL patients(Table 2). 
HLA-A2 subtype frequencies 
HLA-A *02 subtyping failed in 5 cHL patients and 3 controls due to inefficient 
amplification of both exons and/or poor sequencing results. For part of the 
patients subtyping was based only on the exon 3 sequence analyses, which did 
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not allow discrimination between all CWD alleles. SBT results of the 101 cHL 
patients and 76 controls are shown in Table 3. Eight patients and sewn controls 
showed a heterozygous pattern for two HLA-A2 alleles, whereas in all other 
cases only one HLA-A2 allele was obserwd(Table 3). 
Table 2 Phenotype frequencies of HLA-A*02 in Chinese patients with cHL and controls 
Controls All patients EBV+cHL 
N=119 (%) N=161 (%) N= 67 (% ) 
HLA-A *02-pos 79 (66. 4) 104 (64. 6) 47 (70. 1) 
HLA-A *02-neg 40 (33. 6) 57 (33. 4) 20 (29. 9) 
Table 3 CWD HLA-A2 alleles in HLA-A2 positiw controls and cHL patients 
76 controls 99 cHL patients 44 EBV+cHL 
HLA-A * 02 allelesa n= 83 n= 107 n= 50 
A* 02:01/02:03 27 (33. 8% ) 31 (30. 4% ) 9 (19. 1% ) 
A* 02:01/02:03/02:06 17 (21. 3% ) 16 (15. 7% ) 7 (14. 9%) 
A* 02:01/02:03102:05/02:06 2 (2. 5%) 0 (0. 0% ) 0 (0. 0%) 
A* 02:05 1 (1. 3%) 1 (1. 0% ) 0 (0. 0%) 
A* 02:06 11 (13. 8% ) 25 (24. 5%) 9 (19. 1%) 
A* 02:05/02:06/02: 10 1 (1. 3% ) 0 (0. 0% ) 0 (0. 0% } 
A* 02:07 23 (28. 8% } 31 (30. 4% } 24 (51. 1% ) 
A* 02:10 1 (1. 3% ) 3 (2. 9% ) 1 (2. 1% } 
failure 3 (3. 6%) 5 (4. 7% ) 3 (6. 0% } 
EBV-cHL 
N= 94 (% ) 
57 (60. 6) 
37 (39. 4) 
55 EBV-cHL 
n= 57 
22 (40. 0% ) 
9 (16. 4% ) 
0 (0. 0% ) 
1 (1. 8% ) 
16 (29. 1% ) 
0 (0. 0% } 
7 (12. 7% ) 
2 (3. 6% } 
2 (3. 5%) 
8 Five patients and one control were heterozygous for HLA-A* 02:03 and HLA-A* 02:07, two patients and one 
control were heterozygous for HLA-A*02:06 and HLA-A*02:07, one patient was heterozygous for HLA-A*02:06 
and HLA-A*02:10, one control was heterozygous for HLA-A*02:05 and HLA-A*02:07, one control for HLA-A* 
02:01/02:03102:06 and HLA-A*02:07 and three controls were heterozygous for HLA-A*02:01/02:03 and HLA-A 
*02:06. 
T he HLA-A* 02: 01/02: 03 ambiguity was most common in both controls and 
patients. The second most common allele in both controls and cHL patients was 
HLA-A*02:07 and HLA-A*02:06 was the third most common allele. HLA-A*02:05 
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and A*02:10 were rare in patients and controls. 
In contrast to the similar distribution of HLA-A2 subtypes in controls and the 
total cHL patient group, the HLA-A2 subtype frequencies varied greatly between 
EBV+and EBV- cHL patients. The HLA-A*02 :0 7 allele frequency was \ery high in 
EBV+cHL patients(24 out of 50 , 48%) and low in EBV- cHL patients(? out of 57, 
12% ). All other HLA-A * 02 subtypes were less common in EBV + cHL as 
compared to the EBV- cHL patient group. 
Table 4 HLA-A *02'7 carrier frequency in Chinese controls and cHL patients 
Controls All patients EBV+cHL EBV-cHL 
HLA type N % n % n % n % 
A* 02:07 23 19. 8% 31 19. 9% 24 37. 5% 7 7. 6% 
A* 02 (non 02:07) 53 45. 7% 68 43. 6% 20 31.  3% 48 52. 2% 
A* 02 negatiw 40 34. 5% 57 36. 5% 20 31.  3% 37 40. 2% 
failure 3 5 3 2 
HLA-A * 02:07 risk allele analysis 
Analysis of the frequency distribution of HLA-A * 02 negati\e, the HLA-A * 02 :  0 7  
positi\e and the A*02(non 02:0 7) positi\e cases in controls, total, EBV+and EBV­
cHL patient groups rewaled significant differences (Table 4 ). The odds ratio(OR) 
for HLA-A*02:0 7  was strongly increased in EBV+cHL as compared to EBV- cHL 
(OR= 6. 34, Cl 2. 33--17. 28) and controls(OR= 2. 0 9, Cl 0 .  95-4. 57). The HLA-A* 
02(non 02 :0 7) OR was strongly reduced in the EBV+cHL subgroup as compared 
to EBV- cHL(OR= 0 .  77, Cl 0 .  36-1.6mm4) and controls(OR= 0 .  75, Cl 0 .  3 &1. 59). 
In the EBV- cHL group the OR for HLA-A*02:07 was reduced(OR= 0. 33 , Cl 0. 13--





Tab l e  5  H LA - A  *  02 : 0 7  a l l e l e  freq ue nc y  i n  co n t ro l s  and  c H L  pa t i e n t s  s t rat i fi ed  by  E B V  s t at us  
Con t ro l s  '6  E B V +  
Co n t ro l s  w  E B V - E B V +  w  E B V -
H LA - A2  s u b a l l e l e  
p- '\B l u e b  
O R ( 95 %  C l )8  p- va l u e b  O R  ( 95 %  C l )8  
O R  ( 95 %  C P a  p- w l u at'  
A * 0 2 : 0 7  
2 . 0 9  ( 0 . 9 5 - 4 . 6 )  0 . 0 2 8  0 . 33  ( 0 . 1 3
- -
0 . 86 )  0 . 04 5  6 . 34  ( 2 . 3 - - 1 7 )  2 x 1 0
-
5  
A *  0 2  ( n o n  0 2 : 0 7 )  0 . 7 5  ( 0 . 36 - - 1 . 6 )  0 . 9 8  ( 0 . 54 - 1 . 8 )  0 . 7 7  ( 0 . 36-- 1 . 6 )  
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Discussion 
HLA-A2 has been identified as a protecti\e allele and HLA-A 1 as a risk allele for 
the de\elopment of EBV+cHL in the Western population(10, 1 1 ). In this study, we 
found no difference in the HLA-A2 allele carrier frequency between EBV + cHL 
patients and controls from Northern China. A further discrimination between the 
CWD HLA-A2 subtypes in the Chinese population re\ealed that HLA-A * 02: 07 
allele was a risk allele for EBV+ cHL, whereas all other HLA-A *02(non 02:07) were 
protecti\e. The HLA-A 1 frequency was not tested because this allele is 
uncommon in the Chinese population. 
HLA-A*02:07 is almost exclusi\ely present in the eastern Asian population 
and is the second most common allele just after the HLA-A*02:01 allele(13). In 
the southern Chinese population the HLA-A * 02: 07 allele frequency was reported 
to be e\en higher than the HLA-A*02:01 frequency(1 5). The proportion of HLA­
A*02:07 positi\e individuals was slightly higher than the frequency reported in the 
northern Chinese population(1 5). 
Difference between the HLA-A*02:01 allele and the HLA-A*02:07 allele at the 
protein le\el is only one amino acid(Y99 to C) and this variation is not present in 
the HLA-A*01 allele. The question arises if this single amino acid difference can 
indeed make a difference between a risk and a protecti\e allele. An explanation 
for the obseMd differences might be found in differential specificity of binding and 
presentation of antigenic peptides(13). Indeed, HLA-A *02:01 has been shown to 
be more effecti\e in binding and presentation of EBV-deri\ed peptides in 
comparison to other HLA-A*02 subtypes including HLA-A*02:07 ( 17-19 ). 
Interestingly, the HLA-A*02:07 allele is also associated with an increased risk of 
undifferentiated nasopharyngeal carcinoma ( UNPC ) in the southern Chinese 
population(20). UNPC is an EBV-associated malignancy and has an identical 
latency type of infection as compared to cHL with an expression pattern that is 
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restricted to LMP1, LMP2 and EBNA1(6, 21). In the Caucasian population HLA-A 
*02:01 was associated with a decreased risk for UNPC(22). These findings are 
simi lar to our findings in cHL and support a role for the effecti\eness of the 
immuneresponse against latency type II proteins in the pathogenesis of both 
diseases. 
In conclusion, our study reported for the first time that the HLA-A *02:07 
allele has a strong predisposing effect for EBV+ cHL in the Chinese population, 
whi le other HLA-A*02(non 02:07) alleles were protecti\e. Discrimination between 
HLA-A*02 subtypes was of central importance for in\estigating the genetic 
association of HLA-A*02 with EBV+ cHL. Differences in Chinese and Caucasian 
populations pro�des a unique opportunity for further understanding the influence 
of genetic heterogeneity in HLA and its role in the pathogenesis of EBV+ cHL. 
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Background: The pathogenesis of classical Hodgkin lymphoma ( cHL) imol\es 
emAronmental and genetic factors. 
Methodology/Principal Findings: To explore the role of the human leukocyte 
antigen(HLA) genes, we performed a case-control genotyping study in 338 Dutch 
cHL patients and more than 5,000 controls using a PCR-based sequence-specific 
oligonucleotide probe(SSOP) hybridization approach. HLA-DR7 was significantly 
decreased and HLA-B51 significantly increased in the cHL patient population as 
compared to the controls. Three class II associations were obseMd in the EBV­
cHL population with an increase of HLA-DR15(2) and a decrease of HLA-DR4 and 
HLA-DR7. Allele frequencies of HLA-A1, HLA-B37 and HLA-DR10 were 
significantly increased in the EBV+cHL population and these alleles are in strong 
linkage disequilibrium forming a common haplotype in caucasians. The allele 
frequency of HLA-DR11 ( 5 )  was significantly decreased in the EBV + cHL 
population. SSOP analysis re\€aled significant differences between EBV + and 
EBV- cHL patients for 19 probes that discriminate between HLA-A*01 and 
HLA-A*02. 
Conclusion/Significance: ln conclusion, the HLA-A1 and HLA-A2 antigens and not 
a specific single nucleotide variant shared by multiple alleles are responsible for 
the association with EBV+cHL. Se\€ral new protecti\€ or predisposing HLA class 
I and II associations for the EBV+, the EBV- and the entire cHL population were 
identified. 
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Introduction 
Classical Hodgkin lymphoma(cHL) is a typical multi-factorial disease with both 
em,konmental and genetic factors acting together to cause disease ( 1, 2 ). 
Epidemiological studies reporting familial clustering of cHL(3) and racial variation 
in the incidence of cHL(4) ga\e substantial support for an inherited risk to cHL. 
Genetic associations with specific human Leukocyte Antigen(HLA) alleles ha\e 
been reported in both sporadic and familial cHL(5, 6). 
Epstein Barr virus (EBV) is a well-established causal factor in a subset of 
cHL patients ( 7 ). The expression pattern of EBV genes in Hodgkin Reed­
Stemberg(HRS) cells is restricted to the two latent membrane proteins(LMP1 and 
LMP2) and the EBV nuclear antigen 1 ( EBNA 1 ) ( 7 ). Despite the lack of 
immunodominant EBV proteins, LMP and EBNA 1-specific T cell responses can 
be efficiently induced in the context of specific HLA class I or class II molecules 
(8--10 ). The extreme di\ersity of HLA genes influences both the affinity and 
specificity of antigenic peptide binding and is responsible for variations in host 
anti-viral immune defenses. Genetic variation in host anti-viral immune responses 
related to HLA polymorphisms might be an important contributor to the 
de\elopment of virally induced malignancies. 
Initial HLA association studies in cHL were performed without taking EBV 
status into account and associations of HLA-A1, HLA-B5, HLA-88 and HLA-B 1 8  
with cHL ha\e been described, although the degree of reproducibility has been 
low(6, 1 1-1 3). More recently, we focused on the EBV+cHL subgroup by genetic 
screening the entire HLA region and subsequent finescreening and found a 
strong association of specific HLA-A alleles with susceptibility to EBV + cHL in 
Dutch and English patients5, (14). The HLA-A 1 was associated with an increased 
risk for EBV+cHL, whereas the HLA-A2 was associated with a decreased risk for 
EBV+cHL(15). This association was confirmed in 934 Scandinavian and English 
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cHL patients in a recent study by Hjalgrim et al(16). 
In the present study, we performed an extensive screen of the HLA class I 
and II genes to investigate possible associations of HLA alleles in the total, the 
EBV + , and the EBV- cHL ( sub) populations. Furthermore, we intended to 
establish whether specific single nucleotide polymorphism(SNP) positions in the 
HLA genes that might be shared by multiple HLA alleles are responsible for the 
observed genetic associations rather than specific HLA alleles. 
Materials and methods 
Patients and controls 
183 Dutch cHL patients who participated in the previous genotyping study 5 were 
included in the present study. 155 additional patients diagnosed and/or treated 
between 2000 and 2010 at the University Medical Center Groningen in the 
Netherlands were also included. Data on gender, age, and histopathological 
diagnosis was available for all these patients. Classification according to the 
WHO was performed consistently with the previous study and cHL cases that 
could not be unequiwcally subtyped ( usually because of little tissue) were 
classified as cHL not otherwise specified(Table 1 ). The presence of EBV in tumor 
cells was detected in formalin fixed paraffin embedded tissue sections by in-situ 
hybridization(ISH) with a fluorescein-conjugated PNA probe specific for the EBV­
encoded EBER RNAs (DAKO, Glostrup, Denmark). All participants gave written 
informed consent. The protocol was approved by the medical ethics board of the 
University medical Center, Groningen. The control group consisted of blood bank 
donors from the same geographical region typed for HLA-A(n= 7, 099), HLA-B 
(n=7, 283) and HLA-DR(n=5 ,  922) by serological methods and in case of unclear 
results or apparent class II homozygosity additionally by DNA based methods. 
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HLA genotyping 
Blood samples of cHL patients were collected and genomic DNA was extracted 
from the peripheral blood mononuclear cel l pellets using standard laboratory 
protocols. The HLA genotype was analyzed at medium resolution by a 
polymerase chain reaction-based sequence-specific oligonucleotide probe 
hybridization ( PCR-SSOP ) approach using commercial kits ( Gen-Probe, San 
Diego, CA) and Luminex xMAP technology (Luminex Corp. , Austin, TX). The 
assays were performed according to the manufacturer's instruction in a 
European Federation for lmmunogenetics accredited laboratory. Briefly, biotin­
labeled amplification products were generated for exon 2 (for HLA-DRB, HLA­
DPB1) and exon 3(for HLA-A, HLA-B, HLA-Cw and HLA-DQB1) of the HLA genes, 
followed by a hybridization reaction with a series of SSOPs. Of the 401 PCR­
SSOP probes 43 were either positi\e or negati\e for all samples and were 
therefore excluded from the analyses. Of the 358 included probes, 63 were for the 
HLA-A locus, 83 for the HLA-B locus, 53 for the HLA-C locus, 72 for the HLA-DR 
locus, 41 for the HLA-DQB1 locus and 46 for the HLA-DPB1 locus. Each probe 
co\ered 1 to 3 SNP positions. The HLA alleles were defined by specific 
hybridization patterns of multiple probes. HLA genotype was ascertained 
according to the manufacturers instructions using the manufacturer 's software 
and additionally by the SCORE sofl:ware(18), enabling the exclusion of .probes 
with borderline hybridization signals. The presumed antigen or T cell receptor 
binding function of the SNPs were identified according to Bjorkman and Parham 
(18). 
HLA allele frequencies of the cHL patients were deducted from the PCR­
SSOP genotyping data based on the Nomenclature for factors of the HLA system 
(http://hla. alleles. org/nomenclature/naming. html). Split antigens were used as 
indicated in the tables. In case of ambiguous results, the allele combination only 
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consisting of common and well documented alleles (19} were used. For HLA­
DPB1 one ambiguity remained(DPB1*04:02/105:01} which was analyzed as one 
group of alleles. 
Statistical analysis 
For each indi\ndual PCR-SSOP association with EBV status was tested by 
logistic regression in PLINK v1. 07 (20) (http://pngu. mgh. harvard. edu/purcell/ 
plink/) with EBV status as a dependent variable, SSOP as an independent 
variable, and age and histopathological diagnosis of cHL as confounding 
covariates. 
Allele frequencies of HLA-A, HLA-B and HLA-DR of the total cHL group, the 
EBV+subgroup and the EBV- subgroup were compared with allele frequencies of 
the controls and significant differences were assessed by Chi-square tests. 
Allele frequencies for HLA-C, HLA-DP and HLA-DQ of the controls were not 
available. Significant differences in allele frequencies between EBV + and EBV­
cHL patients were also assessed by Chi-square tests. Alleles with a frequency< 
1% in our population were excluded for all these analyses. 
For each phenotype and PCR-SSOP a test was performed, hence a 
correction for multiple testing was required. Because linkage disequilibrium 
exists between the PCR-SSOPs and between the HLA phenotypes, and because 
the HLA-phenotypes are deri'.Ed from the PCR-SSOPs, a Bonferroni test for 401 
PCR-SSOPs and 7 4 phenotypes would be too conservatiw. Therefore, we 
considered p-values smaller than 0. 001 to be significant at a le\€1 of 5% and p­
values <0. 003 to be suggestiw for association. 
Results 
Clinicopathological characteristics 
Characteristics of the patient population in terms of age, gender and 
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histopathological subtype in relation to EBV status is summarized in Table 1 .  
EBV was present in the tumor cells in 78 (25% )  of the 31 1 cHL patients (for 27 
patients EBV status was unknown). In the total group, median age at diagnosis 
was 35 years(range 13 to 8 1 )  and the percentage of males was 52% . 43 of 338 
cHL patients could not be subtyped and were designated cHL NOS. In the 
remaining patients, nodular sclerosis (NS )  was the most common subtype 
accounting for 87% . Mixed cellularity (MC) and lymphocyte rich (LR) subtypes 
were less common with frequencies of 10% and 3% , respectively. The 
lymphocyte depletion (LD ) subtype was absent in this patient group. These 
characteristics are largely consistent with those published for Caucasian cHL 
populations. 
Allele frequency differences compared to controls 
An overview of all allele frequency data, odds ratios and p-values is given in 
supplementary Table 1 .  HLA phenotype frequencies(frequencies of allele carriers) 
including odds ratios and p-values are giwn in supplementary Table 2. This paper 
focuses on the HLA allele frequency analysis and in most cases similar results 
were obserwd for the HLA phenotype frequency analysis. 
In the cHL patient group the allele frequency of the HLA-A68(28), HLA-DR1 1 
(5) and HLA-DR1 5(2) was significantly increased as compared to the controls{5. 
0% vs 0. 9% ; p<10-10 , 1 1 . 5% vs 0. 7% ; p<10-10 , and 21% vs 14. 3% ; p=9. 8x10-7 , 
respectiwly ). In contrast, HLA-DR4 and HLA-DR7 allele frequencies were 
significantly decreased(13% vs 18% ;  p=3. 1x10-4 , and 5. 2% vs 1 1% ;  p= 1 .  4x10-6 
respectively)(Table 2; Figure 1 ). The associations for HLA-DR4, HLA-DR7 and 
HLA-DR1 5(2) were also obserwd in the EBV- cHL subgroup and not in the 
EBV+ cHL group(see below)(Figure 1 ). 
In EBV- cHL patients a significantly decreased allele frequency was found for 
HLA-DR4 and HLA-DR7(1 2% vs 18% ;  p=6. 3x10-4 , 5. 6% vs 1 1% ;  p=1 .  9x10-4 ) as 
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compared to the controls and a significantly increased frequency for HLA-A68 
(28), HLA-DR1 1 (5) and HLA-DR15(2) compared to controls(5. 6% vs 0. 9% ; p< 
10-10 , 13% vs 0.  7% ; p < 10-10 , 23% vs 14% ;  p = 8. 4x10-7 }(Table 3, figure 1 ). The 
association for HLA-DR4, HLA-DR7 and HLA-DR15 (2) are also obseMd in the 
total cHL subgroup, but not in the EBV+ group, whereas the associations for HLA­
A68(28) and HLA-DR1 1 (5) are also observed in the EBV+ cHL(see below). 
For the EBV+ cHL subgroup strong associations were observed for HLA-A 1 ,  
HLA-A2, HLA-A68(28), HLA-B37, HLA-DR10 and HLA-DR1 1 (5)(Table 3 ;  Figure 1 ). 
The HLA-A1 frequency was increased compared to the controls(33% vs 19% ;  p= 
4. 6x10-6 ), whereas the HLA-A2 frequency was decreased(1 6% vs 34% ; p=2. 3x 
10-6 ) in EBV+ cHL. For HLA-A68(28)(3. 2 vs 0. 9; p=2. 1x10-3 ), HLA-B37(8. 4% vs 1 .  
9% ; p= 2. 4x10-10 ) and HLA-DR10(3. 8% vs 1 .  0% ; p = 4. 7x10-4 ) an increased 
frequency was observed in the EBV+ cHL patients as compared to the controls. 
For HLA-DR1 1(5) the allele frequency was decreased in the EBV+ cHL population 
as compared to the controls (4. 5% vs 1 2% ;  p= 1 .  3x10-7 ). The associations for 
HLA-A1 ,  HLA-A2, HLA-B37 and HLA-DR10 were obseMd only in the EBV + cHL 
subgroup and not in the EBV- cHL subgroup. 
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Table 1 Distribution of sex, histological subtype and age in cHL population stratified by EBV 
status 
All patients EBV-Positiw EBV-Negatiw 
n % n % n % 
Sex 
Male 177 52 60 77 107 46 
Female 161 48 18  23 126 54 
Histological subtype 
NS 256 87 46 69 192 92 
MC 29 10 18  27 1 0  5 
LR 10 3 3 4 7 3 
NOS 43 1 1  24 
Median age (range) 35 (13--81 ) 37 (17-70) 32 (13--81) 
Table 2 HLA allele frequencies of HLA-A, -B, and-DR alleles with a (near1y) significant difference 
betvleen controls and cHL patients 
Controls cHL patients Controls w cHL 
n % n % p * 
HLA-A68(28) 124 o. 9 34 5. 0 <10-10 
HLA-B51 (5) 745 5. 1 52 8. 0 1. 2X 10-3 
HLA-860(40) 1037 7. 1 26 4. 0 2. 3x 10·3 
HLA-DR4 2146 18. 1 85 12. 6 3. 1 X 10"4 
HLA-DR7 1 320 1 1 .  1 35 5. 2 1. 4X 10-6 
HLA-DR1 1(5) 87 0. 7 77 1 1 .  5 <10-10 
HLA-DR15(2) 1690 14. 3 142 21 . 1 9. 8x 10-1 
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Figure 1 Odds ratios and 99. 9% confidence intervals of the phenotype allele frequencies. It 
shows the (nearly) significant differences between the controls and either the total cHL patient 
group (grey), the EBV - (white), or the EBV +(black ) subgroup of patients. The size of the 
diamond reflects the allele frequency. 
Table 3 Allele frequencies of HLA-A, HLA-8, and HLA-DR alleles with (nearly) significant 
difference between controls and EBV+or EBV- cHL subgroups 
Controls EBV+cHL EBV-cHL c.ontrds w EBV+ O:rbds '8 EBV-
n % n % n % p· p· 
HLA-A1 2667 18. 8 52 33. 3 85 13. 0 4. 0 X 10" 6 ns 
HLA-A2 4828 34. 0 25 16. 0 153 37. 0 2. 3 X 10"6 ns 
HLA-A68(28) 124 0. 9 5 3. 2 26 5. 6 <10-10 <10-10 
HLA-837 277 1. 9 13  8 .  4 10 2. 2 6. 3X 10-9 ns 
HLA-B51(5}t 745 5. 1 14 7. 4 33 9. 1 ns ns 
84 
Controls EBV+cHL 
n % n % 
HLA-B60(40) 1037 7. 1 8 5. 2 
HLA-DR4 2146 18. 1 26 16. 7 
HLA-DR7 1320 1 1 .  1 7 4. 5 
HLA-DR10 1 18 1 .  0 6 3. 8 
HLA-DR1 1 (5) 87 0. 7 7 4. 5 
HLA-DR15(2) 1690 14. 3 27 17. 3 
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EBV-cHL 
n % 
15  3 .  4 
55 1 1 .  9 
26 5. 6 
5 1 .  1 
60 13. 0 
104 22.  5 





4. 7X 104 





2. 2X 103 
6. 3X 104 
1 .  9X 104 
ns 
<1 010 
8. 4X 107 
• Significant differences (p<O. 001 ) are shown in bold, suggestive ones (p<O. 003) in italic. 
tHLA-851 is included because it had significantly different frequencies in the total group of cases as 
compared to controls (Table 2). 
Differences in HLA allele frequencies behveen EBV+ and 
EBV- cHL patients 
Comparison of the HLA allele frequencies rewaled four significant differences 
between the EBV + and EBV- cHL subgroups ( supplementary Table 1 and 
supplementary Table 2 for the phenotype frequencies). The HLA-A 1 frequency 
was significantly increased ( 33% vs 1 3% ;  p = 9. 2 X 10-5 ) and the HLA-A2 
frequency was significantly decreased( 1 6% vs 37% ; p= 5. 2 X 1 0-5 ) consistent 
with previous publications. In addition, we obsel"\ed a significantly increased 
frequency for HLA-B37(8. 4% vs 2. 2% ; p= 5. 5 X  1 0-4 ) and HLA-Cw6 (14% vs 5. 
9% ; p=2. 2X 10-3 ) in EBV+ cHL patients wrsus EBV- cHL patients(Table 4). 
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Table 4 HLA allele frequencies with a(nearly) significant difference between EBV+and EBV- cHL 
patients 
EBV+cHL EBV-cHL p-value 
n % n % 
HLA-A1 52 33. 3 85 13. 0 9. 2 X 10-5 
HLA-A2 25 16. 0 153 34. 0 5. 2X 1o-5 
HLA-837 13 8. 4 10 2. 2 5. 5X 10"4 
HLA-C6 21 13. 6 27 5. 9 2. 2 X 10-3 
• Significant differences (p<0. 001 ) are shown in bold, suggestiw ones (p<O. 003) in italic. 
Association analysis of indi�dual PCR-SSOPs in EBV+ 
and EBV- cHL patients 
Analysis of each of the 358 PCR-SSOPs re'A3aled a significant difference between 
EBV- and EBV + cHL patients for 19 HLA-A gene PCR-SSOPs ( Figure 2; 
Supplemental Table 3). Ten of the PCR-SSOPs were specific for the HLA-A*01 
allele and were more common in EBV+cHL patients, while the other nine PCR­
SSOPs specific for the HLA-A*02 allele were less common in this patient group 
(Table 2). The 19 SSOPs with significant differences contained polymorphic 
residues within eight of the HLA-A*02-specific and ten of the HLA-A*01 specific 
SSOPs that are located at key positions in the peptide binding pockets(18)(Table 
5). PCR-SSOPs that were less specific for the HLA-A * 01 or HLA-A * 02 alleles 
showed a similar trend in the odds ratio as the significant PCR-SSOPs but with 
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Discussion 
Inherited variations within the HLA genes as well as variations in host immune 
responses haw long been recognized to be associated with susceptibility to 
disease, including cHL(21 ). A number of HLA genes, alleles and serotypes haw 
pre\Aously been reported to be imolwd in the pathogenesis of cHL(5, 6). In this 
study we obserwd multiple associations that are specific for the EBV + , the 
EBV- or the total cHL subpopulations. HLA-A68(28) and HLA-DR1 1  (5) are risk 
alleles for cHL irrespectiw of the EBV status. HLA-DR4 and HLA-DR7 are 
associated with decreased susceptibility and HLA-DR15(2) with an increased risk 
in the EBV- cHL groups. In the EBV+cHL population an increased susceptibility 
was obserwd for HLA-A 1, HLA-B37 and HLA-DR10, whereas resistance to 
disease dewlopment was obserwd for HLA-A2. 
The pre\Aously reported association of the HLA-A gene with EBV+cHL(5, 1 4, 
1 5) was confirmed both in comparison to EBV- cHL and in comparison to healthy 
controls with an increased risk for HLA-A*01 and a reduced risk for HLA-A*02. A 
tentatiw explanation for this association is the known presence of multiple 
cytotoxic T cell epitopes for LMP2 deriwd antigenic peptides restricted through 
HLA-A * 02(8), whereas HLA-A * 01 restricted epitopes to the latent EBV peptides 
haw not been found (22). Analysis of the indi\Adual PCR-SSOPs rewaled a 
significant difference for 19 out of the 358 probes in EBV+as compared to EBV­
cHL. These probes discriminated between the HLA-A* 01 and HLA-A*02 alleles 
and showed only a limited number of cross reacting other alleles. The other, less 
significant HLA-A*01 and HLA-A*02 identifying probes showed a similar risk 
pattern. The less significant lewl of these probes can be explained by their 
broader specificities including some common HLA-A alleles. For example, 
several probes share specificity for both HLA-A 1 and HLA-A 1 1 . HLA-A* 1 1  was 
pre\Aously reported to be a protective allele in EBV-associated undifferentiated 
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nasopharyngeal carcinoma(UNPC} in both endemic and non-endemic regions(23 , 
24}. UNPC has the same EBV latency pattern as cHL with expression of only 
LMPs and EBNA 1 and it was suggested that HLA-A* 11 can efficiently present 
antigenic peptides from these proteins(24, 25}. Therefore, specificity of a probe for 
both HLA-A * 11 and HLA-A *0 1 might diminish the strength of its association with 
EBV+ cHL. Owrall, our genotype analysis clearly demonstrated that not the 
individual probes but the complete HLA-A*0 1 and HLA-A*02 alleles are important 
for this association. The allele frequency analysis supported the importance of 
HLA A1 and HLA-A2 in the association with EBV+cHL. 
The strong linkage disequilibrium obsel'\€d in the HLA region might affect the 
results of our HLA association studies. The HLA-A 1 antigen is known to be in 
strong linkage disequilibrium with HLA-B8 and in contrast to HLA-A1, HLA-B8 is 
capable of presenting EBV-deriwd peptides(26}. We obseMd that in the EBV+ 
cHL population 53% (23/43} of the HLA-A 1 positive patients also possessed the 
HLA-B8 allele, whereas in the EBV- cHL population this percentage was 66% (46/ 
70 }. In theory, presence of HLA-B8 in HLA-A1 carrying EBV + cHL, might 
owrcome the less effectiw presentation of EBV deriwd peptides by HLA-A 1. 
Newrtheless we saw a wry significant effect for HLA-A in this study consistent 
with previous studies(5, 14, 15}, and no significant differences for HLA-B8. 
The predisposing effects of HLA-B37 and HLA-DR10 for EBV+cHL might at 
least be partly attributed to their strong linkage disequilibrium with HLA-A 1 since 
HLA-A1-837-Cw&DR10 -DQ5 is a rather common haplotype in the Caucasian 
population. In our study, 13 of 14 HLA-B37+ and five of six HLA-DR10+EBV+cHL 
patients also carried HLA-A 1. Although we do not have haplotype data available, 
sewn patients were found to potentially possess the HLA-A1-B37-DR10 
haplotype, in which fiw were EBV+. 
Two associations(HLA-A68(28} and HLA-DR11 (5}} were present in both the 
EBV- and EBV+cHL subgroups and are thus specific for the total cHL subgroup 
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irrespecth,e of the EBV status. These associations have not been reported 
previously. An association with HLA-DRS has been reported previously by 
Robertson et al (27) in familial cHL. Significant effects of HLA-A 1, HLA-88 and 
HLA-818 for cHL that have been reported in previous publications(11-13) could not 
be confirmed in the total patient group in our study, whereas the previously 
reported association with HLA-85 (28) was borderline significant in our study. 
These differences might be explained by differences in sample size, patient 
selection, and proportion of EBV+ cases. The previous studies were carried out in 
relatively small numbers of patients ranging from 11 to 137 within different 
countries such as Egypt, Czech Republic, Sweden, Denmark, and United States. 
Distribution of HLA alleles varies widely by ethnicity and geography, which might 
lead to differences in disease-associated HLA alleles among different ethnic 
groups and geographic locations. In addition most case-control studies used low­
resolution serological HLA typing. A limitation of this approach is the inability to 
discriminate between specific allele variants, which might be more or less 
common in different populations. 
The HLA-DR4, HLA-DR7 and HLA-DR15(2) class II associations were not 
obseMd in the EBV+ subgroup and represent associations specific for the EBV­
cHL subgroup. The HLA-A 1 and HLA-A2 class I associations were specific for the 
EBV + cHL subgroup. HLA class II molecules mainly function as binding and 
presenting exogenous antigenic peptides to CD4+ helper T cells , whereas HLA 
class I is known to bind and present peptides derived from endogenous proteins 
to CDS + cytotoxic T lymphocytes (29). Our findings thus support a differential 
immunogenic basis with a more prominent role in the effector phase of the 
immune response for HLA class I in EBV+ cHL and an immunoregulatory role for 
HLA class II in the pathogenesis of EBV- cHL. This suggests presence of a 
specific HLA class II restricted antigen im,olved in the pathogenesis of EBV- cHL. 
Whether this is a pathogen-derived antigen or an antigen derived from a mutated 
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protein remains unknown. 
In conclusion, the current study confirms the previously reported genetic 
association of the HLA-A 1 and HLA-A2 in EBV + cHL. The genetic influence of 
these two HLA antigens is more important than individual SNPs that might be 
shared by multiple HLA-A alleles. In addition, we demonstrated two significant 
associations for the cHL population, three significant HLA class II associations 
specific for the EBV- cHL population and one additional association for the EBV 
+ cHL subgroup. This implies an influence of the interaction between 
environmental and genetic risk factors in the dewlopment of cHL and supports 
heterogeneity in the genetic predisposition to EBV+ and EBV- cHL. 
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c o n t i n u e d  
a l l  cas es  '18r'S u s  cont rols  
O R  99 . 9 % C I  p - '18 l ue  
0 . 3 5  0 . 08  1 . 5 5  1 . 5 E - 0 2  
0.39 0 . 0 7  2.09 5 . 7E - 02  
1 . 2 9  0 . 6 7  2 . 5 2  2 . 0E - 0 1  
0 . 60  
0 . 2 7  
1 . 3 7  4 . 1 E - 0 2  
1 . 1 6  0 . 7 4  
1 . 80  2 . BE - 0 1  
1 . 89  0 . 92  3 . 9 1  3 . 3 E - 03  
0 . 7 3  0 . 25  2 . 1 1  
3 . 3 E - 0 1  
1 . 5 1  0 . 4 2  
5 . 5 1  2 . 9 E - 0 1  
0 . 7 0  0 . 4 4  1 . 1 2  1 . 3 E - 02  
2 . 1 2  0 . 62  7 . 2 2  
3 . B E - 0 2  
1 . 6 1  0 . 99  
2 . 64  1 . 2 E - 03  
0 . 5 3  0 . 1 4  2 . 0 7  1 . 2 E - 0 1  
0 . 7 4  0 . 30  
1 . 8 2  2 . 6 E - 0 1  
0 . 54  0 . 28  
1 . 06  2 . 3 E - 03  
1 . 84  o . n  4 . 38  1 . 9E - 0 2  
0 . 95  
0 . 59  
1 . 5 3  7 . 0 E - 0 1  
1 . 00  0 . 5 5  










C 7  
C8  
C 1 2  
C 1 4  
C 1 5  
C 1 6  
C 1 7  
H.A- 00  
DQ B 2  
DQ B 4  
DQ B 5  
DQ B 6  
DQ B 7  
DQ B 8  
E B V +  
7  
4.5 
2 0  1 3 . 0  
1 6  1 0 . 4  
8  5 . 2  
2 1  1 3 . 6  
58  3 7 . 7  
5  3 . 2  
4  2 . 6  
3  1 . 9  
8  5.2 
3  1 . 9  
1  0 . 6  
1 50  %  
25 1 6 . 7  
8  5 . 3  
30  2 0 . 0  
49  32 . 7  
1 5  1 0 . 0  
2 1  1 4 . 0  
Al lel e  fr8CJ,lency  
E B V -
E B V ?  A l l  c a s e s  
2 5  5.5 1  2 . 2  33  5 . 0  
69  1 5 . 2  
6  1 3 . 0  95  1 4 . 5  
54  1 1 . 9  
6  1 3 . 0  7 6  1 1 . 6  
30  6 . 6  
2  4 . 3  
40  6 . 1  
2 7  5.9 1  2 . 2  49 7.5 
1 84  40 . 5  
23  50 . 0  2 6 5  40 . 5  
1 1  2 . 4  
1  2 . 2  1 7  2 . 6  
1 1  2 . 4  
2  4.3 1 7  2 . 6  
8  1 . 8  
2  4.3 1 3  2 . 0  
13 2.9 1  2 . 2  22  3.4 
3  0 . 7  
1  2 . 2  7  1 . 1  
4  0 . 9  0  0 . 0  
5  0 . 8  
4 54  %  5 2  
%  
656  %  
7 1  1 5 . 6  9  1 7 . 3  1 0 5  1 6 . 0  
7  1 . 5  
1  1 . 9  1 6  2 . 4  
69  1 5 . 2  
1 0  1 9 . 2  1 09  
1 6 . 6  
1 6 9  3 7 . 2  
1 7  3 2 . 7  235  
35 . 8  
90  1 9 . 8  
1 3  2 5 . 0  1 1 8  
1 8 . 0  
32  
7.0 2  3 . 8  55  8 . 4  
E B V +  wrs u s  E B V -
Co n t ro l s  O R  
99 . 9 % C I  p- \0 I U 8  
0 . 8 2  0 . 1 9  3.46 6 . 4E - 0 1  
0 . 83  0 . 34  2 . 0 5  5 . 0E - 0 1  
0 . 86  0 . 32  
2 . 3 1  6 . 1 E - 0 1  
0 . 7 7  0 . 2 0  
2 . 9 8  5 . 3E - 0 1  
2 . 50  0 . 9 1  6 . 8 7  2 . 2 E - 03  
0 . 89  0 . 4 7  1 . 6 7  5 . 3 E - 0 1  
1 . 35  
0 . 22  8 . 1 9  5 . BE - 0 1  
1 . 0 7  0 . 1 5  
7 . 5 2  
9 . 0E - 0 1  
1 . 1 1  0 . 1 2  1 0 . 50  8 . 8 E - 0 1  
1 . 86  0 . 4 1  
8 . 4 3  1 . 7 E - 0 1  
2 . 99  0 . 2 0  
44.64 1 . 6 E - 0 1  
0 . 7 4  0 . 02  2 9 . 50  7 . B E - 0 1  
1 . 08  0.47 2 . 4 9  7 . 7E - 0 1  
3 . 60  0 . 64  
2 0 . 34  9 . 7 E - 03  
1 . 39  0 . 63  3 . 1 0  1 . 7 E - 0 1  
0 . 82  0 . 4 2  1 . 58  3 . 1 E - 0 1  
0 . 4 5  0 . 1 7  1 . 1 9  5 . 9 E - 03  
2 . 1 5  0 . 80  5.73 9 . 1 E - 0 3  
E B V +  wrs u s  c ont rol s  E B V - w rs u s  c ont rol s  
O R  99 . 9 % C I  
p- \0 l u e  
O R  99 . 9 % C I  
p - \0 l u e  
c o n t i n u e d  
al l  cas es  wrs u s  c ont rol s  





















DQ 8 9  
HA �  
D R 1  
D R 3  
D R 4  
D R 7  
D R S  
D R9  
D R 1 0  
D R 1 1  
D R 1 2  
D R 1 3  
D R 1 4  
D R 1 5  
Ot h e rs  
H LA - D F  
CPO'l :O'  
rP0201  
E B V +  
2  
1 . 3  
1 56  o/o  
1 7  
1 0 . 9  
2 4  1 5 . 4  
26  
1 6 . 7  
7  4.5 
8  5 . 1  
0  0 . 0  
6  3 . 8  
7  4 . 5  
2  1 . 3  
2 4  1 5 . 4  
6  3 . 8  
2 7  1 7 . 3  
2  1 . 3  
1 56  
%  
4  2 . 6  
26  
1 6 . 7  
Al lel e  freq uency  
E B V -
E B V ?  
A l l  c a s e s  
Co n t r o l s  
1 6  
3 . 5  0  
0 . 0  1 8  
2 . 7  
462  
%  54  o/o  6 7 2  o/o  
1 1 844  %  
46  
1 0 . 0  8  
1 4 . 8  7 1  1 0 . 6  
1 50 1  1 2 . 7  
60  
1 3 . 0  
7  
1 3 . 0  9 1  
1 3 . 5  
1 8 7 1  1 5 . 8  
56  1 1 . 9  4  7.4 85  1 2 . 6  2 1 46  1 8 . 1  
2 6  
5 . 6  
2  3.7 35  
5 . 2  1 32 0  1 1 . 1  
9  
1 . 9  1  1 . 9  1 8  
2 . 7  
4 29  3 . 6  
5  1 . 1  0  
0 . 0  5  
0 . 7  1 8 7  1 . 6  
5  
1 . 1  
0  
0 . 0  1 1  
1 . 6  
1 1 8  1 . 0  
60  1 3 . 0  1 0  1 8 . 5  n  1 1 . 5  
8 7  0.7 
6  1 . 3  1  1 .9 9  1 . 3  
2 83  2 . 4  
68  
1 4 . 7  
8  
1 4 . 8  1 00  1 4 . 9  
1 6 1 3  1 3 . 6  
1 6  3.5 2  3 . 7  2 4  3 . 6  
384  3 . 2  
1 04  22 . 5  1 1  
2 0 . 4  1 4 2  2 1 . 1  1 690  1 4 . 3  
2  
0 . 4  0  
0 . 0  
4  





672  %  
2 0  4.3 4  7.4 28  4 . 2  
4 8  1 0 . 4  3  
5 . 6  n  1 1 . 5  
E B V +  wrs us  E B V -
E B V +  wrs u s  cont rol s  
O R  99 . 9 % C I  
p- '81 u e  O R  
99 . 9 % C I  
p- va l u e  
0 . 3 7  0 . 03  4 . 45  
1 . 7E - 0 1  
1 . 1 1  0 . 4 1  2 . 9 7  
7 . 4 E - 0 1  0 . 84  
0 . 3 6  1 . 9 7  
5 . 1 E - 0 1  
1 . 22  
0 . 5 2  2 . 88  4 . 5 E - 0 1  0 . 9 7  
0 . 4 6  2 . 0 2  
8 . 9 E - 0 1  
1 .48 0 . 63  3 . 4 6  1 . 3 E - 0 1  0 . 90  
0 . 44  
1 .84 6 . 4 E - 0 1  
0 . 7 9  0 . 1 9  3 . 3 1  
5 . B E - 0 1  0 . 3 7  
0 . 1 0  
1 .34 8 . 4 E - 03  
2 72  
0 . 53  1 3 . 8 7  3 . 6 E - 02  1 . 44  
0 . 4 3  4 . 80  3 . 2 E - 0 1  
nd  
n d  nd  
nd  n d  
n d  
nd  
n d  
3 . 66  0 . 4 9  2 7 . 46  
2 . 4 E - 02  3 . 9 7  
0 . 98  
1 6 . 1 7  
4 . 7 E - 04  
0 . 3 1  0 . 08  1 . 22  3 . 2 E - 03  6 . 35  
1 . 69  2 3 . 79  
1 . 3E - 0 7  
0 . 99  0 . 0 7  1 4 . 7 5  
9 . 9E - 0 1  0 . 53  
0 . 05  5 . 56  3 . 7E - 0 1  
1 . 0 5  0 . 45  
2 . 46  
8 . 4 E - 0 1  1 . 1 5  
0 . 5 5  2 . 4 1  5 . 2 E - 0 1  
1 . 1 2  0 . 22  
5 . 56  8 . 2 E - 0 1  1 . 1 9  
0 . 30  
4.75 6 . 7 E - 0 1  
0 . 7 2  0 . 33  1 . 58  1 . 7 E - 0 1  
1 . 2 6  
0 . 6 2  2 . 54  
2 . B E - 0 1  
2 . 99  0 . 1 1  8 1 . 3 7  2 . 5 E - 0 1  
0 . 7 0  
0 . 0 7  7 . 39  6 . 2 E - 0 1  
0 . 58  
0 . 09  3 . 62  3 . 2 E - 0 1  
1 .73 0 . 72  4 . 1 0  
3 . 7 E - 02  
E B V - wrs u s  cont rol s  
O R  99 . 9 % C I  
p- \8 ( U e  
0 . 7 6  
0 . 4 5  
1 . 2 8  8 . 4 E - 0 2  
0 . 8 0  
0 . 50  1 . 26  1 . 0 E - 0 1  
0 . 6 1  
0 . 38  
0 . 99  6 . 3 E - 04  
0 . 4 8  0 . 2 4  
0 . 9 3  1 . 9E - 04  
0 . 5 3  
0 . 1 7  1 . 6 2  5 . 7E - 0 2  
0 . 68  
0 . 1 5  
3 . 05  4 . 0 E - 0 1  
1 . 09  
0 . 2 4  4 . 92  8 . 6E - 0 1  
20 . 1 7  1 1 . 33  
35 . 9 1  < 1 0 E - 1 C  
0 . 54  0 . 1 4  2 . 1 1  1 . 3E - 0 1  
1 . 09  0 . 7 0  1 . 7 0  
5 . 0 E - 0 1  
1 . 0 7  
0 . 4 6  
2.52 7 . 9E - 0 1  
1 . 7 5  1 . 20 ·  
2 . 54  8 . 4 E - 0 7  
0 . 2 4  
0 . 0 2  
2 . 45  2 . 7 E - 0 2  
c o n t i n u e d  
a l l  cas es  wrs u s  cont rols  
O R  99 . 9 % C I  
p- '8 l u e  
0 . 8 1  0 . 5 3  
1 . 2 4  1 . 1 E - 0 1  
0 . 8 3  0 . 5 7  1 . 2 2  1 . 2 E - 0 1  
0 . 6 5  0 . 4 4  0 . 9 7  3 . 1 E - 04  
0 . 4 4  0 . 2 5  0 . 7 8  1 . 4 E - 06  
0 . 7 3  0 . 33  
1 . 6 3  2 . 0 E - 0 1  
0 . 4 7  0 . 1 0  
2 . 09  8 . 7 E - 02  
1 . 6 5  0 . 58  
4 . 7 1  1 . 1 E - 0 1  
17,4g 1 0 . 2E  
29 . 00  < 1 0E - 1 0  
0 . 5 5  
0 . 1 8  
1 . 7 0  7 . 9 E
- 02  
1 . 1 1  o . n  
1 . 60  3 . 5 E - 0 1  
1 . 1 1  
0 . 56  2 . 2 4  
6 . 4 E - 0 1  
1 . 6 1  1 . 1 7  
2 . 2 2  9 . B E - 0 7  





Al l el e  frequency  
E B V +  E B V - E B V ?  A l l  c a s e s  
IF04 :0::  
5  3 . 2  4 1  8 . 9  7  1 3 . 0  5 3  
7 . 9  
/ 1 0 5 : 0 1  
lFCR01  
22  1 4 . 1  85  1 8 . 4  1 2  22 . 2  1 1 9  1 7 . 7  
IF04 : 01  
79  50 . 6  
1 94  4 2 . 0  
2 1  
38 . 9  
294  
43 . 8  
[P(li-()1 
3  1 . 9  
8  
1 . 7  0  0 . 0  1 1  1 . 6  
IF00: 01  
3  1 . 9  
5  
1 . 1  3  5 . 6  1 1  1 . 6  
IF 1 001  1  0 . 6  
5  
1 . 1  1  
1 . 9  7  1 . 0  
IF 1 3;01  
4  
2 . 6  9  
1 . 9  
0  
0 . 0  1 3  1 . 9  
IF 1 4 : 0 1  1  0 . 6  1 4  
3 . 0  
0  
0 . 0  1 5  
2 . 2  
CP 1 9:0'  
5  3.2 8  1 . 7  0  0 . 0  1 3  1 . 9  
O t h e rs  3  1 . 9  
25 5 . 4  3  5 . 6  3 1  4 . 6  
•  A l l e l i c  fre q u e n c y <  1 %  wa s  e x c l u d e d  
E B V +  w rs u s  E B V -
Co n t ro l s  
O R  99 . 9 % C I  p- w l u e  
0 . 34  0 . 0 7  
1 . 6 7  
2 . 0 E - 02  
0 . 7 3  0 . 3 1  1 . 7 1  2 . 2 E - 0 1  
1 . 4 2  o . n  
2 . 6 1  
6 . 0 E - 02  
1 . 1 1  0 . 1 2  
1 0 . 55  
8 . BE - 0 1  
1 . 7 9  
0 . 1 6  2 0 . 2 1  4 . 2 E - 0 1  
0 . 59  0 . 02  
2 1 . 96  6 . 3E - 0 1  
1 . 32  0 . 1 8  9 . 8 0  6 . 4 E - 0 1  
0 . 2 1  0 . 0 1  6 . 3 1  9 . 4 E - 02  
1 . 88  
0 . 2 8  1 2 . 58  2 . 7 E - 0 1  
0 . 34  0 . 04  
2 . 6 2  
7 . 0 E - 02  
E B V +  \GIS U S  cont rol s  E B V - \GIS U S  cont rol s  
O R  99 . 9 % C I  p- w l u e  O R  99 . 9% C I  p- \a l u e  
c o n t i n u e d  
a l l  cas es  \Gl"S u s  cont rol s  
O R  99 . 9 % C I  























T a b l e  S 2  H LA  p h e n o ty p e  freq u e n c i es  i n c l ud i ng  O R  a n d  p- va l u e  
H I.A  P henotype  
E B V +  wra us  E B V -
E B V +  
E B V - E B V ?  A l l  c a s e s  Co n t ro l s  
O R  99 . 9 % C I  p- w l u e  
HI.A-A 
78  %  232  %  27  %  'J3 7  %  7099  %  
A 1  
43  55 . 1  7 0  30 . 2  7  2 5 . 9  1 2 0  35 . 6  
2 4 2 6  34 . 1 7  2 84  1 . 1 7  6 . 89  
7 . 4 E - 05  
A 2  
2 3  
29.5 1 23  5 3 . 0  1 6  5 9 . 3  1 6 2  4 8 . 1  405 2  5 7 . 08  0 . 3 7  0 . 1 5  0 . 93  
3 . 2 E - 04  
A 3  
2 7  34 . 6  56  2 4 . 1  1 1  4 0 . 7  94  2 7 . 9  
2296  3 2 . 34  1 . 66  0 . 66  
4 . 22  7 . 1 E - 0 2  
A 1 1  8  1 0 . 3  30  1 2 . 9  0  0 . 0  38  1 1 . 3  
7 1 3  1 0 . 04  0 . 7 7  0 . 1 9  
3 . 08  5 . 3 E - 0 1  
A2 3  
3  3 . 8  4  1 . 7  0  0 . 0  7  2 . 1  1 5 1  2 . 1 3  
2 . 28  0 . 1 8  29.23 2 . 8 E - 0 1  
A 2 4  1 4  1 7 . 9  4 2  
1 8 . 1  5  1 8 . 5  
6 1  
1 8 . 1  
1 2 58  1 7 . 72  
0 . 99  0 . 32  3 . 04  9 . 8 E - 0 1  
A2 5  2  2 . 6  
6  2 . 6  1  
3 . 7  
9  
2 . 7  
83  
1 . 1 7  
0 . 99  0 . 0 7  1 5 . 08  9 . 9 E - 0 1  
A26  4  5 . 1  8  3.4 0  0 . 0  1 2  3 . 6  
2 59  
3.65 1 . 5 1  0 . 1 9  1 1 . 9 1  
5 . 1 E - 0 1  
A 29  3  3 . 8  8  3.4 1  3.7 1 2  3 . 6  3 58  5.04 1 . 1 2  0 . 1 2  1 0 . 85  8 . ? E - 0 1  
A 30  
1  1 . 3  0  
0 . 0  
0  
0 . 0  1  0 . 3  
1 85  2 . 6 1  nd  n d  
n d  8 . 4 E - 02  
A 3 1  
1  1 . 3  1 6  
6 . 9  1  3 . 7  
1 8  
5 . 3  
405  
5 . 7 1  0 . 1 8  0 . 0 1  5 . 36  
6 . 0 E - 0 2  
A 32  
6  
7.7 1 3  
5 . 6  
4  
1 4 . 8  23  6 . 8  
4 9 1  6 . 9 2  1 . 4 0  0 . 26  7 . 57  5 . 1 E - 0 1  
A 68  4  5 . 1  2 6  1 1 . 2  3  1 1 . 1  
33  9.8 1 2 4  1 . 7 5  
0 . 4 3  0 . 0 7  2 . 65  1 . 2 E - 0 1  
O t h e rs  
2  2 . 6  2  
0 . 9  
0  
0 . 0  4  
1 . 2  1 2 7  1 . 7 9  
3 . 0 3  0 . 1 1  8 3 . 85  
2 . 5E - 0 1  
1-1.A - B  77  %  222  
%  25  %  324  %  7283  %  
B 7  
2 5  32 . 5  79  
35 . 6  1 0  40 . 0  1 1 4  35 . 2  22 3 3  30 . 7  0 . 8 7  0 . 35  
2 . 1 9  6 . 2 E - 0 1  
B 8  24 3 1 . 2  58  26 . 1  5  2 0 . 0  8 7  2 6 . 9  
1 93 2  26 . 5  1 . 28  0 . 49  3.32 3 . 9 E - 0 1  
E B V +  wra u s  cont rols  E B V - wra u s  cont rol s  
all  cas es  w rs u s  cont rols  
O R  99 . 9 % C I  
p- va l u e  O R  99 . 9 % C I  p- w l u e  
O R  99 . 9 % C I  p- w l u e  
2 . 3 7  1 . 1 1  5 . 03  1 . 1 E - 04  0 . 8 3  0 . 52  1 . 34  2 . 1 E - 0 1  1 . 0 7  0 . 7 3  1 . 56  5 . 9 E - 0 1  
0 . 3 1  0 . 1 4  0 . 7 1  1 . 0 E - 06  0 . 8 5  
0 . 55  1 . 32  2 . 2E - 0 1  0 . 7 0  0 . 4 8  
1 . 0 1  1 . 1 E - 0 3  
1 . 1 1  
0 . 50  2 . 4 3  6 . ? E - 0 1  0 . 6 7  
0 . 4 0  1 . 1 1  8 . 4E - 0 3  
0 . 8 1  0 . 54  
1 . 2 2  8 . 7E - 02  
1 . 02  0 . 3 0  3.52 9 . 5 E - 0 1  1 . 3 3  
0 . 69  2 . 5 7  1 . 5E - 0 1  1 . 1 4  0 . 64  
2 . 04  4 . 6 E - 0 1  
1 . 84  0 . 2 6  1 3 . 02  3 . 0 E - 0 1  0 . 8 1  0 . 1 5  4.34 6 . ?E - 0 1  0 . 98  0 . 2 7  3 . 5 3  9 . 5E - 0 1  
1 . 02  
0 . 38  
2 . 7 0  
9 . 6 E - 0 1  1 . 0 3  
0 . 58  1 . 82  
8 . 8 E - 0 1  1 . 0 3  0 . 64  1.65 8 . 6 E - 0 1  
2 . 22  
0 . 2 0  2 4 . 1 6  2 . 6 E - 0 1  2 . 2 4  
0 . 55  9 . 1 8  5 . 2E - 0 2  2 . 3 2  0 . 72  
7 . 4 7  1 . S E - 02  
1 . 4 3  
0 . 2 6  7 . 8 3  4 . 9 E - 0 1  0 . 94  
0 . 28  3.14 8 . ?E - 0 1  
0 . 98  0 . 36  2 . 6 2  9 . 3 E - 0 1  
0 . 7 5  
0 . 1 1  5 . 2 7  6 . 3E - 0 1  0 . 6 7  
0 . 20  2 . 2 3  2 . ?E - 0 1  0 . 7 0  0 . 26  1 . 86  2 . 2 E - 0 1  
0 . 49  0 . 0 2  1 3 . 44  4 . 6 E - 0 1  n d  nd  
n d  1 . 3E - 0 2  
0 . 1 1  0 . 00  3 . 0 3  8 . 0 E - 03  
0 . 2 1  
0 . 0 1  5 . 9 1  
9 . 3 E - 02  
1 . 22  
0 . 5 1  2 . 92  4 . 4 E - 0 1  
0 . 9 3  0 . 4 1  2 . 1 1  
7 . 8 E - 0 1  
1 . 1 2  0 . 2 7  4 . 58  7 . 9 E - 0 1  0 . 80  0 . 3 1  2 . 0 7  4 . 4E - 0 1  
0 . 99  0 . 48  2 . 04  9 . S E - 0 1  
3 . 04  0 . 55  1 6 . 90  2 . 5 E - 02  
7 . 1 0  3.36 1 4 . 9 8  < 1 0E - 1 C  6 . 1 1  3 . 1 2  1 1.97 < 1 0E - 1 0  
1 . 44  0 . 1 3  1 5 . 54  
6 . 1 E - 0 1  0 . 4 8  0 . 05  5 . 0 2  2 . 9 E - 0 1  
0 . 66  0 . 1 2  3 . 54  4 . 1 E - 0 1  
1 . 09  
0 . 4 9  2 . 4 3  7 . 3E - 0 1  1 . 2 5  0 . 7 8  
2 . 00  1 . 2E - 0 1  
1 . 2 3  0 . 8 3  1 . 8 2  8 . 4 E - 02  
1 . 2 5  0 . 56  2 . 83  3 . 6E - 0 1  0 . 9 8  0 . 59  
1 . 63  8 . 9E - 0 1  
1 . 0 2  0 . 6 7  1 . 5 5  9 . 0 E - 0 1  
C)  
"-l  
B 1 3  
B 1 4  
B 1 8  
B 2 7  
B 3 5  
B 3 7  
B 39  
B 4 1  
B 44  
B 4 9  
B 5 1  
B 55  
B 5 7  
B 60  
B 6 1  
B 62  
O t h e rs  
tl.A -C  
C 1  
E B V +  
0  0 . 0  
3  3.9 
4  5 . 2  
1  
1 .3 
1 2  1 5 . 6  
1 3  1 6 . 9  
3  3 . 9  
1  1 . 3  
1 2  1 5 . 6  
2  2 . 6  
1 3  1 6 . 9  
0  0 . 0  
7  9 . 1  
8  1 0 . 4  
4  5 . 2  
9  1 1 . 7  
7  9.1 
77  %  
0  0 . 0  
H LA  P henotype  
E B V -
E B V ?  
A l l  c a s e s  C o n t r o l s  
5  2 . 3  0  0 . 0  5  1 . 5  3 1 1  4.3 
9  4 . 1  1  4 . 0  1 3  4 . 0  
22 4  
3 . 1  
1 7  7 . 7  
6  2 4 . 0  
27 8 . 3  465  6 . 4  
1 4  6 . 3  
1  4 . 0  1 6  4 . 9  60 3  8 . 3  
4 3  1 9 . 4  4  1 6 . 0  59  1 8 . 2  
1 2 1 4  
1 6 . 7  
1 0  4.5 
0  0 . 0  23  
7 . 1  2 7 0  
3 . 7  
7  3.2 
0  0 . 0  
1 0  3.1 3 06  4 . 2  
4  1 . 8  
1  4 . 0  
6  1 . 9  1 04  
1 . 4  
37 1 6 . 7  
3  1 2 . 0  52  1 6 . 0  1 6 93  2 3 . 2  
5  2 . 3  
1  4 . 0  8  
2 . 5  85  
1 . 2  
3 1  1 4 . 0  
5  
2 0 . 0  
49 1 5 . 1  7 4 4  1 0 . 2  
6  2 . 7  
0  0 . 0  
6  1 . 9  2 5 2  3.5 
7  3.2 0  0 . 0  1 4  4.3 4 2 1  5.8 
1 4  
6 . 3  
3  1 2 . 0  2 5  7 . 7  
1 03 7  
1 4 . 2  
1 1  5 . 0  
1  4 . 0  
1 6  4 . 9  1 9 7  
2 . 7  
38  1 7 . 1  4  1 6 . 0  5 1  1 5 . 7  
1 2 72  
1 7 . 5  
2 3  1 0 . 4  
3  1 2 . 0  3 3  
1 0 . 2  739 1 0 . 1  
m  %  23  %  '3Zf  %  
1 5  6 . 6  0  0 . 0  1 5  4 . 6  
E B V +  wrs u s  E B V -
E B V +  wrs u s  cont rol s  
O R  99 . 9 % C I  p- "8 1 U e  O R  
99 . 9 % C I  p- "8 1 U e  
n d  n d  n d  1 . BE - 0 1  n d  n d  nd  
6 . 4 E - 0 2  
0 . 96  
0 . 1 0  9 . 00  9 . 5 E - 0 1  1 . 2 8  0 . 1 8  8 . 99  
6 . B E - 0 1  
0 . 66  
0 . 1 0  4 . 34  4 . 7E - 0 1  
0 . 80  
0 . 1 5  4.39 6 . 7 E - 0 1  
0 . 20  0 . 0 1  6 . 06  8 . 3 E - 0 2  0 . 1 5  0 . 0 1  4 . 0 1  
2 . 6 E - 0 2  
0 . 77  0 . 2 4  2 . 4 9  4 . 6 E - 0 1  0 . 92  0 . 3 3  2 . 6 1  
8 . 0E - 0 1  
4 . 3 1  1 . 00  1 8 . 57  
4 . 4 E - 04  
5 . 2 8  1 . 90  
1 4 . 66  2 . 2 E - Q 9  
1 . 2 5  0 . 1 2  1 2 . 59  7 . 5 E - 0 1  0 . 9 2  0 . 1 3  6 . 4 8  
8 . 9 E - 0 1  
0 . 7 2  0 . 02  
2 9 . 1 5  7 . 7 E - 0 1  
0 . 9 1  
0 . 03  25.33 9 . 2 E - 0 1  
0 . 9 2  0 . 2 8  3.04 8 . 3 E - 0 1  0 . 6 1  0 . 22  1 . 7 2  1 . 1 E - 0 1  
1 . 1 6  0 . 0 7  1 8 . 8 1  8 . 6 E - 0 1  2 . 2 6  0 . 2 1  2 4 . 5 2  
2 . S E - 0 1  
1 . 2 5  0 . 38  
4 . 1 0  5 . 3 E - 0 1  1 . 7 9  0 . 6 5  
4.90 5 . 5 E - Q 2  
n d  n d  
n d  1 . S E - 0 1  
n d  
n d  nd  
9.7E-Q2 
3 . 0 7  0 . 50  1 8 . 88  3 . 4 E - 02  1 . 63  
0 . 44  6 . 0 7  
2 . 2 E - 0 1  
1 . 7 2  0 . 3 7  7 . 94  2 . 4 E - 0 1  0 . 7 0  0 . 2 0  
2 . 40  3 . 4 E - 0 1  
1 . 05  0 . 1 5  7.56 9 . 3 E - 0 1  1 . 9 7  0 . 3 6  1 0 . 86  1 . B E - 0 1  
0 . 64  
0 . 1 7  2 . 3 7  2 . 6 E - 0 1  0 . 63  
0 . 1 9  2 . 02  1 . BE - 0 1  
0 . 8 7  0 . 1 9  3 . 8 5  7 . 5 E - 0 1  0 . 89  
0 . 2 4  
3.28 7 . 6 E - 0 1  
n d  n d  
n d  2 . 1 E - 0 2  
E B V - wrs u s  cont rol s  
O R  
99 . 9 % C I  p- "8 1 U e  
0 . 5 2  0 . 1 2  
2 . 3 2  1 . 4E - 0 1  
1 . 3 3  0 . 4 3  4 . 1 7  
4 . 1 E - 0 1  
1 . 2 2  
0 . 52  2 . 83  4 . S E - 0 1  
0 . 7 5  0 . 30  
1 . 8 7  2 . 9 E - 0 1  
1 . 2 0  
0 . 68  
2 . 1 2  2 . 9 E - 0 1  
1 . 2 3  0 . 4 1  3 . 62  
5 . 4 E - 0 1  
0 . 7 4  0 . 2 1  2 . ol  
4 . 4 E - 0 1  
1 . 2 7  
0 . 2 3  6 . 88  
6 . 5 E - 0 1  
0 . 66  0 . 36  1 . 2 0  
2 . 2 E - 0 2  
1 . 9 5  0 . 4 2  
9 . 02  1 . 4 E - 0 1  
1 . 4 3  0 . 7 4  
2 . 73  7 . 1 E - 02  
0 . 7 8  0 . 20  
3 . 0 7  5 . 4 E - 0 1  
0 . 5 3  
0 . 1 5  1 . 90  
9 . 6 E - 0 2  
0 . 4 1  
0 . 1 6  1 . 0 1  7 . 9 E - 04  
1 . 88  0 . 66  
5.33 4 . 4 E - 02  
0 . 9 8  0 . 54  
1 . 77  8 . 9E - 0 1  
1 . 0 2  0 . 4 9  
2 . 1 4  9 . 2 E - 0 1  
c o n t i n u e d  
a l l  cas es  wrs u s  cont rol s  
O R  99 . 9 % C I  p- "8 1 U e  
0 . 35  
0 . 08  1 . 5 7  
1 . 6 E - 0 2  
1 . 3 2  
0 . 5 1  3 . 4 3  
3 . 4 E
-
0 1  
1 . 3 3  
0 . 68  
2 . 63  
1 . 6 E - 0 1  
0 . 58  
0 . 2 4  1 . 35  
3 . 1 E - 02  
1 . 1 1  
0 . 69  
1 . 8 1  4 . 7 E - 0 1  
1 . 98  
0 . 95  
4 . 1 6  1 . 9 E - 03  
0 . 7 3  0 . 2 5  2 . 1 3  
3 . 2 E - 0 1  
1 . 30  0 . 32  5 . 2 5  
5 . 3 E - 0 1  
0 . 6 3  0 . 38  1 . 05  
2 . 6 E - 03  
2 . 1 4  0 . 63  7.35 3 . 7 E - 02  
1 . 5 7  0 . 9 3  2 . 65  
4 . 7 E - 0 3  
0 . 53  0 . 1 3  2 . 08  
1 . 2 E - 0 1  
0 . 7 4  
0 . 30  
1 .84 2 . 7 E - 0 1  
0 . 50  
0 . 2 5  
1 . 0 1  9 . 2 E - 04  
1 . 8 7  0 . 7 8  4.49 1 . 7 E - 02  
0 . 88  0 . 5 3  
1 . 4 7  
4 . 2 E - 0 1  
1 . 00  0 . 54  1 . 86  

























C 5  
C 6  
C 7  
C8  
C 1 2  
C 1 4  
C 1 5  
C 1 6  
C 1 7  
HA- IX  
00 8 2  
DQ B 4  
00 8 5  
00 8 6  
00 B 7  
00 8 8  
E 8 V +  
6  7 . 8  
1 9  2 4 . 7  
1 5  
1 9 . 5  
8  1 0 . 4  
2 0  26 . 0  
4 6  
59.7 
5  6 . 5  
4  5 . 2  
3  3.9 
8  1 0 . 4  
3  3 . 9  
1  
1 . 3  
7 5  %  
23  30 . 7  
8  
1 0 . 7  
2 6  34 . 7  
38  50.7 
1 3  1 7 . 3  
20  2 6 . 7  
E 8 V -
2 4  1 0 . 6  
6 2  2 7 . 3  
4 9  
2 1 . 6  
29  1 2 . 8  
26  1 1 . 5  
1 38  
60 . 8  
1 1  4 . 8  
1 1  
4 . 8  
8  3 . 5  
1 2  
5 . 3  
3  1 . 3  
4  1 . 8  
w  %  
64  2 8 . 2  
7  3 . 1  
59  
26 . 0  
1 3 3  
58 . 6  
7 8  
34 . 4  
2 8  1 2 . 3  
HlA  P henotype  
E 8 V ?  
A l l  c a s e s  
C o n t ro l s  
1  4 . 3  3 1  9 . 5  
6  
2 6 . 1  8 7  26 . 6  
6  
2 6 . 1  7 0  
2 1 . 4  
2  
8 . 7  39  1 1 . 9  
1  4.3 47 1 4 . 4  
1 6  
6 9 . 6  200  6 1 . 2  
1  
4 . 3  1 7  5 . 2  
2  8 . 7  1 7  
5 . 2  
2  
8 . 7  1 3  4 . 0  
1  4 . 3  2 1  
6 . 4  
1  4.3 7  2 . 1  
0  
0 . 0  5  1 . 5  
26  
%  328  %  
8  
30 . 8  95  29 . 0  
1  
3 . 8  1 6  4.9 
9  
34 . 6  94  2 8 . 7  
1 6  
6 1 . 5  1 8 7  
57 . 0  
1 2  4 6 . 2  1 0 3  
3 1 . 4  
1  3 . 8  4 9  1 4 . 9  
E B V +  wrs us  E B V -
O R  99 . 9 % C I  
p- "8 1 U e  
0 . 7 1  0 . 1 5  3.43 4 . 8 E - 0 1  
0 . 8 7  0 . 32  2 . 3 7  6 . 5 E - 0 1  
0 . 88  0 . 30  2 . 60  7 . 0 E - 0 1  
0 . 7 9  0 . 20  3 . 1 9  5 . 8 E - 0 1  
2 . 7 1  0 . 9 1  8 . 1 2  2 . 1 E - 03  
0 . 96  0 . 39  2 . 32  8 . ?E - 0 1  
1 . 36  0 . 22  8 . 50  5 . 8 E - 0 1  
1 . 08  0 . 1 5  7 . 7 3  9 . 0 E - 0 1  
1 . 1 1  0 . 1 1  1 0 . 7 6  8 . 8 E - 0 1  
2 . 08  0 . 43  
9.98 1 . 2 E - 0 1  
3 . 03  0 . 2 0  4 6 . 0 7  1 . 6 E - 0 1  
0 . 7 3  0 . 0 2  29 . 8 1  7 . 8 E - 0 1  
1 . 1 3  0 . 4 3  2 . 93  6 . B E - 0 1  
3 . 7 5  0 . 64  2 1 . 90  8 . 8 E - 0 3  
1 . 5 1  0 . 59  3 . 8 7  1 . 5 E - 0 1  
0 . 7 3  
0 . 30  1 . 7 5  2 . 3 E - 0 1  
0 . 4 0  
0 . 1 3  1 . 2 1  
5 . 3 E - 0 3  
2 . 58  
0 . 8 7  7 . 66  
3 . 2 E - 03  
E B V +  \81"B U S  cont rol s  
E B V - wrs u s  control s  
O R  99 . 9 % C I  
p- "8 1 U e  O R  99 . 9% C I  p- "8 1 u e  
c o n t i n u e d  
a l l  cas es  wrs u s  cont rols  





008 9  
HA �  
D R 1  
D R3  
D R 4  
D R ?  
D RS  
D R 9  
D R 1 0  
DR 1 1  
D R 1 2  
D R 1 3  
D R 1 4  
D R 1 5  
Ot h e rs  
HA IF  
[F()1 :01  
�  
E B V +  
2  2 . 7  
78  
%  
1 6  
20 . 5  
22  2 8 . 2  
2 3  2 9 . 5  
7  9 . 0  
8  1 0 . 3  
0  0 . 0  
6  7 . 7  
7  9 . 0  
2  2 . 6  
2 3  
29 . 5  
6  7 . 7  
23 29 . 5  
2  2 . 6  
78  %  
4  5 . 1  
2 5  32 . 1  
H LA  P henotype  
E B V -
E B V ?  A l l  c a s e s  Co n t ro l s  
1 5  6 . 6  
0  0 . 0  
1 7  5.2 
23 1  
%  Z1  
%  336  %  
5922  
%  
4 1  1 7 . 7  
7  2 5 . 9  64  1 9 . 0  
1 4 1 6  
23 . 9  
55  2 3 . 8  
7  2 5 . 9  84  
2 5 . 0  1 7 34  29.3 
4 3  
1 8 . 6  
3  1 1 . 1  69  2 0 . 5  1 969  33 . 2  
2 5  
1 0 . 8  
2  7 . 4  34  1 0 . 1  
1 2 46  
2 1 . 0  
9  3 . 9  
1  
3 . 7  1 8  5 . 4  4 2 1  7 . 1  
5  2 . 2  
0  0 . 0  5  
1 . 5  1 85  3.1 
5  
2 . 2  
0  0 . 0  1 1  3 . 3  
1 1 8  
2 . 0  
51  2 4 . 7  1 0  3 7 . 0  74 22 . 0  8 7  1 . 5  
5  2 . 2  
1  
3 . 7  8  2 . 4  2 83  
4.8 
6 1  2 6 . 4  
8  29 . 6  9 2  2 7 . 4  1 6 1 2  2 7 . 2  
1 6  6 . 9  
2  
7 . 4  2 4  
7.1 3 84  6 . 5  
9 1  39.4 1 0  3 7 . 0  1 2 4  36.9 1 690  28 . 5  
2  0 . 9  0  0 . 0  4  
1 . 2  2 1 5  
3 . 6  
23 1  
%  
Z1  
%  336  %  
1 9  8 . 2  4  1 4 . 8  2 7  8 . 0  
4 5  
1 9 . 5  
3  1 1 . 1  7 3  2 1 . 7  
E B V +  \GrS U S  E B V -
E B V +  \GrS U S  cont rol s  
O R  
99 . 9 % C I  p-- 1.0 l u e  
O R  
99 . 9 % C I  p-- 1.0 l u e  
0 . 39  
0 . 0 3  4 . 8 0  2 . 0 E - 0 1  
1 . 20  0 . 4 0  3 . 5 3  5 . 9 E - 0 1  0 . 82  0 . 3 2  2 . 08  
4 . B E - 0 1  
1 . 26  
0 . 4 8  3 . 3 2  4 . 4 E - 0 1  0 . 95  0 . 4 1  2 . 1 8  8 . 4 E - 0 1  
1 . 83  0 . 68  
4 . 9 1  4 . 3E - 02  0 . 84  
0 . 3 7  1 . 9 1  4 . B E - 0 1  
0 . 8 1  0 . 1 9  
3 . 5 6  6 . 4E - 0 1  0 . 3 7  0 . 1 0  
1 . 3 7  
9 . 2 E - 0 3  
2 . 82  0 . 54  1 4 . 85  3 . 3E - 02  1 . 4 9  0 . 4 3  
5 . 1 6  2 . B E - 0 1  
nd  
n d  n d  
1 . 9 E - 0 1  
n d  n d  nd  
1 . 1 E - 0 1  
3 . 7 7  0 . 49  
2 9 . 02  2 . 3E - 0 2  4 . 1 0  0 . 9 8  1 7 . 1 5  
4 . 4 E -
Q4  
0 . 30  
0 . 0 7  1 . 22  3 . 1 E - 03  6 . 6 1  1 . 7 1  2 5 . 54  
1 . 1 E - 0 7  
1 . 1 9  0 . 0 7  
1 9 . 32  8 . 4 E - 0 1  0 . 5 2  0 . 0 5  
5 . 59  3 . 6 E - 0 1  
1 . 1 7  
0 . 45  3 . 0 2  6 . 0 E - 0 1  1 . 1 2  0 . 4 9  2 . 55  
6 . 6 E - 0 1  
1 . 1 2  
0 . 22  5 . 7 6  8 . 2 E - 0 1  1 . 2 0  0 . 2 9  4.92 6 . ? E - 0 1  
0 . 64  0 . 2 5  1 . 63  
1 . 2 E - 0 1  
1 . 05  0 . 4 6  
2 . 38  8 . 5 E - 0 1  
3 . 0 1  
0 . 1 1  8 3 . 2 8  2 . 5 E - 0 1  0 . 7 0  0 . 0 7  7 . 4 6  
6 . 2 E - 0 1  
0 . 60  
0 . 09  
3.89 3 . 7 E - 0 1  
1 . 95  0 . 7 4  5 . 1 3  2 . 2 E - 02  
E B V - \81'8 U S  cont rol s  
O R  
99 . 9 % C I  
p-- \0 l u e  
0 . 6 9  0 . 39  
1 . 22  3 . 1 E - 02  
0 . 7 5  0 . 4 5  1 . 2 7  
7 . 2 E - 02  
0 . 46  0 . 26  0 . 8 1  
3 . 3 E - 06  
0 . 46  0 . 23  0 . 92  
1 . ? E - 04  
0 . 5 3  0 . 1 7  1 . 64  
6 . 0 E - 02  
0 . 6 9  
0 . 1 5  3 . 1 0  
4 . 1 E - 0 1  
1 . 09  0 . 2 4  
4.97 8 . 5 E - 0 1  
2 1 . 9 7  1 1 . 88  
4 0 . 6 5  <1 CE- 1 0  
0 . 44  
0 . 1 0  1 . 98  
6 . 5 E - 02  
0 . 96  0 . 58  
1 . 58  7 . 9 E - 0 1  
1 . 0 7  
0 . 4 5  2 . 56  
7 . 9 E - 0 1  
1 . 63  1 . 0 3  
2 . 56  3 . 6 E - 04  
0 . 2 3  0 . 0 2  
2 . 4 3  
2 . 5 E - 02  
c o n t i n u e d  
a l l  cas es  \81'8 u s  cont rol s  
O R  99 . 9 % C I  
p-- \0 l u e  
0 . 7 5  
0 . 4 7  
1 . 2 0  4 . 1 E - 0 2  
0 . 8 1  0 . 5 3  1 . 2 3  
9 . 3 E - 02  
0 . 5 2  0 . 33  0 . 82  
1 . 3 E - 06  
0 . 4 2  0 . 2 3  0 . 7 7  
1 . 4 E - 06  
0 . 7 4  0 . 33  1 . 67  
2 . 2 E - 0 1  
0 . 4 7  0 . 1 0  
2 . 1 1  8 . 9 E- 02  
1 . 66  
0 . 58  
4 . 7 8  1 . 1 E - 0 1  
1 8 . 94  
1 0 . 82  
33.17 < 1 0E - 1 0  
0 . 4 9  0 . 1 5  1 . 60  
4 . 2 E - 02  
1 . 0 1  
0 . 6 7  
1 . 5 2  9 . 5 E - 0 1  
1 . 1 1  0 . 54  2 . 2 8  
6 . 3 E - 0 1  
1 . 4 6  
1 . 00  
2 . 1 5  1 . 0 E - 0 3  
0 . 3 2  0 . 06  1 . 7 0  






















H LA  P henotype  
E B V +  
E B V -
E B V ?  
A l l  c a s e s  
[P()4 :0:  
5  
6 . 4  
4 0  
1 7 . 3  6  2 2 . 2  5 1  1 5 . 2  
/ 1 0 5 : 0 1  
CP03:0'  
2 1  
26 . 9  
76  
32 . 9  1 0  3 7 . 0  1 0 7  
3 1 . 8  
Cf>04 :0'  
60  7 6 . 9  1 50  
64 . 9  1 3  48 . 1  22 3  66 . 4  
[P(li()'  3  3 . 8  8  
3 . 5  0  0 . 0  1 1  
3 . 3  
CP0001  
3  3 . 8  
5  2 . 2  3  
1 1 . 1  1 1  
3 . 3  
CP100 1  1 . 3  4  1 . 7  1  3 . 7  6  
1 . 8  
CP13:01 4  5 . 1  9  3.9 0  0 . 0  1 3  3.9 
CP 1 4 : 0'  
1  1 . 3  
1 3  5 . 6  0  0 . 0  1 4  
4 . 2  
[P �  5  6 . 4  8  3.5 0  0 . 0  1 3  3.9 
Ot h e rs  
3  3.9 2 4  
1 0 . 4  3  
1 1 . 1  30  
8 . 9  
•  A l l e l i c  freq u e n c y <  1 %  wa s  ex c l u d e d  
E B V +  wrs us  E B V -
C o n t r o l s  
O R  99 . 9% C I  
p- \0 1 U e  
0 . 3 3  0 . 06  1 . 66  
1 . 8 E - 02  
0 . 7 5  0 . 29  
1 . 96  
3 . 3 E - 0 1  
1 . 80  0 . 6 7  4 . 86  5 . 0E - 0 2  
1 . 1 2  0 . 1 2  
10 . 80  8 . 7E - 0 1  
1 . 8 1  0 . 1 6  
20 . 80  
4 . 2 E - 0 1  
0 . 7 4  0 . 0 2  
29.94 7 . 9E - 0 1  
1 . 3 3  0 . 1 8  
1 0 . 1 1  6 . 4E - 0 1  
0 . 22  0 . 0 1  
6 . 8 1  
1 . 1 E - 0 1  
1 . 9 1  0 . 2 8  1 3 . 1 2  2 . 6 E - 0 1  
0 . 3 5  0 . 04  
2 . 73  7 . 7E - 0 2  
E B V +  wrs u s  cont rol s  
E B V - \el'S U S  cont rol s  
O R  99 . 9 % C I  
p- \0 1 U e  O R  
99 . 9% C I  p- \01 u e  
c o n t i n u e d  
a l l  ca s e s  \el'S u s  cont rols  



































lndi\4dual PCR-SSOP analysis including OR and p-wlues 
POS EBV+ EBV-
32 96, 2% 85, 8% 
35 96, 2% 85, 8% 
35 2, 6% 10, 3% 
35 96, 2% 90, 1% 
35 5, 1% 9, 0% 
35 38, 5% 41, 2% 
35 0, 0% 0, 0% 
49 0, 0% 0, 0% 
105 1, 3% 3, 0% 
105 5, 1% 4, 3% 
105 0, 0% 0, 4% 
107 76, 9% 60, 5% 
107 76, 9% 60, 5% 
107 65, 4% 78, 1% 
107 38, 2% 48, 1% 
107 5, 1% 3, 0% 
107 44, 4% 50, 7% 
107 5, 1% 8, 6% 
107 10, 3% 12, 5% 
107 1, 3% 0, 0% 
127 5, 1% 3, 0% 
129 1, 3% 2, 2% 
171 1, 3% 8, 6% 
171 82, 1% 71, 2% 
171 37, 2% 45, 9% 
171 33, 3% 42, 2% 
171 33, 3% 42, 1% 



























































OR (99. 9% Cl) 
5. 2 (0. &43. 1) 
5. 2 (0. &43. 1) 
o. 2 (0. 0-2. 3) 
4. 1 (0. 5--36. 0) 
0. 7 (0. 1-4. 9) 
0. 9 (0. 3--2. 3) 
n. a. (n. a. -n. a. ) 
n. a. (n. a. -n. a. ) 
0. 4 (0. 0-17. 0) 
0. 8 (0. 1-7. 0) 
n. a. (n. a. -n. a. ) 
2. 3 (0. 8- 6. 6) 
2. 3 (0. 8-6. 6) 
0. 5 (0. 2-1. 4) 
0. 6 (0. 2-1. 7) 
1. 7 (0. 2-16. 7) 
0. 8 (0. 3 --2. 2) 
0. 7 (0. 1-5. 1) 
0. 8 (0. 2-3. 5) 
n. a. (n. a. -n. a. ) 
1. 7 (0. 2-16. 7) 
0. 9 (0. 0-41. 1) 
0. 1 (0. 0-3. 8) 
2. 0 (0. &6. 4) 
0. 7 (0. 3--1. 7) 
0. 7 (0. 3--1. 8) 
0. 7 (0. 3--1. 8) 
1. 8 (0. 4-8. 9) 
HLA associations in Dutch cHL 
continued 
GENE PROBE POS EBV+ EBV- NMISS p OR (99. 9% Cl) 
HLA-DPB1 c62 171 1, 3% 1, 8% 296 0, 51 0. 4 (0. 0-24. 6) 
HLA-DPB1 c67 171 1, 3% 0, 0% 304 1, 00 n. a. {n. a. -n. a. ) 
HLA-DPB1 c19 171 0, 0% 0, 0% 311 n. a. n. a. {n. a. -n. a. ) 
HLA-DPB1 c44 199 98, l°lo 92, 7% 311 0, 073 6. 7 (0. 2-223. 8) 
HLA-DPB1 c27 199 34, 6% 42, 1% 311 0, 32 0. 7 (0. 3-2. 0) 
HLA-DPB1 c21 199 0, 0% 0, 0% 309 n. a. n. a. {n. a. -n. a. ) 
HLA-DPB1 c24 199 0, 0% 0, 0% 311 n. a. n. a. {n. a. -n. a. ) 
HLA-DPB1 c70 206 3, 8% 2, 1% 311 0, 64 1. 4 (0. 1-19. 7) 
HLA-DPB1 c71 208 7, 7% 25, 3% 311 3, 2E-03 0. 3 (0. 1-1. 2) 
HLA-DPB1 c60 208 1, 3% 4, l°lo 311 0, 10 0. 2 (0. 0-6. 1) 
HLA-DPB1 c04 208 43, 6% 30, 9% 311 0, 17 1. 5 (0. 6-3. 9) 
HLA-DPB1 c06 208 29, 5% 38, 2°/o 311 0, 25 0. 7 (0. 3-1. 9) 
HLA-DPB1 c58 208 28, 2% 34, 2°/o 309 0, 46 0. 8 (0. 3-2. 2) 
HLA-DPB1 c25 208 0, 0% 0, 0% 311 n. a. n. a. {n. a. -n. a. ) 
HLA-DPB1 c72 210 0, 0% 0, 0% 311 n. a. n. a. {n. a. -n. a. ) 
HLA-DPB1 c30 216 93, 6% 93, 1% 311 0, 48 1. 5 (0. 2-9. 7) 
HLA-DPB1 c20 218 0, 0% 0, 0% 311 n. a. n. a. {n. a. -n. a. ) 
HLA-DPB1 c40 226 0, 0% 0, 0% 311 n. a. n. a. {n. a. -n. a. ) 
HLA-DPB1 c41 228 98, 1°/o 90, 0% 304 0, 047 8. 0 (0. 3-252. 8) 
HLA-DPB1 c29 228 34, 6% 45, 1% 311 0, 20 0. 7 (0. 3-1. 8) 
HLA-DPB1 c53 228 5, 1% 8, 6% 311 0, 60 0. 7 (0. 1-5. 1) 
HLA-DPB1 c15 228 11, 5% 7, 7% 311 0, 64 1. 2 (0. 3-5. 7) 
HLA-DPB1 c69 228 6, 5% 6, 0% 309 0, 75 0. 8 (0. 1-5. 5) 
HLA-DPB1 c65 228 0, 0% 2, 2% 309 1, 00 n. a. {n. a. -n. a. ) 
HLA-DPB1 c61 256 2, 6% 10, 3% 311 0, 026 0. 2 (0. 0-2. 3) 
HLA-DPB1 c03 256 91, 0% 82, 4% 305 0, 041 2. 6 (0. 6-11.6mm) 
HLA-DPB1 c42 256 50, 0% 59, 9% 310 0, 14 o. 7 (0. 3-1. 7) 




GENE PROBE POS EBV+ EBV- NMISS p OR (99. 9% Cl) 
HLA-DQ81 c257 26 93, 3% 93, 8% 302 0, 42 0. 6 (0. 1-4. 3) 
HLA-DQ81 c251 40 18, 4% 35, 8% 308 8, 6E-03 0. 4 (0. 1-1. 3) 
HLA-DQ81 c240 40 32, 9% 25, 4% 308 0, 56 1. 2 (0. 4-3. 4) 
HLA-DQ81 c250 40 32, 9% 25, 4% 308 0, 56 1. 2 (0. 4-3. 4) 
HLA-DQ81 c216 75 8, 1% 2, 6% 305 0, 16 2. 5 (0. 3-21. 3) 
HLA-DQ81 c241 77 0, 0% 0, 0% 308 n. a. n. a. (n. a. -n. a. ) 
HLA-DQ81 c272 79 0, 0% 0, 0% 305 n. a. n. a. (n. a. -n. a. ) 
HLA-DQB1 c226 83 38, 4% 28, 1% 304 0, 45 1. 3 (0. 5-3. 5) 
HLA-DQ81 c255 83 50, 0% 53, 9% 306 0, 72 0. 9 (0. 4-2. 3) 
HLA-DQ81 c205 89 18, 4% 35, 9% 307 8, 6E-03 0. 4 (0. 1-1. 3) 
HLA-DQ81 c232 89 8, 1% 3, 0% 305 0, 16 2. 5 (0. 3-21. 3) 
HLA-DQ81 c201 90 32, 9% 25, 4% 308 0, 56 1. 2 (0. 4-3. 4) 
HLA-DQ81 c212 90 32, 9°/o 28, 9% 308 0, 61 1. 2 (0. 4-3. 2) 
HLA-DQ81 c207 90 50, 0% 53, 9% 308 0, 70 0. 9 (0. 4-2. 3) 
HLA-DQ81 c206 90 27, 6% 25, 0% 308 0, 94 1. 0 (0. 4-2. 9) 
HLA-DQB1 c211 90 0, 0% 0, 4% 308 1,  00 n. a. (n. a. -n. a. ) 
HLA-DQ81 c221 111 0, 0% 0, 9% 295 1, 00 n. a. (n. a. -n. a. ) 
HLA-DQ81 c270 114 29, 0% 18, 6% 307 0, 082 1. 8 (0. &5. 2) 
HLA-DQ81 c242 114 42, 1% 48, 3% 308 0, 37 0. 8 (0. 3-2. 0) 
HLA-DQ81 c256 114 55, 3% 58, 6% 308 0, 60 0. 9 (0. 3-2. 2) 
HLA-DQ81 c233 114 1, 3% 0, 0% 307 1, 00 n. a. (n. a. -n. a. ) 
HLA-DQ81 c213 135 17, 1% 35, 3% 308 6, 9E-03 0. 4 (0. 1-1. 2) 
HLA-DQ81 c223 144 42, 1% 53, 9% 308 0, 11 0. 6 (0. 2-1.6mm) 
HLA-DQ81 c202 147 26, 3% 19, 4% 308 0, 69 1. 1 (0. 4-3. 5) 
HLA-DQ81 c263 147 0, 0% 0, 0% 308 n. a. n. a. (n. a. -n. a. ) 
HLA-DQ81 c235 153 25 , 7% 40, 6% 298 0, 039 0. 5 (0. 2-1. 5) 
HLA-DQ81 c217 168 10, 5% 3, 0% 308 0, 031 3. 5 (0. 5-24. 1) 
HLA-DQ81 c253 171 17, 1% 34, 9% 308 7, 5E-03 0. 4 (0. 1-1. 2) 
108 
HLA associations in Dutch cHL 
continued 
GENE PROBE POS EBV+ EBV- NMISS p OR (99. 9% Cl) 
HLA-0081 c214 171 20, 3% 36, S°/o 290 9, 8E-03 0. 4 (0. 1-1 . 3) 
HLA-DQ8 1 c215 171 24, 0% 12, 2% 305 0, 019 2. 4 (0. 7-7. 8) 
HLA-DQ81 c203 171 2, 6% 1 ,  1°/o 308 0, 30 2. 7 (0. 1-65. 0) 
HLA-DQ81 c243 171 32, 0% 26, 3% 299 0, 50 1 .  2 (0. 4-3. 4) 
HLA-008 1 c262 171 32, 9% 28, 3% 306 0, 55 1 .  2 (0. 4-3. 3) 
HLA-0081 c244 171 0, 0% 0, 0% 308 n. a. n. a. (n. a. -n. a. ) 
HLA-0081 c204 178 31 , 6% 24, 1% 308 0, 59 1 .  2 (0. 4-3. 4) 
HLA-0081 c208 180 42, 1 %  53, 9% 308 0, 1 1  0. 6 (0. 2-1 .6mm) 
HLA-DQ81 c265 189 0, 0% 0, 0% 308 n. a. n. a. (n. a. -n. a. ) 
HLA-DQ81 c252 200 93, 4% 96, 6% 308 0, 36 0. 6 (0. 1 -4. 5) 
HLA-DQ81 c264 200 0, 0% 0, 0% 290 n. a. n. a. (n. a. -n. a. ) 
HLA-DQ8 1 c273 213 43, 2% 54, 8% 302 0, 15 0 .  7 (0. 3-1 .  7) 
HLA-008 1 c271 213 42, 7% 53, 7% 304 0, 17 0.  7 (0. 3-1 .  7) 
HLA-0081 c245 213 32, 9% 25, 4% 308 0, 56 1 .  2 (0. 4-3. 4) 
HLA-008 1 c237 216 9, 3% 3, 4% 307 0, 089 2. 8 (0. 4-20. O) 
HLA-008 1 c236 216 48, 0% 50, 9% 303 0, 58 0. 9 (0. 3-2. 2) 
HLA-DQ81 c209 216 1, 3% 0, 4% 308 0, 78 1 .  5 (0. 0-1 91 . 0) 
HLA-DQ81 c303 405 2, 6% 5, 6% 307 0, 18 0 .  3 (0. 0-5. 0) 
HLA-DQ8 1 c304 420 31 , 6% 24, 2% 307 0, 30 1 .  4 (0. 5-3. 9) 
HLA-0081 c301 504 0, 0% 0, 0% 306 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB1 C17 25 37, 2% 50, 7% 303 0, 037 0. 5 (0. 2-1 .  4) 
HLA-DRB1 C12 25 7, 7% 2, 2% 303 0, 68 1 .  3 (0. 1-12. 6) 
HLA-DRB1 C04 31 29, 5% 1 8, 2% 303 0, 024 2. 1 (0. 7-6. 1 )  
HLA-DRB1 C73 31 9, 0% 1 1 , 1% 303 0, 32 0. 6 (0. 1-3. 0) 
HLA-DRB1 C11  31  0 ,  0% 2, 2% 303 1 ,  00 n. a. (n. a. -n .  a. ) 
HLA-DRB1 C47 32 20, 5% 17, 8% 303 0, 73 1 .  1 (0. 3-3. 7) 
HLA-DRB1 C10 36 9, 0% 10, 9% 307 0, 33 o. 6 (0. 1-3. 1 )  




GENE PROBE POS EBV+ EBV- NMISS p OR (99. 9% Cl) 
HLA-DRB1 C18 37 32, 1% 40, 0% 303 0, 35 0. 8 (0. 3--2. 0) 
HLA-DRB1 cos 39 12, 8% 6, 1% 307 0, 12 2. 1 (0. 4-9. 6) 
HLA-DRB1 C07 39 66, 7% 67, 3% 307 0, 97 1. 0 (0. 4-2. 7) 
HLA-DRB1 C34 76 32, 1% 46, 9% 302 0, 024 o. 5 (0. 2-1. 4) 
HLA-DRB1 C20 76 35, 9% 29, 5% 302 0, 36 1. 3 (0. 5 -3. 5) 
HLA-DRB1 C39 86 38, 2% 31, 1% 295 0, 30 1 .  4 (0 . 5-3. 7) 
HLA-DRB1 C63 88 28, 2% 39, 1% 303 0, 16 0. 6 (0. 2-1. 8) 
HLA-DRB1 C01 88 20, 5% 17, 9% 307 0, 77 1. 1 (0. 3--3. 6) 
HLA-DRB1 C33 90 0, 0% 0, 0% 307 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB1 C27 94 7, 7% 5, 2% 307 0, 37 1. 7 (0. 2-11. 3) 
HLA DRB1 C84 94 7, 7% 2, 2% 307 0, 66 1. 3 (0. 1-12. 8) 
HLA-DRB1 C49 111 3, 8% 3, 1% 307 0, 76 1. 3 (0. 1-14. 2) 
HLA-DRB1 C06 111 2, 6% 2, 6% 307 1, 00 1. 0 (0. 1-17. 5) 
HLA-DRB1 C35 112 28, 2% 39, 1% 303 0, 16 0. 6 (0. 2-1. 8) 
HLA-DRB1 C36 112 23, 1% 21, 8% 307 0, 86 1. 1 (0. 3--3. 3) 
HLA-DRB1 C25 113 53, 9% 45, 4% 307 0, 44 1. 2 (0. 5-3. 1) 
HLA-DRB1 C94 113 8, 6% 4, 5% 235 0, 50 1. 5 (0. 2-12. 4) 
HLA-DRB1 C16 115 38, 5% 28, 9% 303 0, 090 1. 7 (0. &4. 4) 
HLA-DRB1 C72 150 0, 0% 0, 0% 307 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB1 C74 176 9, 0% 24, 0% 307 0, 011 0. 3 (0. 1-1. 4) 
HLA-DRB1 cos 178 9, 0% 24, 0% 307 0, 011 0. 3 (0. 1-1. 4) 
HLA-DRB1 C23 178 7, 7% 7, 0% 307 0, 51 1. 4 (0. 2-8. 2) 
HLA-DRB1 C29 179 11, 5% 4, 0% 303 0, 043 3. 0 (0. 5-17. 3) 
HLA-DRB1 C19 179 50, 0% 46, 2% 303 0, 78 1. 1 (0. 4-2. 7) 
HLA-DRB1 C79 202 0, 0% 0, 0% 301 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB1 C40 208 30, 8% 30, 1% 307 0, 92 1. 0 (0. 4-2. 7) 
HLA-DRB1 C37 211 0, 0% 0, 0% 303 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB1 C48 212 29, 5% 39, 3% 302 0, 21 0. 7 (0. 3--1. 8) 
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HLA-DRB1 C86 212 29, 5% 38, 8% 302 0, 22 0. 7 (0. 3-1. 9) 
HLA-DRB1 C14 213 32, 1% 39, 7% 307 0, 34 0. 8 (0. 3-2. 0) 
HLA-DRB1 C13 213 29, 5% 27, 1% 307 0, 87 1. 1 (0. 4-2.  9) 
HLA-DRB1 C24 213 0, 0% 1, 3% 307 1, 00 n. a. (n. a. -n. a. ) 
HLA-DRB1 C85 214 2, 6% 0, 9% 303 0, 26 3. 3 (0. 1-102. 4) 
HLA-DRB1 C53 215 0, 0% 0, 0% 307 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB1 C21 216 39, 7% 22, 7% 307 0, 017 2. 1 (0. 8-5. 6) 
HLA-DRB1 C80 216 2, 6% 0, 9% 303 0, 26 3. 3 (0. 1-102. 4) 
HLA-DRB1 C41 216 18, 0% 23, 1% 307 0, 47 0. 8 (0. 2-2. 5) 
HLA-DRB1 C64 219 29, 5% 29, 3% 307 0, 82 0. 9 (0. 3-2. 6) 
HLA-DRB1 C51 221 9, 0% 20, 5% 307 0, 049 o. 4 (0. 1-1. 8) 
HLA-DRB1 C38 221 9, 1% 11, 2% 300 0, 84 1. 1 (0. 2-5. 3) 
HLA-DRB1 C43 222 34, 6% 19, 2% 302 0, 022 2. 1 (0. 7-5. 8) 
HLA-DRB1 C09 222 10, 3% 3, 5% 307 0, 068 2. 8 (0. 4-17. 1) 
HLA-DRB1 C15 222 43, 6% 35, 1% 306 0, 16 1. 5 (0. &3. 9) 
HLA-DRB1 C67 229 10, 3% 10, 7% 303 0, 84 1. 1 (0. 2-5. 0) 
HLA-DRB1 C03 231 28, 2% 23, 6% 307 0, 47 1. 3 (0. 4-3. 6) 
HLA-DRB1 C26 255 5, 1% 4, 4% 307 0, 81 1. 2 (0. 1-9. 7) 
HLA-DRB1 C87 258 56, 4% 61, 6% 302 0, 50 0. 8 (0. 3-2. 1) 
HLA-DRB1 C89 259 1, 3% 0, 4% 303 0, 56 2. 6 (0. 0-587. 1) 
HLA-DRB3 C32mix 48 0, 0% 0, 0% 205 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB3 C39mix 86 40, 0% 32, 4% 198 0, 49 1. 3 (0. 4-4. 1) 
HLA-DRB3 C57mix 90 68, 6% 77, 9% 205 0, 26 0. 6 (0. 2-2. 3) 
HLA-DRB3 C27mix 94 0, 0% 0, 0% 205 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB3 C36mix 112 11, 8% 10, 4% 205 0, 42 1.6mm (0. 3-9. 4) 
HLA-DRB3 C25mix 113 80, 4% 67, 3% 204 0, 27 1.6mm (0. 4-6. 1) 
HLA-DRB3 C45mix 117 13, 1°/o 37, 7% 205 4, 1E-03 0. 3 (0. 1-1. 2) 
HLA-DRB3 C76mix 143 11, 8% 12, 3% 205 0, 63 1. 3 (0. 2-7. 5) 
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HLA-DRB3 C46mix 148 92, 2% 92, 1% 203 0, 54 0. 7 (0. 1-5. 6) 
HLA-DRB3 C74mix 176 13, 7% 36, 4% 205 5, 9E-03 0. 3 (0. 1-1. 3) 
HLA-DRB3 C78mix 177 0, 0% 0, 0% 205 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB3 C05mix 178 13 , 7% 36, 4% 205 5, 9E-03 0. 3 (0. 1-1. 3) 
HLA-DRB3 C23mix 178 11, 8% 10, 4% 205 0, 42 1.6mm (0. 3-9. 4) 
HLA-DRB3 C44mix 179 80, 4% 66, 9% 205 0, 24 1.6mm (0. 4-6. 3) 
HLA-DRB3 C29mix 179 0, 0% 1, 9% 205 1, 00 n. a. (n. a. -n. a. ) 
HLA-DRB3 C88mix 179 0, 0% 0, 0% 205 n. a. n. a. (n. a. -n. a. ) 
HLA DRB3 C28mix 199 13, 7% 31, 2% 205 0, 032 0. 4 (0. 1-1. 7) 
HLA-DRB3 C69mix 208 0, 0% 0, 0% 205 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB3 C97mix 212 0, 0% 5, 2% 205 1, 00 n. a. (n. a. -n. a. ) 
HLA DRB3 C13mix 213 45 , 1% 37, 7% 205 0, 47 1. 3 (0. 4-4. 0) 
HLA-DRB3 C14mix 213 0, 0% 0, 0% 205 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB3 C98mix 216 13, 7% 31, 2°/4 205 0, 032 0. 4 (0. 1-1. 7) 
HLA-DRB3 C21mix 216 0, 0% 0, 0% 205 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB3 C51mix 221 13, 7% 31, 2% 205 0, 032 0. 4 (0. 1-1. 7) 
HLA-DRB3 C15mix 222 11, 8% 10, 4% 205 0, 42 1.6mm (0. 3 -9. 4) 
HLA-DRB3 C70mix 222 41, 2% 35, 1% 205 0, 55 1. 2 (0. 4-3. 9) 
HLA-DRB3 C93mix 230 0, 0% 0, 0% 205 n. a. n. a. (n. a. -n. a. ) 
HLA-DRB3 C30mix 250 86, 3% 81, 1% 204 0, 39 1. 5 (0. 3-7. 3) 
HLA-DRB3 C31mix 258 21, 6% 26, 1% 204 0, 75 0. 9 (0. 2-3. 4) 
HLA-B c282 98 28, 4% 23, 1% 295 0, 44 1. 3 (0. 4-3. 8) 
HLA-B c261 106 34, 2% 40, 2°/4 305 0, 31 0. 7 (0. 3-2. 0) 
HLA-B c265 106 2, 6% 3,  1% 307 0, 85 1. 2 (0. 1-21. 1) 
HLA-B c268 141 15 , 6% 13, 2°/4 305 0, 66 1. 2 (0. 3-4. 3) 
HLA-B c224 146 38, 9% 45, 2°/4 280 0, 25 0. 7 (0. 3-1. 9) 
HLA-B c287 167 41, 6% 36, 1% 304 0, 43 1. 3 (0. 5 -3. 3) 
HLA-B c213 207 62, 8% 66, 4% 307 0, 50 0. 8 (0. 3-2. 1) 
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HLA-B c212 210 21, 8% 24, 9% 307 0, 57 0. 8 (0. 3--2. 5) 
HLA-B c210 213 35, 9% 31, 0% 307 0, 56 1. 2 (0. 4-3. 2) 
HLA-B c211 215 51, 3% 41, 0% 305 0, 42 1. 3 (0. 5-3. 2) 
HLA-B c226 250 6, 4% 8, 3% 307 0, 47 0. 7 (0. 1-4. 2) 
HLA-8 c264 258 9, 0% 3, 1% 307 0, 14 2. 4 (0. 3--16. 7) 
HLA-B c234 269 59, 0% 53, 7% 307 0, 93 1. 0 (0. 4-2. 6) 
HLA-B c266 270 85, 9% 82, 5% 307 0, 59 1. 2 (0. 3--4. 5) 
HLA-B c203 273 9, 0% 3, 5% 307 0, 21 2. 0 (0. 3--13. 3) 
HLA-8 c207 277 7, 7% 8, 7% 307 0, 60 0. 8 (0. 1-4. 2) 
HLA-8 c202 277 0, 0% 0, 0% 307 n. a. n. a. (n. a. -n. a. ) 
HLA-8 c204 278 62, 8% 56, 6% 306 0, 75 1. 1 (0. 4-2. 8) 
HLA-B c206 279 55, 1% 52, 4% 307 0, 76 1. 1 (0. 4-2. 8) 
HLA-B c205 280 30, 8% 36, 2% 307 0, 47 0. 8 (0. 3--2. 2) 
HLA-B c235 280 30, 8% 36, 2% 307 0, 47 0. 8 (0. 3--2. 2) 
HLA-B c292 280 0, 0% 0, 0% 307 n. a. n. a. (n. a. -n. a. ) 
HLA-B c201 282 1, 3% 7, 0% 307 0, 22 0. 3 (0. 0-8. 9) 
HLA-B c285 283 30, 8% 36, 2% 307 0, 47 0. 8 (0. 3--2. 2) 
HLA-8 c233 283 0, 0% 0, 0% 307 n. a. n. a. (n. a. -n. a. ) 
HLA-B c246 302 0, 0% 0, 0% 307 n. a. n. a. (n. a. -n. a. ) 
HLA-B c274 303 1, 3% 7, 0% 307 0, 22 0. 3 (0. 0-8. 9) 
HLA-B c216 303 0, 0% 0, 4% 307 1, 00 n. a. (n. a. -n. a. ) 
HLA-8 c218 304 44, 9% 54, 0% 306 0, 17 0. 7 (0. 3--1. 7) 
HLA-B c215 304 39, 7% 38, 9% 307 0, 53 0. 8 (0. 3--2. 2) 
HLA-B c277 314 88, 5% 93, 5% 307 0, 18 0. 5 (0. 1-2. 6) 
HLA-8 c220 314 14, 1% 18, 3% 307 0, 23 0. 6 (0. 2-2. 3) 
HLA-B c278 314 0, 0% 1, 7% 307 1, 00 n. a. (n. a. -n. a. ) 
HLA-B c222 319 18, 0% 11, 4% 307 0, 55 1. 3 (0. 3--4. 8) 
HLA-8 c231 320 19, 2% 15, 1% 303 0, 50 1. 3 (0. 4-4. 3) 
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HLA-8 c291 320 15 , 6% 13, 2% 305 0, 66 1. 2 (0. 3--4. 3) 
HLA-8 c244 320 16, 7% 14, 4% 307 0, 69 1. 2 (0. 3--4. 1) 
HLA-8 c229 320 15 , 4% 1 3, 5% 307 0, 78 1. 1 (0. 3-4. 1) 
HLA-8 c232 320 0, 0% 1, 7% 307 1, 00 n. a. (n. a. -n. a. ) 
HLA-8 c283 322 51, 3% 48, 3% 306 0, 47 o. 8 co. 3-2. 1) 
HLA-8 c286 322 11, 7% 10, 6% 304 0, 75 1. 2 (0. 3-5. 0) 
HLA-8 c221 324 88, 5% 93, 5% 307 0, 18 0. 5 (0. 1-2. 6) 
HLA-8 c223 324 26, 9% 22, 3% 307 0, 78 1. 1 (0. 4-3. 2) 
HLA-8 c332 363 9, 0% 3, 1% 307 0, 14 2. 4 (0. 3-16. 7) 
HLA-8 c327 363 29, 5% 34, 8% 305 0, 31 o. 7 co. 3-2. 0) 
HLA-8 c331 363 3, 8% 3, 9% 307 0, 84 1. 2 (0. 1-13. 2) 
HLA-8 c319 369 1, 3% 6, 6% 306 0, 27 o. 3 co. 0-10. 1) 
HLA-B c330 369 6, 4% 5,  3% 306 0, 35 1. 8 (0. 2-13. 0) 
HLA-8 c333 369 42, 3% 46, 9% 304 0, 51 0. 8 (0. 3-2. 1) 
HLA-B c324 369 20, 5% 19, 2% 307 0, 74 1. 1 (0. 4-3. 5) 
HLA-8 c334 369 59, 7% 57, 5% 305 0 ,  82 1 .  1 (0. 4-2. 8) 
HLA-8 c329 369 0, 0% 0, 0% 307 n. a. n. a. (n. a. -n. a. ) 
HLA-8 c394 379 85, 9% 86, 8% 305 0, 96 1. 0 (0. 3-3. 8) 
HLA-8 c339 404 0, 0% 2, 2% 307 1, 00 n. a. (n. a. -n. a. ) 
HLA-8 c336 414 62, 3% 56, 2°/4 303 0, 44 1. 3 (0. 5-3. 3) 
HLA-8 c350 420 1 ,  3% 7, 4% 307 0, 18 0. 2 (0. 0-7. 8) 
HLA-8 c340 420 2, 6% 0, 4% 306 0, 19 5. 1 (0. 1-304. 4) 
HLA-8 c341 420 24, 4% 12, 3% 305 0, 22 1.6mm (0. 5-5. 2) 
HLA-8 c311 420 57, 9% 47, 5% 297 0, 22 1. 4 (0. 6-3. 7) 
HLA-8 c370 420 37, 7% 29, 7% 303 0, 30 1. 4 (0. 5-3. 7) 
HLA-8 c355 420 5, 1% 4, 4% 307 0, 41 1. 8 (0. 2-16. 5) 
HLA-8 c337 420 13, 0% 15, 4% 305 0, 41 0. 7 (0. 2-2. 8) 
HLA-8 c335 420 37, 2% 41, 4% 305 0, 50 0. 8 (0. 3-2. 1 )  
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HLA-8 c338 420 29, 9% 34, 2°/o 305 0, 57 0. 8 (0. 3--2. 3) 
HLA-B c389 420 1, 3% 1, 3% 307 0, 77 1. 4 (0. 0-74. 0) 
HLA-B c353 420 0, 0% 4, 8% 307 1, 00 n. a. (n. a. -n. a. ) 
HLA-B c356 425 3, 8% 4, 8% 307 0, 50 0. 6 (0. 1-6. 2) 
HLA-B c393 512 10, 3% 7, 0% 307 0, 48 1. 4 (0. 3-7. 1) 
HLA-8 c442 528 61, 5% 67, 7% 307 0, 66 0. 9 (0 . 3--2. 3) 
HLA-8 c459 528 83, 3% 81, 1% 306 0, 92 1. 0 (0. 3--3. 3) 
HLA-8 c457 546 10, 4% 18, 9% 305 0, 12 0. 5 (0. 1-2. 1) 
HLA-B c443 546 51, 3% 42, 4% 307 0, 40 1. 3 (0. 5-3. 2) 
HLA-B c444 546 30, 8% 35, 4% 307 0, 57 0. 8 (0. 3--2. 3) 
HLA-B c416 548 3, 8% 4, 8% 307 0, 50 0. 6 (0. 1-6. 2) 
HLA-B c451 548 61, 5% 63, 3% 307 0, 97 1. 0 (0. 4-2. 6) 
HLA-8 c478 560 11, 5% 18, 8% 307 0, 21 0. 6 (0. 2-2. 3) 
HLA-8 c405 560 10, 3% 15, 3% 307 0, 24 0. 6 (0 . 1-2. 5)  
HLA-8 c325 560 16, 7% 13, 7% 305 0, 59 1. 2 (0. 3--4. 3) 
HLA-8 c445 564 56, 4% 45, 4% 307 0, 15 1. 5 (0. 6-3. 8) 
HLA-B c462 566 62, 8% 62, 0% 307 0, 74 0. 9 (0. 3--2. 4) 
HLA-B c401 571 44, 9% 51, 1% 307 0, 44 0. 8 (0. 3-2. 0) 
HLA-B c448 573 14, 1% 17, 0% 307 0, 37 0. 7 (0. 2-2. 6) 
HLA-8 c460 573 0, 0% 0, 0% 307 n. a. n. a. (n. a. -n. a. ) 
HLA-8 c488 583 16, 9% 14, 4% 306 0, 66 1. 2 (0. 3-4. 1) 
HLA-8 c447 584 26, 9% 25, 8% 307 0, 69 1. 1 (0. 4-3. 2) 
HLA-8 c471 589 96, 2% 98, 7% 307 0, 13 0. 3 (0. 0-4. 9) 
HLA-B c417 614 82, 1% 80, 8% 307 0, 70 0. 9 (0. 3-2. 9) 
HLA-B c477 616 33, 3% 26, 8% 306 0, 28 1. 4 (0. 5-3. 8) 
HLA-B c494 618 39, 7% 40, 6% 307 0, 92 1. 0 (0. 4-2. 5)  
HLA-C c201 102 0, 0% 4, 6% 265 1, 00 n. a. (n. a. -n. a. ) 
HLA-C c251 103 22, 1% 24, 7% 304 0, 56 0. 8 (0. 3-2. 5)  
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GENE PROBE POS EBV+ 
HLA-C c237 108 22, 4% 
HLA C c250 113 42, 9% 
HLA-C c253 121 7, 8% 
HLA-C c252 134 88, 3% 
HLA-C c243 134 24, 7°/o 
HLA-C c241 141 44, 0% 
HLA-C c249 142 75 , 0% 
HLA-C c256 142 75 , 3% 
HLA-C c255 144 44, 2% 
HLA-C c246 181 16, 9% 
HLA-C c266 270 90, 9% 
HLA-C c228 272 40, 3% 
HLA-C c267 296 59, 7% 
HLA-C c247 312 81, 8% 
HLA-C c271 312 9, 2% 
HLA-C c268 312 63, 9% 
HLA-C c231 312 63 , 6% 
HLA-C c224 343 3, 9% 
HLA-C c272 343 84, 0% 
HLA-C c335 368 35, 3% 
HLA-C c313 368 29, 7% 
HLA-C c318 368 2, 6% 
HLA-C c332 369 9, 1% 
HLA-C c306 387 19 , 5% 
HLA-C c319 411 10, 4% 
HLA-C c369 419 37, 7°/o 
HLA-C c359 420 9, 1% 
HLA-C c336 420 39, 0% 
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24, 9% 301 
39, 8% 303 
10, 6% 304 
81, 9% 304 
27, 0% 303 
40, 0% 300 
67, 7% 302 
73, 5% 303 
46, 7% 304 
17, 2% 304 
96, 4% 300 
36, 1% 304 
57, 7% 304 
88, 1% 304 
12, 4% 302 
62, 4% 290 
56, 8% 304 
13, 2% 303 
81, 1% 292 
17, 9% 258 
34, 8% 295 
3, 5% 302 
10, 2% 302 
22, 0% 304 
5, 3% 304 
39, 7% 304 
4, 8% 304 































OR (99. 9% Cl) 
0. 9 (0. 3-2. 7) 
1. 3 (0. 5 -3. 4) 
0. 7 (0. 1-3. 6) 
1. 4 (0. 3--5. 5) 
1. 0 (0. 3--2. 9) 
1. 4 (0. 5-3. 6) 
1. 2 (0. 4-3. 5) 
0. 9 (0. 3-2. 7) 
0. 9 (0. 3--2. 3) 
1. 2 (0. 3--4. 0) 
0. 3 (0. 0-2. 0) 
1. 3 (0. 5-3. 3) 
1. 3 (0. 5-3. 6) 
0. 6 (0. 2-2. 3) 
0. 8 (0. 2-3. 7) 
1. 1 (0. 4-2. 9) 
1. 0 (0. 4-2. 6) 
0. 3 (0. 0-2. 6) 
1. 2 (0. 3--4. 1) 
1. 8 (0. &5. 6) 
0. 8 (0. 3-2. 3) 
1. 2 (0. 1-18. 7) 
0. 8 (0. 2-3. 9) 
0. 8 (0. 2-2. 5) 
2. 3 (0. 4-12. 5) 
0. 9 (0. 4-2. 5) 
2. 4 (0. 4-14. 4) 
0. 9 (0. 3--2. 3) 
HLA associations in Dutch cHL 
continued 
GENE PROBE POS EBV+ EBV- NMISS p OR (99. 9% Cl) 
HLA-C c358 420 1, 3% 0, 0% 304 1, 00 n. a. (n. a. -n. a. ) 
HLA-C c302 421 20, 3% 30, 2% 296 0, 17 0. 6 (0. 2-1. 9) 
HLA-C c330 427 87, 0% 80, 2% 299 0, 34 1. 5 (0. 4-5. 4) 
HLA-C c309 456 16, 9% 17, 2% 304 0, 69 1. 2 (0. 3-4. 0) 
HLA-C c316 481 1, 3% 0, 9% 304 0, 93 1. 1 (0. 0-97. 8) 
HLA-C c323 481 1, 3% 1, 8% 304 0, 97 1. 1 (0. 0-52. 4) 
HLA-C c361 486 6, 6% 8, 1% 298 0, 63 0. 8 (0. 1-4. 7) 
HLA-C c312 512 59, 7% 61, 2% 304 0, 80 0. 9 (0. 4-2. 4) 
HLA-C c372 527 1, 3% 1, 3% 303 0, 75 1. 5 (0. 0-77. 7) 
HLA-C c325 527 61, 0% 61, 5% 303 0, 76 0. 9 (0. 4-2. 4) 
HLA-C c368 527 59, 7% 61, 1% 303 0, 78 0. 9 (0. 4-2. 4) 
HLA-C c370 531 80, 0% 77, 8% 296 0, 77 o. 9 (0. 3-2. 9) 
HLA-C c357 540 39, 0% 25, 1% 304 0, 34 1. 3 (0. 5-3. 7) 
HLA-C c338 543 35, 5% 44, 3% 302 0, 25 0. 7 (0. 3-1. 9) 
HLA-C c314 543 1, 3% 2, 6% 304 0, 27 0. 3 (0. 0-11. 8) 
HLA-C c320 544 3, 9% 1, 3% 303 0, 40 2. 1 (0. 1-39. O) 
HLA-C c339 544 78, 7% 80, 1% 301 0, 79 1. 1 (0. 3-3. 5) 
HLA-C c304 559 24, 7% 27, 3% 304 0, 90 1. 0 (0. 3-2. 8) 
HLA-C c303 564 9, 1% 12, 0% 303 0, 56 0. 8 (0. 2-3. 6) 
HLA-C c321 583 1, 3% 1, 8% 304 0, 97 1. 1 (0. 0-52. 4) 
HLA-C c362 598 24, 7% 27, 3% 304 0, 90 1. 0 (0. 3-2. 8) 
HLA-C c360 601 18, 2% 19, 4% 304 0, 95 1. 0 (0 . 3-3. 2) 
HLA-C c327 601 0, 0% 0, 0% 304 n. a. n. a. (n. a. -n. a. ) 
HLA-A c204 102 19, 5% 18, 3% 306 0, 93 1. 0 (0. 3-3. 4) 
HLA-A c202 108 23, 1% 20, 2% 306 0, 40 1. 3 (0. 4-4. 0) 
HLA-A c205 108 0, 0% 1, 7% 310 1, 00 n. a. (n. a. -n. a. ) 
HLA-A c234 123 1, 3% 0, 0% 310 1, 00 n. a. (n. a. -n. a. ) 
HLA-A c206 129 0, 0% 0, 0% 310 n. a. n. a. (n. a. -n. a. ) 
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GENE PROBE POS EBV+ EBV- NMISS p OR (99. 9% Cl) 
HLA-A c278 144 2, 6% 0, 4% 310 0, 10 8. 0 (0. 1-548. 7) 
HLA A c279 147 23, 0% 50, 0% 294 4, 3E-04 0. 3 (0. 1-0. 9) 
HLA-A c280 180 10, 3% 9, 1% 310 0, 88 1. 1 (0. 2-4. 9) 
HLA-A c281 203 55 , 8% 29, 3% 306 1, 7E-04 3. 0 (1. 2-7. 9) 
HLA-A c266 203 87, 0% 93, 5% 307 0, 14 0. 5 (0. 1-2. 4) 
HLA-A c237 203 1, 3% 0, 0% 308 1, 00 n. a. (n. a. -n. a. ) 
HLA-A c207 245 2, 6% 6, 9% 310 0, 31 0. 5 (0. 0-6. 0) 
HLA-A c210 261 2, 6% 3, 4% 310 0, 59 0. 6 (0. 0-9. 6) 
HLA-A c211 264 87, 2% 68, 0% 309 1, 6E-03 3. 4 (0. 9-12. 0) 
HLA-A c208 265 29, 5% 53, 0% 310 2, 9E-03 0. 4 (0. 2-1. 1) 
HLA-A c209 270 14, 1% 18, 1% 310 0, 37 0. 7 (0. 2-2. 5) 
HLA-A c212 270 20, 5% 19, 4% 310 0, 84 1. 1 (0. 3-3. 4) 
HLA-A c255 270 0, 0% 0, 0% 310 n. a. n. a. (n. a. -n. a. ) 
HLA-A c271 289 7, 8% 6, 1% 308 0, 60 1. 3 (0. 2-8. 1) 
HLA-A c295 292 80, 8% 53, 9% 310 7, 2E-05 3. 8 (1. 3-11. 5) 
HLA-A c213 292 1, 3% 7, 3% 309 0, 11 0. 2 (0. 0-6. 0) 
HLA-A c270 299 0, 0% 0, 0% 310 n. a. n. a. (n. a. -n. a. ) 
HLA-A c241 300 29, 5% 53, 0% 310 2, 9E-03 0. 4 (0. 2-1. 1) 
HLA-A c277 301 48, 1% 40, 1% 309 0, 20 1. 4 (0. 6-3. 6) 
HLA-A c264 301 51, 3% 44, 0% 310 0, 24 1. 4 (0. 6-3. 5) 
HLA-A c274 301 5, 1% 3, 0% 309 0, 27 2. 1 (0. 2-20. 5) 
HLA-A c214 302 9, 0% 8, 2% 310 0, 78 1. 1 (0. 2-5. 8) 
HLA-A c215 303 59, 0% 35, 5% 309 1, OE-03 2. 6 (1. 0-6. 6) 
HLA-A c282 303 48, 7% 39, 0% 306 0, 13 1. 5 (0. 6-3. 9) 
HLA-A c259 303 20, 5% 19, 4% 310 0, 84 1. 1 (0. 3-3. 4) 
HLA-A c273 307 31, 6% 58, 2% 308 8, 1E-04 0. 4 (0. 1-1. 0) 
HLA-A c244 309 71, 4% 83, 1% 308 0, 055 0. 5 (0. 2-1.6mm) 
HLA-A c272 309 2, 6% 2, 6% 309 0, 96 1. 0 (0. 0-18. 7) 
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GENE PROBE POS EBV+ EBV- NMISS p OR (99. 9% Cl) 
HLA-A c267 311 20, 5% 19, 4% 310 0, 84 1. 1 (0. 3--3. 4) 
HLA-A c216 315 28, 2% 25, 9% 310 0, 59 1. 2 (0. 4-3. 3) 
HLA-A c349 363 26, 9% 53, 0% 310 7, 6E-04 0. 4 (0. 1-1. 0) 
HLA-A c317 363 0, 0% 0, 0% 310 n. a. n. a. (n. a. -n. a. ) 
HLA-A c395 365 84, 6% 61, 2% 310 2, 2E-04 3. 8 (1. 2-12. 4) 
HLA-A c396 368 18, 4% 24, 4% 306 0, 27 0. 7 (0. 2-2. 2) 
HLA-A c345 372 20, 5% 19, 4% 310 0, 84 1. 1 (0. 3--3. 4) 
HLA-A c380 376 0, 0% 0, 0% 310 n. a. n. a. {n. a. -n. a. ) 
HLA-A c363 399 94, 9% 84, 5% 310 0, 018 3. 8 (0. 6-24. 6) 
HLA-A c321 414 85, 9% 68, 8% 309 7, 4E-03 2. 7 (0. 8-9. 3) 
HLA-A c338 420 47, 4% 67, 2% 310 0, 011 0. 5 (0. 2-1. 2) 
HLA-A c368 423 7, 7% 6, 5% 309 0, 64 1. 3 (0. 2-7. 5) 
HLA-A c397 456 51, 3% 72, 8% 310 2, 5E-03 0. 4 (0. 2-1. 1) 
HLA-A c347 456 12, 8% 16, 4% 310 0, 48 0. 8 (0. 2-2. 8) 
HLA-A c348 506 34, 6% 60, 3% 310 6, OE-04 0. 4 (0. 1-1. 0) 
HLA-A c361 506 25, 6% 24, 6% 310 0, 91 1. 0 (0. 4-3. 0) 
HLA-A c325 527 56, 4% 30, 2°/o 310 1, 4E-04 3. 0 (1. 2-7. 9) 
HLA-A c369 527 35 , 9% 23, 7% 310 0, 048 1. 8 (0. 7-5. 0) 
HLA-A c324 528 7, 7% 6, 5% 310 0, 63 1. 3 (0. 2-7. 5) 
HLA-A c350 528 10, 3% 12, 6% 309 0, 75 0. 9 (0. 2-3. 8) 
HLA-A c326 530 16, 7% 18, 1% 310 0, 66 0. 8 (0. 3--2. 9) 
HLA-A c373 531 34, 6% 60, 3% 310 6, OE-04 0. 4 (0. 1-1. 0) 
HLA-A c374 531 18, 0% 18, 5% 310 0, 97 1. 0 (0. 3--3. 3) 
HLA-A c339 532 48, 7% 71, 6% 307 2, OE-03 0. 4 (0. 2-1. 1) 
HLA-A c328 535 1, 3% 0, 0% 310 1, 00 n. a. {n. a. -n. a. ) 
HLA-A c340 542 68, 0% 78, 5% 310 0, 061 0. 5 (0. 2-1.6mm) 
HLA-A c330 545 26, 9% 29, 3% 310 0, 97 1. 0 (0. 4-2. 8) 




GENE PROBE POS EBV+ EBV- NMISS p OR (99. 9% Cl) 
HLA-A c351 561 35, 9% 23, 8% 309 0, 056 1. 8 (0. 7-4. 9} 
HLA-A c346 561 0, 0% 0, 0% 306 n. a. n. a. {n. a. -n. a. ) 
HLA-A c333 563 0, 0% 0, 0% 310 n. a. n. a. (n. a. -n. a. ) 
HLA-A c332 566 66, 7% 45, 9% 309 2, OE-03 2. 5 (0. 9-6. 6) 
HLA-A c378 571 56, 4% 29, 9% 309 1 ,  3E-04 3. 1 (1. 2-8. 0) 
HLA-A c352 573 0, 0% 0, 0% 310 n. a. n. a. (n. a. -n. a. ) 
HLA-A c331 575 7 1 ,  8% 47, 0% 310 3, 4E-04 3. 0 (1. 1-8. O} 
HLA-A c375 576 56, 4% 30, 2% 310 1, 4E-04 3. 0 (1. 2-7. 9} 
HLA-A c342 576 82, 1% 89, 7% 310 0, 15 0. 6 (0. 1-2. 1 )  
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Chapter 6 
S ummary and Discussion 
Classical Hodgkin lymphoma(cHL) is a typical malignant disease with a complex 
pathogenesis that is still not completely understood. In this thesis both 
en�ronmental and genetic risk factors are explored in a Northern Chinese and in 
a Northern Dutch cHL population. 
Epidemiology of cHL 
CHL accounts for about 1% of all cancers and-30% of the lymphoid malignancies 
worldwide(1 ). Interestingly. a striking variation in the incidence of cHL has been 
obseMd between different geographic locations and/or racial groups (2). An 
almost 6-fold difference in the incidence of cHL was reported between Western 
and Oriental population groups with an incidence of 2. 3 and 0. 4 per 100, 000 
inhabitants per year respecth,ely (http://globocan. iarc. fr/). In addition, the age 
distribution pattern of cHL also differs between high and low incidence areas. In 
Western countries, it exhibits a distinctiw bimodal pattern with one peak at 
young adult age and a second peak in the elderly (3, 4 ). In the few available 
studies in Asians, the first incidence peak is obserwd at a younger age, i. e. in 
adolescents. whereas the second peak is usually obseMd at the same age as in 
Western countries, with the exception of a single study from Japan in which a 
unique peak in the elderly was reported (5, 6). It should be noted that these 
studies are based on a limited number of patients varying from 23 to 70(7-9). 
Infection with Epstein Barr Virus(EBV) was identified to play a causal role in 
the pathogenesis of cHL(10, 11 ). Howe\er, the frequency of EBV-associated cHL 
ranges from 30% in Caucasians to an intermediate frequency in Orientals to 
almost 100% in Hispanics ( 4, 12). EBV + cHL was always obseMd more 
frequently in children and elderly as compared to the other age groups regardless 
of the ethnic background(13, 14). 
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In chapter 2 of this thesis, we performed a large epidemiological study 
including 371 cHL patients from the northern part of China. We demonstrated 
both distinctiw and consistent features when comparing the data with previous 
findings in the Asian population. The percentage of EBV + cHL patients was 
around 41 % in the Northern Chinese patients, only a little bit higher than in 
Caucasians. Howewr, a comparison between the Chinese and Dutch patient 
populations showed significant differences in terms of patients' age and gender 
distribution in relation to EBV status. 
Expression of HLA antigens by cHL tumor cells in the 
Chinese cHL patients 
Deficiency in the expression of Human leukocyte antigen(HLA) antigens by tumor 
cells is thought to be an important strategy for malignant cells to escape from 
host immunosurwillance(15, 16). This might be especially important in EBV+cHL, 
because EBV-deri\ed antigenic peptides are known to consistently ewke 
immune responses. Previous studies performed in the Caucasian population ha\e 
found that retention of HLA class I and HLA class II molecules is much more 
common in EBV+cHL as compared to EBV- cHL patients(1 7-1 9). Although there 
is no clear explanation for this paradox, the highly polymorphic nature of the HLA 
genes and the resultant functional variation between the HLA molecules might 
play a role. In addition, persistence of HLA class I expression is advantageous for 
the tumor cells to a\Oid Natural Killer cell-mediated lysis(20 ). 
In chapter 3 we analyzed HLA class I and class II expression in a group of 
145 Chinese cHL patients. In agreement with previous findings in the Caucasian 
population, membrane expression of HLA class I was strongly associated with 
positiw EBV status in the Chinese cHL patients. In contrast, we found no 
significant association of membrane expression of HLA class II with EBV status 
in Chinese cHL. In Chinese EBV+cHL patients, HLA class II expression was lost 
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more often than in Caucasians(48% w 30% ). There is in vitro evidence that EBV 
infection and the related malignant transformation are controlled by CD4+ T cells, 
depending on HLA class II restricted antigen presentation(21 ). Based on extreme 
differences in allele frequencies between racial groups, it can be hypothesized 
that HLA class II alleles that are prevalent in the Chinese population might 
effectiwly present EBV-deriwd peptides to the immune system, thereby exerting 
selection pressure to downregulate HLA class II expression. 
Genetic associations bebNeen HLA alleles and cHL 
The HLA complex, being an essential element of the human immune system, has 
been widely studied in various human diseases for its potential disease 
contribution(15, 16). Since virally infected cells can be strictly controlled by host 
immune surwillance, it is plausible to expect a difference in the HLA 
associations between EBV + and EBV- cHL. Previous studies on HLA and cHL 
associations were mainly performed among Caucasians and significant effects of 
specific HLA genes were found in both sporadic and familial cHL patients 
(reviewed in (22)). Most of the abow mentioned studies applied serological 
determination of usually only a few HLA antigens and EBV status was not taken 
into account. Each HLA serological type usually encompasses a group of 
distinct allele variants and the alleles of a serological group are functionally 
different in peptide binding and presentation ( 23 ). This implies that HLA 
association studies based on serology might giw biased results. In addition, the 
extensiw linkage disequilibrium (LD) in the HLA region between different HLA 
genes and between HLA genes and non-HLA genes might also affect association 
outcomes. Previous results from our research group based on a genetic 
screening analysis of the entire HLA region and subsequent detailed DNA based 
HLA-typing, sho'Ned that HLA-A 1 is clear1y owrrepresented whereas HLA-A2 is 
underrepresented in EBV+cHL patients from the Northern part of the Nether1ands(24). 
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Very recently, a study from Scandina\4a and the United Kingdom showed that HLA-A1 
homozygosity renders an approximately 4-fold increased risk of de\eloping EBV+cHL, 
while HLA-A2 homozygosity predicts a 4-fold decreased risk(25). 
HLA-A associations in the Chinese population 
HLA-A*02 is the most common HLA-A allele in most populations worldwide. In 
Caucasians, HLA-A*02:0 1 is by far the most common allele variant and has been 
found to be a protecth,e allele for the de\elopment of EBV+cHL(24, 25). In the 
Chinese population there are other HLA-A*02 allele variants with a high frequency 
in addition to HLA-A*02 :0 1 such as HLA-A*02:06 and HLA-A*02 :0 7  that are \ery 
infrequent in Caucasians (26). Notably, the HLA-A * 02 subtypes differ in their 
capacity of peptide binding and presentation as well as the subsequent immune 
response(23). HLA-A*0 1 was found to be a risk allele for EBV + cHL in the 
Caucasian population, howe\er HLA-A*0 1 is rare in the Chinese population. 
Because of the strong correlation between EBV + cHL and HLA-A*0 1 in 
Caucasian populations, one would expect that the proportion of EBV+cHL in the 
Chinese cHL patients would be lower. Howe\er, this proportion was consistently 
reported to be higher than in Caucasian patients(4, 12). Therefore HLA-A * 0 1  is 
\ery unlikely to be a predominant susceptibility gene for EBV + cHL among the 
Chinese population. A possible minor effect still needs to be studied by 
determining the allele frequency of HLA-A*0 1  in the Chinese EBV+cHL patients. 
In chapter 4 we analyzed the HLA-A*02  frequency in the Chinese population 
and obseMd similar frequencies in EBV + and EBV- cHL patients. Subsequent 
sequence based typing of the most common HLA-A*02 alleles re\ealed that HLA­
A * 02 :  0 7  is a risk factor for de\eloping EBV + cHL in the Chinese population, 
whereas the other alleles are protecti\e similar to the Western population. HLA­
A*02:0 7 is a distincti\e HLA-A*02 subtype that is almost exclusiw to Orientals 
and has been found to confer a significant risk for the de\elopment of 
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Undifferentiated Nasopharyngeal Carcinoma ( UNPC ) in the southern Chinese 
population(27). A possible explanation for this finding was giwn by the less 
efficient presentation of EBV-deriwd peptides by HLA-A*02:07(28, 29). At least in 
the Chinese population, this allele can wry well explain the distinctiw geographic 
distribution of UNPC. These findings illustrate that HLA-linked ethnic diwrsity 
can explain geographical variation in disease incidence as is seen for cHL. In 
addition, it demonstrates that knowledge of the ethnic background is of particular 
importance for genetic association studies. 
HLA-based genetic susceptibility to cHL in the Dutch 
population 
In chapter 5 of this thesis, we studied a group of Dutch cHL patients(n=338) by 
detailed DNA-based HLA typing. HLA-B51 and HLA-DR7 were found to be a 
susceptible and a protectiw HLA allele for cHL irrespectiw of the EBV status. 
Three class II associations were observed in the EBV- cHL population with an 
increase of HLA-DR15 (2) and a decrease of HLA-DR4 and HLA-DR7. Besides 
confirmation of the strong genetic effects of HLA-A 1 and HLA-A2 in EBV + cHL 
patients, we also found an association of HLA-DR1 O and HLA-837 with EBV + 
cHL. It should be noted that these alleles are in linkage disequilibrium with HLA-A 
*01 . The allele frequency of HLA-DR11 (5) was significantly decreased in the EBV 
+cHL population. SSOP analysis re-..,ealed significant differences between EBV+ 
and EBV-cHL patients for 19 probes that discriminate between HLA-A*01 and 
HLA-A*02. In conclusion, the HLA-A1 and HLA-A2 antigens and not a specific 
single nucleotide variant shared by multiple alleles are responsible for the 
association with EBV + cHL. The differential HLA-based genetic background 
between the EBV + and EBV-cHL suggests that an undefined infectious agent 
other than EBV or a(group of) specific tumor-associated antigen(s) is im,olwd in 
the pathogenesis of EBV- cHL. 
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In conclusion 
In this thesis we showed marked differences in cHL epidemiology between 
Caucasian and Oriental populations. The complex nature of the disease may at 
least be partially explained by differences in genetic background, which is most 
notably in the HLA genes. 
Future perspecthes 
In this thesis , we describe the epidemiological features of a group of cHL patients 
from Northern China in which both similarities and differences were found in 
comparison to the published data. Howewr, as there is only limited data 
regarding the epidemiological features of cHL among Asians, it is worthwhile to 
identify and study more cHL patients to further illustrate the similarities and 
differences. Moreo\er, it should be noted that the previous studies reported on the 
epidemiological features of cHL in Chinese subpopulations from Hong Kong and 
Taiwan, consisting mainly of descendants from the Southern Chinese population 
who are genetically different from the Northern Chinese population. Giwn the 
large differences in the frequency distribution of HLA alleles between Southern 
and Northern Chinese populations, it would be of great value to separately 
analyze and compare cHL patients from Southern and Northern China. 
Currently, a strong association between tumor cell membrane expression of 
HLA class I and EBV+cHL was obser\ed in both Caucasians and Chinese cHL 
patients. Howewr, we did not find an association of membrane expression of HLA 
class II with EBV+cHL in the Chinese population. Our group previously reported 
that in the Dutch population, absence of HLA class II expression was associated 
with ad\erse outcome(30). We found a relati\ely higher frequency of loss of HLA 
class II expression in the Chinese cHL patients compared to the Dutch 
population(46. 2% expression vs 58. 6% expression). Whether the prognostic 
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significance of HLA class II expression in cHL would also be present in the 
Chinese population needs to be studied. Three microsatellite markers within the 
HLA class II region haw been reported to be in close relationship with HLA class 
II expression in cHL in the Dutch population(30). One or more specific HLA alleles 
could be im,olwd, but this association could also be caused by transcriptional 
regulation sites or a non-HLA gene. In the future, a fine screening of the class II 
region should be done to identify which genetic locus or loci account(s) for this 
association. Linking of the HLA typing data to the expression of HLA class II 
molecules may be helpful for illuminating the abow association. Ideally, as a next 
step we should study these HLA class II alleles in combination with HLA class II 
downregulation in the Chinese population. 
Due to differences in the distribution of common and well documented HLA 
alleles between different population groups, it can be expected that different HLA­
linked genetic associations with certain diseases can be found in different ethnic 
groups. We found that the ethnic difference in the distribution of HLA-A*02 
subtypes alters the association between HLA-A*02 and EBV+cHL. In addition to 
HLA-A *02, HLA-A * 01 is also wry common in the Caucasian population, which 
has been identified to confer a significant risk for EBV + cHL. Although the 
frequency of HLA-A*01 is rather low in the Orientals, its frequency in the Chinese 
EBV+cHL patients should be explored since it may be an additional risk factor to 
HLA-A* 02: 07. Some other HLA alleles such as HLA-A* 11 are common in the 
Chinese population but not in the Caucasians. Notably, an effectiw anti-EBV 
immune response can be elicited in the context of HLA-A * 11 and this may wry 
well explain the protective effect of HLA-A * 11 in UNPC(31 ). Therefore, it would be 
ideal to perform a detailed screening of the HLA genes that are imolwd in the 
pathogenesis of cHL in the Chinese population. This would be of particular benefit 
for better understanding the genetic variation of cHL between the Dutch and 
Chinese populations. A small proportion of the Dutch EBV+cHL patients possess 
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the HLA-A*02 allele and it is unclear how the EBV positi've tumor cells escape 
from an effecti've anti-EBV cytotoxic T-lymphocyte immune response. It might be 
hypothesized that the HLA-A*02 allele is no longer functional in the tumor cells of 
these patients. HLA-A * 02 expression might be decreased or completely lost on the 
cell surface of the tumor cells. This could be studied by immunohistochemistry using a 
HLA-A*02-specific antibody. In addition, the peptide-binding cleft of the HLA 
molecule, encoded by exons 2 and 3 of the gene, determines the characteristics 
of presented peptide and hence influences the immune response. Therefore, we 
plan to sequence exons 2 and 3 of the HLA-A * 02 gene in Dutch EBV + cHL 
patients to screen for putati've mutations and/or deletions that could alter the 
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Achtergrond 
Hodgkin lymfoom is een "°rm van B eel kanker die wordt gekarakteriseerd door 
een opvallende minderheid van tumorcellen in een uitgesproken achtergrond van 
reactie\e cellen. Het Epstein-Barr \Arus (EBV) wordt in de tumorcellen van een 
variabel percentage(20-70 % ) van de pati nten aangetroffen en dit percentage is 
afhankelijk van de etnische achtergrond van de pati nten. De incidentie van HL 
varieert per geografische locatie en etniciteit, en is in de westerse be'101king 2, 3 
per 100. 000 inwoners per jaar. Opmerkelijk is dat ook de leeftijds\erdeling 
\erschilt per populatie. In de westerse be'10lking wordt EBV+HL m. n. in kinderen 
/ pubers en ouderen aangetroffen. 
De meest \Oorkomende variant is het klassiek Hodgkin lymfoom. Er wordt al 
jarenlang \eel onderzoek gedaan naar de ontstaanswijze van klassiek Hodgkin 
lymfoom en op basis van deze studies weten we dat er omge\Angs- en genetische 
componenten zijn. In het geval van EBV + HL valt er een afweerreactie te 
\erwachten tegen eiwitten(peptiden) afkomstig van het EBV. Dit gebeurt echter 
niet en in combinatie met de grote owrmaat aan reactie\e cellen in de directe 
omge\Ang van de tumorcellen is dit op zijn minst on\erwacht te noemen. Een 
mogelijke oorzaak zou kunnen zijn dat de expressie van HLA, het molecuul dat 
peptiden van het EBV aan het afweersysteem kan presenteren, wrloren gaat. In 
HL wordt inderdaad vrij vaak \erlies van expressie van HLA ge'10nden op de 
tumorcellen, maar opvallend genoeg '10oral in EBV- HL en \eel minder vaak in 
EBV+ HL. In dit proefschrift hebben we een populatie van klassieke Hodgkin 
lymfoom pati nten onderzocht uit het noorden van China m. b. t. leeftijd en EBV 
wrdeling, HLA klasse I expressie in relatie tot EBV en genetische associatie met 
HLA-A allelen. Daamaast is een populatie van klassiek Hodgkin lymfoom pati 
nten uit noord Nederland onderzocht m. b. t. HLA allel frequenties d. m. v. DNA 
gebaseerde HLA subtypering. 
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Epidemiologie van cHL 
In hoofdstuk 2 van dit proefschrifl: hebben we een epidemiologische studie gedaan 
in 371 Chinese klassiek HL pati nten en deze populatie wrgeleken met de 
Nederlandse populatie. Het percentage EBV positiviteit was 41% , dit is iets 
hoger dan het gemiddelde in de westerse populatie. De incidentie curw \Oor EBV 
+and EBV- klassiek HL liet duidelijke wrschillen zien tussen de Chinese en de 
Nederlandse populatie m. b. t. leefl:ijdswrdeling en geslacht. 
HLA expressie en allelen in Chinese cHL pati nten 
In hoofdstuk 3 hebben we expressie van HLA klasse I en II onderzocht in 145 
Chinese klassieke HL pati nten. In owreenstemming met eerder gepubliceerde 
data in de westerse be\Olking \Onden we dat EBV+pati nten meestal HLA klasse 
I positief waren en dat EBV- pati nten relatief vaak expressie van HLA klasse I 
hadden wrloren. Voor HLA klasse II zagen we geen significante wrschillen 
tussen EBV- en EBV+pati nten, in tegenstelling tot eerder gepubliceerde data in 
de westerse be\Olking. Aangezien het HLA allel bepaalt welke peptiden worden 
gepresenteerd en daarmee dus ook hoe effectief het afweersysteem op bepaalde 
peptiden reageert, kan het wrschil tussen de populaties wrklaard warden door 
bekende etnische wrschillen in HLA allelfrequenties. In de westerse populatie is 
aangetoond dat bepaalde HLA-A types{waarbij elk type een familie is van allelen) 
geassocieerd zijn met EBV + HL. Het HLA-A 1 type is een risicofactor \Oor het 
ontwikkelen van EBV+HL, terwijl het HLA-A2 type juist beschermend werkt. Deze 
associatie kan goed wrklaard worden doordat individuen met het HLA-A2 type 
goed in staat zijn om een effectiew afweerreactie op te wekken tegen EBV 
afkomstige peptiden, terwijl individuen met het HLA-A 1 type dat juist niet kunnen. 
In een wrwlgonderzoek hebben we gekeken naar de frequentie van het HLA­
A2 type in de Chinese HL populatie. Het HLA-A 1 type is niet onderzocht 
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aangezien dit allel heel erg zeldzaam is in de Chinese populatie. In hoofdstuk 4 
hebben we aangetoond dat de HLA-A2 frequentie in de EBV + HL populatie niet 
-._erschilt van EBV- HL en een controle populatie. Aangezien oak de HLA-A2 
subtype(of allel-) frequenties nogal -._erschillen tussen de westerse en Chinese 
populatie hebben we ve,wlgens een "sequence based subtyping" gedaan. Hieruit 
kwam dat de frequentie van het HLA-A *02:07 allel aanzienlijk verhoogd was en de 
frequentie van alle andere HLA-A2 allelen juist sterk verlaagd in EBV + HL t. o. v. 
EBV- en controles. Dit -._erschil kan mogelijk wrklaard warden doordat individuen 
met het HLA-A * 02: 07 allel ook geen effectiew afweerreactie op EBV kunnen 
induceren, -._ergelijkbaar met het HLA-A 1 type in de westerse populatie. 
HLA typering in de Nedertandse klassieke HL populatie 
In hoofdstuk 5 van dit proefschrift hebben we in 338 Nederlandse HL pati nten een 
HLA typering gedaan m. b. v. een op PCR gebaseerde " sequence specific 
oligonucleotide probe"(SSOP) techniek. Als controlegroep hebben meer dan 5. 
000 bloedbank controles gebruikt. HLA-DR7 was significant wrlaagd en HLA-B51 
significant verhoogd in de HL populatie t. o. v. controles. In de EBV- HL pati nten 
\Onden we een sterke associatie met drie HLA klasse II genen. De frequentie van 
HLA-DR15(2) was verhoogd en die van HLA-DR4 en HLA-DR7 verlaagd. In EBV+ 
HL pati nten \Onden we naast de bekende associatie met HLA-A een significante 
toename van de frequenties \Oar HLA-B37 en HLA-DR10 en een wrlaging van de 
HLA-DR11(5) frequentie. Analyse van de individuele SSOPs lieten significante 
verschillen zien tussen EBV+ en EBV- HL pati nten \Oar 19 van de 358 probes. De 
specificiteit van deze 19 probes corresponderen met HLA-A 1 en HLA-A2. Op 
basis van deze studie kunnen we concluderen dat er verschillende genetische 
associaties zijn \Oar EBV- en EBV+ HL. Daarnaast zijn er oak twee associaties 




In dit proefschrift hebben we aangetoond dat er \erschillen zijn in epidemiologie, 
EBV, leeftijd en HLA associatie tussen de Chinese en Nederlandse HL pati nten. 
Daamaast hebben we in de Nederlandse populatie aangetoond dat er zowel 
verschillen als overeenkomsten zijn tussen EBV +en EBV- HL pati nten m. b. t. 
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